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ABSTRACT
Kate Gleason College of Engineering
Rochester Institute of Technology
Degree: Doctor of Philosophy

Program: Microsystems Engineering

Author: Farzad Forouzandeh
Advisor: David A. Borkholder
Dissertation Title: Implantable microsystem technologies for nanoliter-resolution inner
ear drug delivery
Advances in protective and restorative biotherapies have created new opportunities to use site-directed,
programmable drug delivery systems to treat auditory and vestibular disorders. Successful therapy
development that leverages the transgenic, knock-in, and knock-out variants of mouse models of human
disease requires advanced microsystems specifically designed to function with nanoliter precision and
with system volumes suitable for implantation. The present work demonstrates a novel biocompatible,
implantable, and scalable microsystem consisted of a thermal phase-change peristaltic micropump with
wireless control and a refillable reservoir. The micropump is fabricated around a catheter microtubing
(250 μm OD, 125 μm ID) that provided a biocompatible leak-free flow path while avoiding complicated
microfluidic interconnects. Direct-write micro-scale printing technology was used to build the
mechanical components of the pump around the microtubing directly on the back of a printed circuit
board assembly. In vitro characterization results indicated nanoliter resolution control over the desired
flow rates of 10–100 nL/min by changing the actuation frequency, with negligible deviations in presence
of up to 10× greater than physiological backpressures and ±3°C ambient temperature variation. A
biocompatibility study was performed to evaluate material suitability for chronic subcutaneous
implantation and clinical translational development. A stand-alone, refillable, in-plane, scalable, and
fully implantable microreservoir platform was designed and fabricated to be integrated with the
micropump. The microreservoir consists two main components: a cavity for storing the drug and a
septum for refilling. The cavity membrane is fabricated with thin Parylene-C layers, using a
polyethylene glycol (PEG) sacrificial layer. The septum thickness is minimized by pre-compression
down to 1 mm. The results of in vitro characterization indicated negligible restoring force for the
optimized cavity membrane and thousands of punctures through the septum without leakage. The
micropump and microreservoir were integrated into microsystems which were implanted in mice. The
microtubing was implanted into the round window membrane niche for infusion of a known ototoxic
compound (sodium salicylate) at 50 nL/min for 20 min. Real-time shifts in distortion product
otoacoustic emission thresholds and amplitudes were measured during the infusion. The results match
with syringe pump gold standard. For the first time a miniature and yet scalable microsystem for inner
ear drug delivery was developed, enabling drug discovery opportunities and translation to human.

iii

Acknowledgements
To my parents, thank you for believing in me at an early age. I always knew that you
wanted the best for me. I am especially grateful for supporting me emotionally and
financially. To my mother, for inspiring me to be dedicated to my career. To my father,
who taught me how to have a good understanding of the world around me and think big.
Thank you for guiding me integrity and the core values that I live my life by. To my sister,
Firouzeh, who has always been a figure of a successful and down-to-earth person for me
since childhood. To my brother, Farhad, who has believed in my talents since childhood
and has always helped me to grow. To my sister, Farisa, who taught me how to plan for
my work, for spending hours with me during the tough days of my life to help me. Thank
you for inspiring me to find my path for more peace in my life. To my family, thank you
all, this is just as much your Ph.D., as it is mine.
To Dave, my advisor, one of the smartest people I have ever met in my life. If I want to list
out all the things you taught me, it would perhaps require another chapter in this thesis. I
specifically appreciate you for teaching me ‘thinking out of the box’ as a real thing, not
just a nice slogan. I would not be where I am today without your inspiration and support. I
am looking forward to sharing my professional future and career with you as a lifelong
friend.
I would like to thank Bob Carter for helping me, especially in the early stages my Ph.D. I
also appreciate our collaborators at the University of South Florida, Xiao xia, Bob, and Joe,
for their guidance and patience. I would also like to thank my seniors in Borkholder
Biomedical Microsystems Laboratory. Thank you Nick, for helping me to cope with the
difficulties in my professional career. Thank you Jing, for working with me especially in
my early days at RIT to get handy with microfluidics approaches. Additionally, I would
like to thank Ahmed for involving in long, inspirational conversations with me on the
micropump project, opening doors to me to understand and solve many issues that came
along.
Finally, I would like to thank my entire committee, my department, and Lisa Zimmerman.
It has been a pleasure to be part of the microsystems department. I could not be more
grateful for all that I have experienced and learned.

iv

Contents
Chapter 1
Introduction To Inner Ear Drug Delivery ........................................................... 1
1.1 Introduction ..................................................................................................................... 1
1.2 Auditory dysfunction therapy development .................................................................... 2
1.3 Site-directed delivery: Benefits and challenges............................................................... 3
1.4 Mouse model system: Benefits and challenges ............................................................... 4
1.5 Microsystems for inner ear drug delivery........................................................................ 5
1.6 Objectives ........................................................................................................................ 8
Chapter 2
A Review On Peristaltic Micropumps ................................................................ 10
2.1 Introduction ................................................................................................................... 10
2.2 Peristalsis concept ......................................................................................................... 12
2.3 Significant parameters in peristalsis .............................................................................. 18
2.3.1 Actuation frequency ......................................................................................... 19
2.3.2 Stroke volume .................................................................................................. 21
2.3.3 Working fluid ................................................................................................... 23
2.3.4 Sequence and phase difference ........................................................................ 25
2.3.5 Number of chambers ........................................................................................ 29
2.3.6 Summary of different parameters..................................................................... 33
2.4 Actuation methods ......................................................................................................... 34
2.4.1 Piezoelectric ..................................................................................................... 34
2.4.2 Hydrogel .......................................................................................................... 38
2.4.3 DC or step motor .............................................................................................. 39
2.4.4 Pneumatic ......................................................................................................... 44
2.4.5 Electrostatic...................................................................................................... 47
2.4.6 Thermopneumatic ............................................................................................ 49
2.4.7 Phase-change.................................................................................................... 51
2.4.8 Shape memory alloy......................................................................................... 53
2.4.9 Summary of actuation methods........................................................................ 54
2.5 Evaluation and discussion of peristaltic micropumps ................................................... 55
2.5.1 Advantages and disadvantages of PMPs .......................................................... 55
2.5.2 Comparison of different PMPs......................................................................... 57
2.6 Conclusion ..................................................................................................................... 62
Chapter 3
A Nanoliter Resolution Micropump For Murine Inner Ear Drug Delivery ... 65
3.1 Introduction ................................................................................................................... 65
3.2 System overview and concept ....................................................................................... 68
3.3 Electronic control .......................................................................................................... 73
3.3.1 Electronic design .............................................................................................. 73
3.3.2 Android application.......................................................................................... 74

v

3.4 Heat transfer analysis .................................................................................................... 79
3.5 Fabrication process ........................................................................................................ 83
3.6 In vitro characterization ................................................................................................. 86
3.7 In vivo experiment ......................................................................................................... 86
3.7.1 Drug infusion system and solutions ................................................................. 87
3.7.2 Animal and surgical procedures ....................................................................... 88
3.7.3 Auditory function assessment .......................................................................... 89
3.8 In vitro results and discussion ....................................................................................... 92
3.8.1 Micropump performance characterization at physiological backpressures ..... 92
3.8.2 Pump performance at different ambient temperatures ..................................... 93
3.8.3 Pump assessment for in vivo acute experiment ................................................ 94
3.8.4 Flow rate resolution ......................................................................................... 94
3.9 In vivo results and discussion ........................................................................................ 96
3.10 Conclusion ................................................................................................................... 99
Chapter 4
Biocompatibility Of Microsystem Materials ................................................... 100
4.1 Introduction ................................................................................................................. 100
4.2 Materials and methods ................................................................................................. 101
4.3 Biocompatibility results............................................................................................... 105
4.4 Conclusion ................................................................................................................... 109
Chapter 5
A Modular Microreservoir For Active Implantable Drug Delivery.............. 110
5.1 Introduction ................................................................................................................. 110
5.2 System overview and concept ..................................................................................... 115
5.3 Fabrication process ...................................................................................................... 118
5.4 Benchtop experimental method ................................................................................... 122
5.4.1 Septum test ..................................................................................................... 122
5.4.2 Cavity membrane test..................................................................................... 124
5.5 In vitro results and discussion ..................................................................................... 127
5.5.1 Septum characterization ................................................................................. 127
5.5.2 Cavity membrane characterization ................................................................. 128
5.6 Conclusion ................................................................................................................... 131
Chapter 6
Fully Implantable Microsystem For Inner Ear Drug Delivery...................... 133
6.1 Introduction ................................................................................................................. 133
6.2 Fabrication process ...................................................................................................... 134
6.3 Experimental methods ................................................................................................. 135
6.3.1 Subcutaneous implantation and biocompatibility .......................................... 135
6.3.2 Inner ear drug delivery ................................................................................... 136
6.3.3 Micropump air bubble-tolerance experiment ................................................. 139
6.4 Results and discussion ................................................................................................. 140
6.4.1 Inner ear drug delivery ................................................................................... 140

vi

6.4.2 Long-term biocompatibility ........................................................................... 142
6.4.3 Bubble-tolerance capability ........................................................................... 144
6.5 Conclusion ................................................................................................................... 145
Chapter 7
Future work and final remarks ........................................................................ 146
7.1 Introduction ................................................................................................................. 146
7.2 Technology enhancement ............................................................................................ 147
7.2.1 Normally-closed pumping mechanism .......................................................... 147
7.2.2 A single actuator micropump with check valves ........................................... 148
7.3 Application extension .................................................................................................. 151
7.3.1 Chronic drug delivery of Salicylate to the inner ear ...................................... 151
7.3.2 Pneumatic-driven pump for LOC applications .............................................. 151
7.3.3 Pulse-free flow ............................................................................................... 153
7.4 Conclusion ................................................................................................................... 155
References…………………………………………………………………...........……………………..157
Appendix A …………………………………………………........……………………............………...180

vii

List Of Figures
Figure 1.1. A schematic of the integrated microsystem implantation for inner ear drug delivery.
....................................................................................................................................... 9
Figure 2.1. Examples of a) a discrete-channel (adapted from [37]) and b) a continuous-channel
PMPs (adapted from [53]). .......................................................................................... 14
Figure 2.2. Classification of different rectification methods that have been used for PMPs in
the literature. In this table, the fluid channel is shown to be discrete for
simplification. However, this is not the case for all PMPs. Some pumps use a
microtubing/tubing and make the structure around it. ................................................. 17
Figure 2.3. Typical Q-f curve for PMPs. The curve shows an average of Q-f curve for nine
different PMPs. The flow rates and frequencies are normalized to the values at
maximum flow rate. Most of the reports present the linear section of the curve......... 20
Figure 2.4 Three different sequences have been compared in. The results show that a
maximum flow rate occurs in 120° case, followed by 90° and 60°. The legend
represents with “1” and “0” a closed (actuated) or open (deactivated) chamber,
respectively. The arrows represent the flow direction. “ Adapted from [125]”........... 26
Figure 2.5 Three different sequences were compared in a PZT-driven PMP. Their results show
that the maximum flow rate is for case A, followed by B and C. The legend
represents with “1” and “0” a closed (actuated) or open (deactivated) chamber,
respectively. The arrows represent the flow direction. “Adapted from [78], [126],
[127]” ........................................................................................................................... 27
Figure 2.6. Four different sequences have been compared in an electrostatic PMP. According
to their results, a larger maximum flow rate occurs in cases D, C, B, and A,
respectively. The legend represents with “1” and “0” a closed (actuated) or open
(deactivated) chamber, respectively. The arrows in the channel represent the flow
direction. “Adapted from [51]”.................................................................................... 28
Figure 2.7. a) An ideal comparison in PMPs with three, four, and five chambers showing that
for an increasing number of chambers, the flow rate increases in a nonlinear
manner. The legend represents with “1” and “0” an active or inactive chamber
(closed or open channel respectively), respectively. The arrows in the channel
represent the flow direction. V= boluses, T= cycle time, Q= total flow rate. b) Ideal
peristaltic micropump behavior, where the increase in the number of chambers
increases the flow rate. Note: The flow rate is normalized to the flow rate of a 3chamber PMP. In all cases, the actuation sequence always guarantees to have two
chambers closed. .......................................................................................................... 31
Figure 2.8. a) A Review On Peristaltic MicropumpsCross-sectional and front view of
peristaltic micropump using traveling waves on a polymer membrane [102]. The
bottom membrane of the hydraulic displacement amplification mechanism is
vibrated by an actuator at its edge, and traveling waves are generated in one
direction to drive fluid. The long and thin format of this micropump could be
beneficial when it is attached to catheter-type devices. (Adapted from [102]) b) A

viii

single-actuation piezoelectric PMP developed by Pečar et al. [104]. i) suction
phase ii) pumping phase. (Adapted from [104]) .......................................................... 37
Figure 2.9. Hydrogel PMP a) Schematic set-up. b) Operating principle. (Adapted from
[Ritcher 2008 - Hydrogel]) c) Photograph. (Reproduced from [137] with
permission from the Royal Society of Chemistry.) ..................................................... 38
Figure 2.10. a) A DC-motor PMP with magnetic transmission (Adapted from [138]). b) A
PMP with DC-motor as the actuator and magnetic fluid as the transmission
medium. The magnetic fluid rotates with permanent magnets attached to the DC
motor to provide a peristaltic pumping (Adapted from [139]). ................................... 41
Figure 2.11. A DC motor-driven PMP with roller transmission. Left) A prototype of a tubingbased PMP. Right) a prototype of a PDMS-based PMP (Reproduced from [114]
with permission from Elsevier). .................................................................................. 43
Figure 2.12. a) A novel method for transmission of DC motor rotation into a peristaltic
pumping (Adapted from [106]). b) iPRECIO®-SMP300 is one of the most popular
PMPs. This micropump works with a DC motor and seven followers (pin fingers)
(Reproduced from [111] with permission from Elsevier). .......................................... 44
Figure 2.13 Operation mechanism for two single-actuation mechanism PMPs. a)
serpentine(Adapted from [99]). b) different chamber sizes (Adapted from [98]). ...... 46
Figure 2.14. Electrostatic actuation method for gas chromatography application. a) Top view
of the electrodes design (Vectorized from [51]). b) Fabricated devices (Reproduced
from [51] with permission of Elsevier). ...................................................................... 48
Figure 2.15. a) An image of a PDMS-based thermopneumatic PMP, chambers with the
resistive heating element. b) size comparison of the fabricated
micropump.(Reproduced from [170] with permission from Elsevier). c)
Conceptual view of a peristaltic micropump with low-temperature elevation on
working fluid (Reproduced from [173] with permission from Elsevier). .................... 51
Figure 2.16. Photograph of a gallium-based PMP with plena and capillary tubing. Visible are
the interconnected capillary tubes, heaters, diaphragm chambers, plena, and heater
contact pads (Reproduce from [37] under CC BY 4.0). b) Photograph of a waxbased phase-change PMP 3D-printed around a commercially available catheter
microtubing on the back of a printed circuit board “Reproduce from [73] with
permission from Elsevier”. .......................................................................................... 53
Figure 2.17. Comparison of several reported PMPs based on flow rate, package size,
maximum backpressure, actuation method, and operating voltage. *Note: As
illustrated in the legend, the color indicates the actuation method, the marker size
indicates operating pressure range, and the shape correlates to the drive voltage
range. ........................................................................................................................... 61
Figure 3.1. A conceptual drawing of the implantation of the subcutaneous microsystem in the
mice. ............................................................................................................................ 70
Figure 3.2. Left) Cyclic phase-change actuation of the three chambers compressed the
microcatheter tubing and drove peristalsis. The left and right actuators are in the
liquid state, compressing the tubing to eject fluid. Right) Schematic of the

ix

peristaltic micropump built around a commercially available microcatheter
directly on the back of a PCBA using 3D-printing technology. .................................. 72
Figure 3.3. Left) Image of the fabricated electronics on front side of the printed circuit board.
The electronics assembly was used for actuation, closed-loop feedback to control
chamber temperatures, and wireless control. Right) Block diagram of the pump
control electronics. Res, resistive heater; Ther, thermistor.......................................... 74
Figure 3.4. Once starting the application, it starts to look for micropumps around. If the pump
is on the application finds it and shows the pump’s unique ID at the left and RSSI
number at the right side of the screen. ......................................................................... 75
Figure 3.5. The main screen of the application for the micropump. Along with RSSI and ID
number the available battery voltage is shown. Also, the ‘start pumping’
starts/stops the micropump and the ‘start recording’ saves the data in a ‘.txt’ file.
The ‘update temperature’ button shows the current temperature. ............................... 76
Figure 3.6. The micropump is calibrated with ‘low temp’ and ‘high temp’ linearly, based an
external gold standard. ................................................................................................. 77
Figure 3.7. Left) the micropump can be programmed in the ‘configure’ section (not shown in
this figure) and by choosing ‘edit’ under ‘program’. Right) Each chamber can be
set to the desired temperature (preferably in calibration range) for a specific time
at each sequence. The pump can have multiple sequences using ‘add after’ button.
..................................................................................................................................... 78
Figure 3.10. Heat transfer analysis of optimized micropump design demonstrated temperature
prediction and control. A) The temperature elevation of chamber 1 during the 0.33
Hz actuation, which is sufficient to provide target flow rate of 100 nL/min. The
chamber temperatures could fluctuate between the wax melting point (in this case,
Nonadecane with melting of ~32 °C) and 5°C lower, which allowed the wax to
melt and solidify during each cycle. This simulation shows the micropump can
work at this frequency without thermal saturation. B) The design provided
effective thermal insulation between the chambers. During a steady state
simulation, the temperatures of chambers 1 and 3 were set at the melting point and
the chamber 2 temperature remained at approximately 9˚C cooler than the melting
point. ............................................................................................................................ 82
Figure 3.11. Fabrication process of the micropump. A) The electronic components for
actuation, temperature control, and wireless communication were assembled on
the front side of the PCB. B) The micro-heaters and thermistors were assembled
on the backside of the PCB, forming a template for three linear chambers and a
catheter microtubing. C) A commercially available catheter microtubing (250μm
OD, 125μm ID) was placed within a printed template. A precise volume of wax
was placed in each chamber in contact with the microtubing and integrated microheater and thermistor. D) The chambers were covered with a rigid resin. .................. 85
Figure 3.12. A) Photograph of the peristaltic micropump with a commercially available
microcatheter and a 3D-printed structure around it on the back of a printed circuit
board. B) The pump was characterized at 10–100 nl/min flow rates and 0–5 kPa
back pressures optimized for the target intracochlear drug delivery application.
Each data point is the mean value of five trials; error bars represent one standard

x

deviation. C) Performance of the pump at 50 nL/min (required for the in vivo test)
for 20 min indicated precise flow rate control. D) Characterization of micropump
resolution at flow rates of 10, 50, and 100 nL/min; the greatest resolution was 2.39
nL/min. Each point is the mean value of five trials; error bars represent one
standard deviation. E) Pump performance at different frequencies and ambient
temperatures. The variation in flow rate was not statistically significant by
changing the ambient temperature by ±3˚C. Each point is the mean value of five
one-min trials; error bars represent one standard deviation. ........................................ 95
Figure 3.13. In vivo intracochlear delivery of sodium salicylate elevated otoacoustic emission
thresholds from 8 to 51 kHz in three mice. In each mouse, the cannula was
implanted near the round window via a bullaostomy. A) Mean DPOAE threshold
shifts from three mice recorded during 20 min after the start of a salicylate infusion.
DPOAE thresholds systematically increased as a function of perfusion time from
the start of the perfusion (0 min) to 20 min. B) The mean DPOAE threshold shift
for the most basal cochlear region, 51 kHz plotted as a function of time following
the start of the sodium salicylate infusion. Post 20 and post 40 min denote the
measurement times after turning off the pump. PS = post surgery; post 20 = 20
min after stopping infusion; post 40 = 40 min after stopping infusion. ....................... 97
Figure 3.14. DPOAE threshold shift (51 kHz) for the most basal cochlear region, following
sodium salicylate infusion, plotted as a function of time for three micropumps. The
time points refer to DPOAE acquired at PS-post surgery, 0 min – start of pumping,
and 10 and 20 min following the onset of pumping. ................................................... 98
Figure 4.1. One representative sample from the last day of an 11-day cell growth period. The
five areas indicating where cells were counted are illustrated. The mean values
from five areas were calculated, and then the total cell counts among the 10
samples from Day 11 were averaged to obtain one cell count value for Day 11.
Similar analyses were performed on Days 1–10. The data were plotted to obtain
the cell growth curves ................................................................................................ 102
Figure 4.2. A) Micrographs taken from the center of a sample (Section 3 in Figure 4.1) at Day
1, Day 2, Day 5, Day 7, Day 8, and Day 11. The photographs illustrate how the
numbers of cells increased each day, and that cell morphology became more
developed over time. B) Cell growth curve of the human mammary epithelial cells.
The curve was similar to the expected exponential growth curve. This result
indicated that the cell line used for the cell viability biocompatibility assays met
the healthy growth metrics requirement. The curve followed the trend line (blue
line, y= 23.322 e0.3262x) exponential curve, residual value = 0.95. C) Micrograph
illustrates the polyurethane-based catheter tubing placed in the well containing
human mammary epithelial cells. Under experimental biocompatibility conditions,
cells were harvested from the regions directly around the tubing and cell viability
assays were performed. The results were quantitatively compared to the cells in
the control dishes, which were presented in Figure 4.1, Figure 4.2A, and B. D)
Histogram results indicate there is no statistically significant difference in the cell
health and viability quantitative measurements for the human mammary epithelial
cells, with and without the pump components. The “materials” measurements
represent a comparison condition where only the components were in the dish,
with no cells. Under the “materials & cells” conditions, the components were

xi

placed in the cell culture dishes on Day 0; the components were in the dishes as
the cell size and number increased over a period of 7 days. The far-right bar on the
three histograms is the “Cells only” Control condition (i.e., no pump components
were present in the dish during cell growth).............................................................. 107
Figure 4.3. Photos showing the system following subcutaneous implantation in a CBA mouse
following one month of implantation. Note the lack of inflammation or infection
in the skin surrounding the implant area, and the mouse health and behavior was
normal. ....................................................................................................................... 108
Figure 5.1. A) Conceptual schematic of the microreservoir. The structure of the microreservoir
is made of two main sections: the refill port for refilling the microreservoir by
injections through a septum, and the cavity area for storing the drug. The structure
is made with 3D-printing technology using a biocompatible resin, enabling
printing micro-scale features that are readily scalable, enabling applications from
mice to humans. B) The septum cap incorporates a compression ring that causes
the septum to be compressed both vertically and laterally. The vertical
compression ensures sealing from the bottom and holds the septum during multiple
injections. The lateral compression induces internal stress in the septum to improve
its performance with numerous injections without leakage. This feature enables
reduction of the septum thickness while maintaining high resistance to numerous
punctures. C) The cavity membrane is made of a pre-formed dome-shape thin
parylene layer, enabling negligible restoring force after partial/full discharge of the
cavity when the pumping mechanism is switched off. This feature facilitates the
integration of the microreservoir to normally-open micropumps and eliminates the
necessity of using check valves for low-backpressure environments. Further, when
integrated to normally-close micropumps, the constant backpressure on the check
valves are eliminated and the pumping efficiency increases. Finally, since the
entire internal surface of the microreservoir, including the septum and the cavity
membrane, is coated with a parylene layer, long-term biocompatibility for drug
storing is ensured. ...................................................................................................... 117
Figure 5.2. A cut-view schematic of the microreservoir fabrication process. 1) The substrate
of the microreservoir was 3D-printed using a biocompatible resin, followed by 1
µm parylene-C deposition. 2)A microtubing (250 μm OD, 125 μm ID) was inserted
into the substrate outlet port and sealed in place with cyanoacrylate. The substrate
was placed on a cold plate at room temperature and molten PEG at 70 °C was
deposited on the cavity area to solidify and create the microreservoir volume. This
was followed by another Parylene-C deposition to create the deformable
microreservoir membrane capable of withstanding 100 kPa backpressure. 3) A
silicone gasket was fabricated using a micro-molding technique and was placed
within the cavity around the PEG dome. A 3D-printed Parylene-C coated cap was
affixed on top of the cavity area with cyanoacrylate, compressing the O-ring to
reinforce sealing between the two Parylene-C layers, and to protect the cavity from
mechanical stress. The cap has vents to allow egress/ingress of air or fluid between
the membrane and the cap during filling/discharging. 4) The substrate was placed
on a hotplate at 70 °C to melt the PEG and wash it by gentle injection of 100 mL
of DI water at 70 °C 5) A 2.5-mm diameter, 1-mm-thick septum made of longterm implantable silicone rubber was micro-molded and coated with parylene-C.
The septum was placed in the refilling port (2.5 mm diameter). 6) A 3D-printed,

xii

Parylene-C coated septum cap with an extruded compression (2.5 mm OD, 1.8 mm
ID) was affixed on top of the septum with cyanoacrylate to compress the septum
providing a sealing force on the bottom and sides while enhancing the self-healing
properties when punctured with refilling needles. 7) schematic cut view of the
fabricated microreservoir being filled by a refilling needle. 8) A schematic fullbody view of the microreservoir. ............................................................................... 121
Figure 5.3. Benchtop characterization test setup for septum (Top) and cavity membrane
(Bottom) characterization. Septum characterization: A) A custom-made 3Dprinted pneumatic puncture device. Inset: a 30 Ga non-coring 12° beveled needle
used for puncture test. B) The septum test samples were punctured in a single point
following a logarithmic number of punctures with the puncture device fed by a 0.2
Hz sine wave signal. C) With the needle extracted, backpressure was gradually
increased to 100 kPa while the fluid front displacement was quantified by visual
observation under a microscope. Cavity characterization: D) Following the filling
of the microreservoir cavity and fluidically blocking the inlet, the fluid in the cavity
membrane was pumped out via a static pneumatic pressure on the membrane to
provide forward flow. E) The pneumatic pressure was released, and the backflow
in the tubing due to the restoring force of the membrane was quantified under a
microscope. Different tubing sizes were used for the three different cavity
capacities (1, 10, 100 µL) to maintain a minimum resolution of 0.1% of the full
microreservoir capacity. ............................................................................................ 126
Figure 5.4. A) Photograph of completed microreservoirs with capacities of 1, 10, 100 µL,
showing the scalability of the design and fabrication process. B) Septum
characterization results show that the samples without the compression ring leaked
at less than 5 kPa backpressure with just one puncture with a 30 Ga needle. Adding
a compression ring to the septum cap increased the number of punctures before
failure to ~65,000 at 100 kPa backpressure when puncturing with a 30 Ga needle.
This design can provide no leakage up to 55 injections at 100 kPa backpressure
when punctured by a 27 Ga needle. N=4, mean ± SD. C) Comparison between the
fabricated volume and the target volume shows 1.5 ± 0.09, 9.63 ± 0.12, and 100.04
± 9.43 for target volumes of 1, 10, and 100 µL. N=4, mean ± SD. D) The average
results of the backflow due to restoring force for three different capacities of 1, 10,
and 100 µL normalized by the total volume of each cavity. The results show that
the overall backflow is not significant (2% average) and occurs quickly (< 2 min)
after pneumatic pressure release, suggesting stable behavior of the cavity
membrane in long-term. The last step of the experiment shows the total extraction
percentage. N=27, mean ± SD. .................................................................................. 130
Figure 6.1. Fluid in a 12° beveled non-coring 30 Ga needle and trapped air between it and the
septum. The trapped air can introduce air bubbles to the system as big as 7.5 nL. ... 139
Figure 6.2. A) Photograph of the microreservoir integrated with a micropump for inner ear
drug delivery that was recently reported [60]. The microsystem is optimized for
subcutaneous implantation in mice with an overall thickness of 3 mm. B)
Photograph of a microsystem before implantation demonstrates thinness of the
microsystem, which makes it optimized for subcutaneous implantation in mice.
Inset: An image of the microsystem after implantation via insertion of the
microsystem in a small incision made in the center of the upper back of a mouse.

xiii

C) Side view and top view of a microsystem implanted showing the visibility of
the refilling port. D) Results of the mean threshold shift of the most basal region
(F2 = 51.4 kHz) for implanted microsystems and the syringe pump show perfect
consistency, demonstrating successful performance of the microsystem (N=6 for
syringe pumps, N=2 for microsystems). E) A typical 60 µm-thick section of the
skin surrounding the microsystem shows no sign of any active inflammatory cells.
A fibrotic layer (pink) fully encapsulated the microsystem. ..................................... 143
Figure 6.3. Self-priming of the micropump at 50 nL/min in presence of ~60 nL air bubble. A)
t = 0, the bubble is introduced to the micropump. B) t = 20 s, the micropump sucks
in the liquid. C) t = 40 s, the micropump pushes the fluid further toward
downstream. D) t = 60 s, the micropump pushed the bubble toward the downstream
completely. ................................................................................................................ 144
Figure 7.1. A schematic view of the proposed single actuator micropump with check valves.
A filter between the refill port and the cavity area reduces possibilities of infections
due to refills. One phase-change actuator pushes the microtubing and moves the
working fluid, while two in-line check valves rectify the fluid flow in the
microtubing. An outlet port connects the pump to a microtubing with a larger
diameter in the micropump end and orders of magnitude smaller diameter in the
downstream. Inset) A photograph of the fitting at the outlet port, which has been
tested at 200 kPa for 48 hrs without leakage. ............................................................ 150
Figure 7.2. A schematic view of a Pneumatic-driven pump for LOC applications. .................... 152
Figure A.1. The model geometry of the micropump used in the COMSOL simulation. The
resin around the chambers and on top of it are not shown. The resistive heaters in
the chambers are covered with wax. All four layers of the copper are considered in
the geometry model, but in this figure they are masked with PCB. .......................... 181
Figure A.2. Consistency between numerical and experimental data where two side chambers
are on and the middle chamber is off shows validity of the model to predict steady
state conditions. ......................................................................................................... 182
Figure A.3. Consistency between numerical and experimental data where two side chambers
are on for 10 s and off for 10 s, while the middle chamber is off shows validity of
the model to predict transient conditions. .................................................................. 183
Figure A.4. A sample peristaltic cycle of chamber 1. Similar cycles are defined for chambers
2 and 3 with phase-lags. ............................................................................................ 187
Figure A.5. Comparison of the temperature elevation of the wax in chamber 1 shows that
spreading the copper increases the actuation frequency by 21%............................... 190
Figure A.6. Temperature distribution of the wax in chamber 1, at the time that it reaches the
set temperature shows a significant improve in the homogeneity of the temperature
using the Spread copper, compared to Reference. Spread copper reduces the
temperature standard deviation by 35%. ................................................................... 190
Figure A.7. Reducing the thickness of the copper layers on the PCB increases the operation
frequency by 55% due to reduced thermal mass and heat transfer away from the
chamber. .................................................................................................................... 191

xiv

List Of Tables
Table 2.1. Rectification methods of reciprocating mechanical micropumps. ................................ 13
Table 2.2. Qualitative comparison of different actuation methods for PMPs. ............................... 55
Table 2.3. Summary of significant PMPs with their experimental output. The data is arranged
by groups in based on “actuation method” and in chronological order. ...................... 59
Table 3.1. Targets for implantable microsystem design for inner drug delivery ........................... 70
Table 7.1. Comparison of current microsystem with other state of the art and commercially
available microsystems for inner ear drug delivery. .................................................. 156
Table A.1. Components and their material properties used in the COMSOL heat transfer
simulation. ................................................................................................................. 185

xv

Chapter 1

Introduction To Inner Ear Drug
Delivery

1.1 Introduction

In this chapter a brief introduction for inner ear drug delivery is presented. In the ‘auditory
dysfunction therapy development’ section major auditory issues and available therapies are
discussed, along with the necessity of therapy development. Benefits and challenges of
site-directed delivery methods in mice are presented in the next sections. Finally, the
advantages and challenges of microsystem-based delivery methods are discussed, along
with objectives of this thesis.
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1.2 Auditory dysfunction therapy development

Hearing loss affects 466 million people worldwide as estimated by the World Health
Organization in 2018 [1]. Sensorineural hearing loss (SNHL) is of the most common inner
ear diseases [2], which is caused by damage to or death of hair cells due to aging disease,
drug ototoxicity, or noise exposure. SNHL accounts for 90% of permanent hearing loss,
affecting approximately 278 million worldwide [3]. According to the American SpeechLanguage-Hearing Association, SNHL rarely responds to current medical or surgical
therapies.
Current treatments for hearing loss include cochlear implants or hearing aids, which do not
address the biological cause of hearing loss, instead reduces the symptoms by amplifying
sound with low efficacy. There are several bases for hearing loss, such as hair cell damage
due to aging and noise damage, which each of them needs targeted therapy. To address
these biological bases gene, stem cell and pharmaceutical-based therapies for auditory
dysfunction have been investigated. Gene-based therapies can ameliorate or cure some
types of auditory dysfunctions, which can be delivered either through systemic or sitedirected delivery.
Conventional routes for inner ear drug delivery (i.e., injections and oral delivery) are
relatively ineffective, principally because of the blood-cochlear barrier [4]–[6], delivery to
unintended targets, unknown cochlear drug concentration levels, and toxicity [2].
Furthermore, to deliver a small amount of therapeutic compound a large amount of it
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should be taken by the patient (orally, or injection). Finally, due to effects of metabolism
and blood circulation on the dose profile, it is a challenge to control the dose profile. In a
review paper about bioMEMS devices for drug delivery, Nuxoll & Siegel concluded that
success of therapeutic treatments requires site-directed delivery with ‘proper temporal
presentation’ [7]. Site-directed therapies require the desired therapeutics to be delivered in
the target site with a controlled dose profile, allowing efficacy improvement and systemic
side-effect reduction.

1.3 Site-directed delivery: Benefits and challenges

Site-directed delivery of therapeutic agents with controlled dose profiles has significantly
influenced the quality and success of disease treatment [8]. Akil et al. showed the potential
benefits of site-directed for deafness research by using gene therapy to restore hearing to a
deaf mouse, a mouse model of congenital deafness in human [9]. Delivery was
accomplished with microinjections into the cochlea either via an apical cochleostomy or
through the round window membrane. Studies like this demonstrate the necessity of
delivery directly to the cochlea for therapy development in deafness research.
Targeting the cochlea, Izumikawa et al. successfully regrown auditory hair cells in guinea
pigs via intracochlear Atoh1 gene infusion [10]. The importance of site-directed delivery
of pharmaceuticals and gene therapies is highlighted in this study. Site-directed,
programmable drug delivery systems are needed to leverage recent advances in protective
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and restorative biotherapies that have created new opportunities to treat auditory and
vestibular disorders [11]–[13].
On the other hand, the inner ear is one of the most challenging drug delivery target organs
due to its small size and relative inaccessibility. It is surrounded by the temporal bone,
which is the hardest bone in the body and the diameters of the coiled tubes within the inner
ear are < 2 mm for human. The cellular machinery within the cochlea (e.g., the hair cells
in the organ of Corti) are extremely sensitive to mechanical and chemical damage [2].

1.4 Mouse model system: Benefits and challenges

Rats, chinchillas, and guinea pigs are of interest of researchers [14], mainly due to their
larger size, routine surgical approaches to access the cochlea, and larger cochlear volume
which makes fluidic access easier. On the other hand, mouse models are beneficial to inner
ear studies mainly because their genome is fully mapped, and transgenic mice are available
to model human disease in a controlled model system for therapy development.
Transgenic technology has assisted researchers for the in vivo study of different genes on
auditory function, by enabling gene function studies and modeling human diseases. For
instance, Schütz et al. investigated human bilateral middle/high frequency hearing loss,
utilizing transgenic mice to replicate mutation in the GJB2 and GJB6 genes, which are the
most common cause of prelingual deafness in humans not associated with a syndrome [15].
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Further, Inbred mouse strains have been identified to model deafness and presbycusis [16],
which is the most common type of SNHL caused by the natural aging of the auditory
system. The capacity for regeneration of the same anomaly that causes human deafness in
a mouse model enables gene-therapy approach for this type of deafness. Mouse model
provides a capacity to study human diseases in transgenic and mutant animals, which
makes it a more desirable animal model than large animals such as guinea pigs.
However, working with mouse models presents new and significant challenges for inner
ear drug delivery due to the extremely small size of the mouse cochlea. For instance, the
mouse cochlea contains approximately 620 nL of fluid (perilymph)[17] while the human
cochlea contains 150-200 µL perilymph [18], [19]. This small volume of perilymph in the
cochlea makes it vulnerable to prolonged high-flow rate intracochlear delivery [20], [21].
Further, the small size of the cochlea restrains surgical approaches and fluidic interfacing
with the mouse cochlea (e.g. [22]).

1.5 Microsystems for inner ear drug delivery

Therapy development is optimized by multiple agent deliveries at desired flow rates and
duration for maximum impact. This has been traditionally accomplished only with animals
tethered to a syringe as described in [23]–[25]. On the other hand, an implantable pump
technology allows user control of the rate and duration of delivery. Implantable devices
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facilitate chronic studies by allowing the animal to recover, while syringe pumps only
allow acute studies.
To address the challenges regarding running chronic experiments on mice, and for safe and
efficacious inner ear delivery, microsystems-based approaches have emerged [8], [26]–
[29]. Such systems require precise and programmable ultra-low flow rates with a
controllable profile, due to the small volume of perilymph and high sensitivity of the
auditory organ to possible damage. Further, a pumping system must be sufficiently small
and lightweight, with a planar form factor [30] to be subcutaneously implanted. Also, the
system must be robust enough to provide highly controlled, time-sequenced, and ultra-low
flow rates over periods of months to years [2], with the capability of remote
activation/deactivation, and programming for automated delivery [13].
These and other considerations limit the applicability of many commercially available
inner ear drug delivery microsystems-based devices. Current osmotic pumps (e.g., Alzet®
micropumps) have been used for preclinical experiments for inner ear delivery in larger
mammals, including some rodents [14], [31]–[33]. However, osmotic pumps lack delivery
precision and cannot be started or stopped, nor can the flow rate be changed once the
infusion is started. Recently, iPrecio® SMP-300 peristaltic micropump was used for
infusion of fluorescein isothiocyanate-dextran-labeled dextran as a concentration marker
into guinea pig cochlea, using a coupler to connect the tubing of the micropump tubing to
a microcatheter [34]. Although these micropumps can provide controlled low flow rates,
the overall size and the tubing dimensions are prohibitive for practical subcutaneous
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implantation in smaller rodents and mice. Further, the weight of the micropump is 3.3
grams, which is too large for implantation in mice.
Recently a team from Draper Laboratory and the Massachusetts Eye and Ear Institute
developed a head-mount reciprocating delivery system for direct intracochlear delivery in
guinea pigs utilizing conventional machining and UV laser cutting [13], [35]. The system
works based on infusion and withdrawal of the drug through the cochlear perilymph.
Although it includes a micropump and a drug reservoir, it is too large for implantation,
even in the guinea pig.
Microelectromechanical system technologies (MEMS) have also been used for fabrication
of drug delivery microsystems [36]. In 2016, our laboratory reported the development of a
miniaturized planar MEMS-based peristaltic micropump for nanoliter cochlear perfusion
[37]. However, the device had to overcome significant microfluidic interconnection
challenges [38] to allow integration of sub-mm scale in-plane microcatheter tubing without
adding significant micropump volume. In addition to microfluidic interconnect challenges,
incorporation of control electronics to MEMS-based micropumps can be accomplished
either through expensive application specific integrated circuits (ASICS) integrated onchip or via a separate printed circuit board assembly (PCBA) that adds significant bulk to
the assembled system. Scaling of MEMS-based systems also requires modification of the
fabrication processes and masks, creating challenges for scalability to human clinical
translation.
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However, peristalsis remains as one of the most robust mechanisms for drug delivery.
Peristaltic micropumps have been widely used in drug delivery applications due to their
robustness, precise flow rate, bubble tolerance and resistance to high backpressures,
without contaminating the working fluid (drug).

1.6 Objectives

The outcome of this research is intended to be an advanced drug delivery microsystem for
inner ear. The microsystem consists of a microreservoir and a micropump that are
integrated in a single platform. A novel miniaturized, wirelessly controlled, fully
implantable, and scalable phase-change peristaltic micropump that provides programmable
and accurate drug delivery for inner ear applications is developed. A miniature, scalable,
implantable, and refillable microreservoir is developed.
Novel direct-write printing approaches is used to fabricate the micropump around a
catheter microtubing directly on top a Printed Circuit Board (PCB) to integrate the
mechanical and control electronic components. The flow path is leak-free and
biocompatible and is free of complex microfluidic interconnects. Stereolithography 3Dprinting technology is used to build the structure of the microreservoir using a
biocompatible resin to enable biocompatibility and scalability.
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Background on the peristaltic micropumps is provided in Chapter 2 to provide the
necessary information to understand the micropump actuation approach, presented in
Chapter 30. The details of the micropump design are discussed in Chapter 3, including
design concept, control electronics, heat transfer analysis, and fabrication process. Further,
the characterization data for both in vitro and in vivo experiments are presented. In Chapter
4 the details of the biocompatibility of the materials used in the microsystem are presented
along with in vivo data. The details of design, fabrication, and in vitro characterization of
the microreservoir are provided in Chapter 5. The micropump and microreservoir are
integrated and characterized in vivo (Chapter 6). Future work and final remarks are
presented in Chapter 7.

Figure 1.1. A schematic of the integrated microsystem implantation for inner ear drug
delivery.
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Chapter 2

A Review On Peristaltic
Micropumps

2.1 Introduction

In recent decades, microsystems technology has made significant progress, and it has made
an impact on many fields such as biology, biomedical engineering, biochemistry research,
among other research areas. Micropumps are the heart of microfluidics systems since they
provide the necessary power for moving the working fluid in a microfluidic system. In this
work, we use the definition of micropump according to [39], where the prefix ‘micro’ is
considered to be appropriate for devices with prominent features having space dimension
scale in the order of hundreds of microns or smaller. Most micropumps can be categorized
into two groups: mechanical micropumps (with moving parts) and non-mechanical
micropumps (with no moving parts) [39]–[41]. Mechanical micropumps employ
10

reciprocating pistons or oscillating diaphragms to do pressure work on the working fluid
through a deformable and moving boundary in the pumping chamber, while rectification
components such as active or passive check valves at the inlet and outlet control the flow
direction.
Peristalsis is one of the essential physiological transport mechanisms in living organs and
organisms [42], [43], enabling functions such as swallowing, urethral transport, blood flow
in the circulatory system, etc. [44], [45]. This elegant transport mechanism has inspired
researchers to investigate the applicability of peristaltic pumping in the realm of
microfluidic devices. In the literature, peristaltic micropumps (PMPs) are often listed as a
subcategory of mechanical micropumps [46], typically with three or more pumping
chambers that operate in a particular sequence to push a working fluid in a desired direction
within a microfluidic path [36], [39], [41], [46], [47]. The first PMP was introduced by
Smits in 1990, using micro-electromechanical systems (MEMS) fabrication techniques.
The device had a set of three piezoelectric actuators, which used a six-step sequence to
create a peristalsis transport mechanism [48]. This micropump had a maximum flow rate
(Qmax) of 3 µL/min and a maximum pressure (Pmax) of 5.9 kPa.
Since the introduction of PMPs, they have been widely used in various applications such
as cell sorting/counting and cytometry [49], DNA hybridization [50], gas chromatography
[51], droplet microfluidics [52], microfluidic filtration [53]–[55], cell culture [50], [56],
blood transportation [57], morphine detection [58], aeronautics [59], biosampling [60],
implanted artificial sphincter system [61], multi-organ-chip [62]–[65] , parallel processing
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of cell cultures and DNA microarrays [66], and integration to micro total analysis systems
[67]. Further, PMPs have been used for drug delivery, such as implantable drug delivery
systems [68], high-resolution volumetric dosing [69], size-constrained drug delivery [37],
[70]–[73], and insulin delivery [74], [75]. Key features that make PMPs attractive for drug
delivery applications are resistance to high backpressure [76]–[78], bubble tolerance,
endurance [79], self-priming and bi-directional flow capabilities [78].
This review introduces the peristalsis transport mechanism concept using and defines the
different configurations that exist in the literature. This is followed by a discussion on the
most critical parameters for the functionality of PMPs. The different actuation methods
that have been used to achieve such devices are presented with selected examples from the
state-of-the-art of micropumps technology. Finally, the review closes with a discussion,
comparison, and evaluation of the developed PMPs over the past 30 years.

2.2 Peristalsis concept

In the literature, PMPs are either frequently categorized either as a subcategory of
mechanical micropumps listed as actuation methods or vaguely explained among other
micropumps [39], [46], [80], [81]. However, it is important to note that peristalsis is a
rectification method in which the working fluid is sequentially actuated to move from inlet
to outlet. This review considers peristalsis as a rectification method for mechanical
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micropumps, and not as a subcategory of mechanical micropumps [40], [41], [82]. Table
2.1 shows a categorized summary of rectification methods for mechanical micropumps.

Table 2.1. Rectification methods of reciprocating mechanical micropumps.
Active (e.g., cantilever, diaphragm)
Dynamic Valves
Passive (e.g., flip valves, check valves)
Active (e.g., laser, local heating)
Static Valves
Passive (e.g., nozzle/diffuser)
Discrete (e.g., multiple chamber/diaphragm configuration)
Peristalsis
Continuous (e.g., DC motor-driven rollers on microchannels)

The PMPs can be categorized by the fluidic channel configuration either as a continuouschannel or discrete-channel PMP. A continuous-channel PMP design, has its deflecting
actuators fabricated around or along a single microtubing (Figure 2.1a), while a discretechannel PMP is composed by two or more layers to create a microfluidic channel(Figure
2.1b). Typically, discrete-channel PMPs are designed with ports to connect to other
elements in a larger system. The multi-layer design approach used for the discrete-channel
PMPs usually increases the complexity of the fabrication. This introduces challenges that
need to be addressed for a successful device fabrication such as having a strong bond
between layers to seal the microchannels and to avoid leakage within the device, layers
alignment, channel clogging and addition of port interconnections. In addition, the
interface with other elements in the system can increase dead volume at the port
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connection, and sometimes even making a port connection impossible when working with
microdevices with significant small dimensions (e.g., [38]).

Figure 2.1. Examples of a) a discrete-channel (adapted from [37]) and b) a continuouschannel PMPs (adapted from [53]).

Actuation of the PMPs can also be classified into two general schemes regarding the
transportation of the fluid: continuous and discrete. In the continuous scheme the actuator
moves along the fluid path (e.g., PMPs with rollers or cams [74], [83]) while in the discrete
ones the actuators move perpendicular to the fluid path (e.g., PMPs with piezoelectric or
pneumatic actuators [84]–[88]), see Figure 2.2. The operation concept of continuousscheme PMPs is usually based on the miniaturization of peristaltic pumps. Although the
continuous-scheme concept of PMPs has been improved in the past two decades, most of
the PMPs in the literature are discrete-scheme, which fits well with the microscale
fabrication processes and actuation methods.
In the literature PMPs are usually defined as micropumps with three or more chambers
[36], [39], [46], [89]] (Figure 2.2B, C), which are the most common type of the PMPs.
However, PMPs with multiple actuators require complicated multiphase excitation
controllers limiting their functionality in potential applications. Therefore, researchers
14

have investigated PMPs with one or two actuators [90], [91]. One of the first two-chamber
PMPs was introduced by Berg et al. in 2003 [79], with a structure similar to Figure 2.2A.
In this study, two PMPs were developed using two and three actuators, while other
parameters remain identical. The micropump was fabricated on glass and PDMS
(Polydimethylsiloxane) and used pneumatic pressure as the actuation source. The results
show that a two-chamber PMP can provide up to 94% of the flow rate and 73% of the back
pressure of the counterpart three-chamber PMP. The study suggests that two-stage PMPs
may be a more viable choice in limited chip area conditions, or where the backpressure is
low. In 2007, another group reported a backpressure-independent piezoelectric PMP
designed for an optimized low flow regime range from 0.1 - 50 µL/min using two
chambers[76].
In a discrete-scheme/discrete-channel PMP with a single driving diaphragm and two active
valves (e.g., Figure 2.2B), an optimal phase sequence implementation of the diaphragm
will induce a peristaltic motion, which can be approximated to a traveling wave. The fluid
is set in motion due to the transferred momentum initiated by the diaphragm deflection,
without the use of any rectification elements. Since rectification is the prime function of
the chambers at the inlet and outlet ports (i.e., valves), this type of PMPs has not been
considered as peristaltic devices by some research groups [43]. However, the fluid
displacement contribution of these valves can be significant depending on the device
design. Therefore, this PMP configuration is often referred as a “peristaltic micropump”
by other groups [41], [48], [92]–[97]. All in all, the exact definition of PMPs can be
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questionable. In this review, the micropumps with one diaphragm and two valves are also
considered PMPs, due to the contribution of the valves in the pumping action.
Single-actuator PMPs (SAPMPs) have also been developed to eliminate the necessity of
multiphase controllers. One type of SAPMPs have one actuator and one actuation site,
where the created momentum is transferred to the fluid by a transverse motion of the
diaphragm in direct contact with the fluid. The second type, have one actuator and its
actuation is transferred to three or more actuation sites [98], [99]( Figure 2.2D). The
sequential motion can be realized either by the mechanical properties of a membrane
[100]–[103] or by an actuator [104]–[106]. All the reported SAPMPs with this structure
are either pneumatic-driven [98], [99], [107], [108] or vacuum-driven [90]. Peristalsis
occurs in SAPMPs by using the fluidic resistance of the microfluidic path between the
chambers, which enables the required phased lag (Δϕ) in the actuated system.
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Figure 2.2. Classification of different rectification methods that have been used for PMPs in
the literature. In this table, the fluid channel is shown to be discrete for simplification.
However, this is not the case for all PMPs. Some pumps use a microtubing/tubing and make
the structure around it.
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2.3 Significant parameters in peristalsis

Many researchers explored the effect of different parameters on the operation of the PMPs,
such as the actuation frequency, the number of chambers, sequence, phase difference, and
the working fluid [96], [109]–[112]. One simple way to understand the effect of different
parameters affecting the flow rate can be formulated by equation (2.1):
Q = ΔV × f

(2.1)

Where ΔV (net volume) stands for the net fluid volume being moved from inlet to outlet
by the PMP in a single cycle, f (frequency) stands for the number of cycles in each second,
and Q is the flow rate. One way of increasing the flow rate using equation (2.1) is to
increase the actuation frequency. Although the equation suggests a linear relationship
between the flow rate and the frequency, it is not always the case. The increase in the flow
rate due to increasing the frequency depends on the operation conditions such as the
response time of the pumping diaphragm, the actuation time of each pumping chamber,
and the flow conditions at the inlet and the outlet of the pump, etc. The other way to
increase the flow rate is to increase ΔV. The significant factors that influence the net volume
are stroke volume (Vstroke), sequence, phase difference, and number of chambers. In this
section, all these elements are discussed, along with the effect of the working fluid on the
functionality of the PMPs.
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2.3.1 Actuation frequency

One of the best tools to control a PMP after its fabrication is the tuning of the actuation
frequency. A noticeable characteristic behavior can be observed among several variations
of PMPs investigated in this study: the flow rate increases almost linearly with the increase
of the actuation frequency in the relatively low-frequency range, followed by a maximum
flow rate (at fQmax), and then the flow rate decreases with a further increase of the actuation
frequency. Figure 2.3 shows this trend among nine different PMPs with different actuation
methods (e.g., piezoelectric, DC motor, etc.). The average line clearly shows this behavior,
which is consistent with the graphs reported elsewhere [80], suggesting that this is expected
from all micropumps and not just for the PMPs.
This relation enables an effective and reliable way of controlling the flow rate in the linear
range. This behavior can be a function of geometry, membrane material and response time
of the chambers (which is a function of geometry and material of the chamber, and the
actuation method). In [48], the authors discuss that the descending curvature of the flow
rate-frequency curve is attributed to the viscosity of the water, as the water resists to be
pushed through narrow channels. Further, the actuation amplitude of the chambers is a
function of the actuation frequency, in different actuation methods such as piezoelectric
and thermo-pneumatic [77]. For instance, in a thermo-pneumatic PMP, the actuation
amplitude starts to decrease at frequencies higher than fQmax because of the decrease in the
actuation amplitude of the membrane due to insufficient heating [113]. In some cases, the
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actuation frequency is limited to the release time of the membrane. For example, in a
pneumatic PMP, the maximum flow rate is constrained by the release time of the
compressed air. At high frequencies, the air cannot be released properly, causing a decrease
in the flow rate [99].

Figure 2.3. Typical Q-f curve for PMPs. The curve shows an average of Q-f curve for nine
different PMPs. The flow rates and frequencies are normalized to the values at maximum
flow rate. Most of the reports present the linear section of the curve.
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2.3.2 Stroke volume

Optimization of the stroke volume is another way to improve the net volume (ΔV) propelled
through the system in one cycle. Stroke volume is defined as the volume of the working
fluid being swept by each chamber in one cycle. In other words, stroke volume is the
difference between the maximum and minimum chamber volume as the membrane actuates
in a peristaltic cycle. As the stroke volume increases with the increase of the membrane
displacement amplitude, the dead volume decreases. The dead volume is defined as the
volume in each chamber that is not swept by the membrane.
The key parameters affecting the stroke volume are the geometry of the chambers, the
mechanical properties of the membrane, the working fluid, and the actuation mechanism.
Geometry of the PMP structure affects stroke volume by several factors such as size and
shape of pumping chambers [114], [115], diaphragm cross-section (e.g. [116], [117]) and
dimensions of microchannels (e.g. [114], [118]). It is worth to mention that an optimized
geometry can reduce the dead volume (e.g. [117]). Mechanical properties of the membrane
such as Young's modulus, Poisson's ratio, and viscoelasticity affect the displacement
amplitude and response time of the membrane (e.g. [119]). Further, the actuation
mechanism defines the magnitude and frequency of force applied to the membrane, which
directly impacts the stroke volume (e.g. [117]). The number of parameters impacting the
stroke volume suggests that they should be optimized for each specific design depending
on the application.
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Several of these parameters have been considered by researchers in analytical and
experimental approaches. Huang et al. analyzed the effects of geometry on an S-shaped
SAPMP [118]. They changed the width and length of the pneumatic microchannel. They
found that the maximum flow rate increased by increasing the actuation length up to a
specific point, and then it reduced, suggesting an optimized actuation length for the system.
The optimized actuation length in this particular example is due to the increase in the time
needed to actuate the pneumatic pressure. Increasing the width of the chamber also has an
optimized flow rate. In both cases, the flow rate follows similar curves, suggesting that the
main affecting element is the fluidic resistance. Wang and Lee reported the effects of
actuation pressure in a pneumatic-driven PMP [99]. In one of their experiments, they tested
actuation pressures of 10, 15, and 20 psi using an S-shaped SAPMP with five intersections,
at frequencies ranging from 0 to 20 Hz. They found that increasing the actuation pressure
from 10 to 15 and 20 psi increases the maximum flow rate by 58% and 21% respectively
due to greater membrane displacement, and therefore, larger stroke volume. Lee et al.
developed a novel fabrication method to reduce the dead volume in a PMP with an
electrostatic actuation mechanism for a gas chromatography application [120]. In this
study, a 3D fabrication technique known as detachment lithography was employed to
fabricate a stepwise chamber to minimize the dead volume.
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2.3.3 Working fluid

Although working fluid is not one of the structural or functional elements of a PMP, it can
affect the stroke volume significantly. Thus, it should be considered by the researchers and
engineers for the design and fabrication of a PMP. Viscosity is the dominant reason for the
effect of the working fluid on the volumetric flow rate. In 2005 Goldschmidtböing et al.
developed a generic analytical model for micro-diaphragm pumps with active valves, in
which fluidic resistance has a direct relation to fluid viscosity since they considered viscous
losses to be dominant [96]. They show that modeling the behavior of PMPs by treating
only the viscous forces at the valves is valid as long as the frequency is relatively low (in
the order of tens of Hz) and the flow regime is laminar, which is the case for most PMPs.
Goulpeau et al. considered the effect of working fluids with different viscosities on the
flow rate of a PDMS-based piezoelectric PMP [121]. There is almost a linear relationship
between the maximum flow rate frequency and maximum flow rate when the viscosity is
increased. They found out that the viscosity of the working fluid controls the low-frequency
working range (<fQmax).
Jeong and Konishi developed a PDMS-based pneumatically-driven PMP with three
chambers, two of them in inlet and outlet [122]. They compared the effect of working fluid
by testing DI water, a mix of DI water and glycerin (glycerin mix), and diffusion pump oil
(oil) with viscosities of 1, 5, and 21.7 cps and densities of 998, 1035, and 939 kg/m3. The
results show that for the glycerin and oil mix, the flow rate reduces by 17% and 88%,
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respectively. Note that the density of glycerin mix is higher than that of DI water, while
the density of the oil is lower than the DI water, but in both cases the flow rates decreased,
suggesting that viscosity is the dominant factor. Vinayakumar et al. found the effects of
using different flow rates in a continuous-channel DC motor-driven PMP [74]. They found
the effects of using Isopropyl Alcohol (IPA), silicone oil, and Dimethylacetamide (DMA)
as the working fluid. Their results show that utilizing IPA, silicone oil, and DMA reduces
the flow rate compared to DI water by 6%, 9%, and 9%, respectively.
The working fluid can also impact the deflection of the membrane. Lee et al. reported the
effects of using air and DI water as working fluid on both the deflection of the membrane
and the flow rate in a piezoelectric PMP [116], [123]. According to this report, when
pumping air the membrane deflection of their circular diaphragm is larger, with an increase
of 397% along with a 371% increase in the flow rate. In a study by Hsu et al., the authors
compared the deflection of membranes and the flow rate in a piezoelectric PMP, using
blood and water as the working fluid [57]. The results show that the use of blood as the
working fluid causes a reduction in diaphragm deformation and flow rate by 66% and 54%,
respectively. The working fluid can also affect the maximum backpressure and the
maximum flow rate frequency of a PMP. Pečar et al. compared the function of their single
actuator piezoelectric PMP working with water and air [104]. It has been found that using
air as the working fluid increased the maximum flow rate frequency and the maximum
flow rate by 100% and 277%, while reduces the maximum back pressure by 82%.
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2.3.4 Sequence and phase difference

The sequence of actuation of the chambers directly affects the flow rate, since it determines
the number of pumped boluses of the working fluid in each cycle. Researchers have
investigated the operating sequence parameter with numerical, computational, or
experimental methods. The optimization of the actuation sequence improves the control of
the flow rate of the PMPs, where the sequence is not embedded as part of the device such
as the PMPs that have magnets or cams on a motor shaft [124] or SAPMPs (e.g. [98], [103],
[104], [106]). This section describes the effect of the sequence variation for PMPs
operation with three and four chambers. Other sequences for operating PMPs with two
chambers (e.g. [79]), and more than four chambers (e.g. [113]) have also been reported.
In 2008, a study compared three phase difference actuation sequences (Figure 2.4) for a
piezoelectric bimorph cantilever-actuated PMP with three chambers [125]. The results
show that the 120° signal provided the highest flow rates and backpressures in different
actuation frequencies, followed by the case of 90° and 60° signals. The reason for this can
be that for the 120° signal, at least one chamber is entirely closed in the whole cycle. In the
case of 90° signal between step two and three, there is a moment in which all three
chambers are open. For the case of 60° signal, the situation is worse: in step three, all three
chambers are open.
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Figure 2.4 Three different sequences have been compared in. The results show that a
maximum flow rate occurs in 120° case, followed by 90° and 60°. The legend represents with
“1” and “0” a closed (actuated) or open (deactivated) chamber, respectively. The arrows
represent the flow direction. “ Adapted from [125]”.

Jang et al. studied different cycles for piezoelectric-driven PMPs with three chambers in
several publications [78], [126], [127]. In all these studies, 191µm thick lead-zirconatetitanate (PZT) bulks were bonded to a glass diaphragm with a diameter of 12mm and
thickness of 191µm, with 200µm deep channels connecting them. The depth of the
chambers was 30µm. Figure 2.5 shows the sequences that have been used in these studies.
The results show that although the maximum membrane displacement is almost equal in
all cases, the maximum flow rates are QA > QB > QC. It is also reported in [78] that at the
maximum flow rate frequency, the same phenomenon occurs at different actuation
voltages. They also show that at 100 Hz the power consumption is almost equal in all cases,
suggesting that the case A and the case B are more power efficient than the case C,
considering their higher flow rate. Finally, they show that the maximum backpressure at
the maximum flow rate frequency, applying a maximum voltage increases by 57% and
70% in cases B and A compared to case C. The same group also published a paper in 2008,
in which every other geometrical element is the same, along with the actuation sequence,
but the chamber thickness is 10 µm, instead of 30 µm which is the case for their previous
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publication [128]. They show that the maximum flow rate is QB > QA > QC. The latter,
shows that the dependency of the flow rate on the actuation sequence is subjective and
needs to be analyzed for each system.

Figure 2.5 Three different sequences were compared in a PZT-driven PMP. Their results
show that the maximum flow rate is for case A, followed by B and C. The legend represents
with “1” and “0” a closed (actuated) or open (deactivated) chamber, respectively. The
arrows represent the flow direction. “Adapted from [78], [126], [127]”

Yang and Liao investigated the effect of actuation sequence on the flow rate of thermopneumatic PMP for three, five, and seven chambers [113]. For the case of three chambers,
they compared a three-phase and four-phase actuation identical to the ones described in
Figure 2.6B and C. They found that in all the frequencies, the flow rate in the case of the
three-phase is larger than the four-phase, with an approximate of 5% difference in the
maximum flow rate frequency. The maximum flow rate frequency is almost equal in both
cases. The results contradict the results found by Jang et al. suggesting a dependency
optimization of the actuation cycling on various parameters, including geometry and the
actuation method. Lee et al. investigated the effect of actuation cycles for an
electrostatically driven PMP with four actuation sites [51]. In this pump, all chambers are
connected, and four actuators are located sequentially. They compared four different
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actuation sequences shown below. The results show that the maximum flow rates are QD
> QC > QB > QA (Figure 2.6).

Figure 2.6. Four different sequences have been compared in an electrostatic PMP.
According to their results, a larger maximum flow rate occurs in cases D, C, B, and A,
respectively. The legend represents with “1” and “0” a closed (actuated) or open
(deactivated) chamber, respectively. The arrows in the channel represent the flow direction.
“Adapted from [51]”

Although many studies consider the effect of different sequences on the flow rate and
maximum backpressure of the PMPs, only a few of them consider the effect of phase-lag,
Δϕ. Leu et al. analyzed the effect of phase difference and the number of chambers on the
flow rate of PMPs using both numerical and experimental approaches [47]. In this study, a
simple sequence was investigated in which chambers close consequently with equal phaselag. In both numerical and experimental studies, they changed the phase-lag from 10° to
120° and found its effect on the flow rate. They found that the optimization of the phaselag can increase the efficiency by up to six-fold. They also found that the optimized phaselag decrease by increasing the number of chambers. Further, the effect of optimization of
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the phase-change increases by increasing the number of chambers (e.g., in the case of the
three chambers optimization, the flow rate increases by 17%, while in the case of eight
chambers the flow rate increase is of 233%).

2.3.5 Number of chambers

A different way of increasing the net volume is to increase the number of chambers, which
can be linearly proportional to the net volume [16], [47]. It should be taken into account
that the increase in the number of chambers increases the number of boluses being pumped
in each cycle if a proper sequence is provided. If we have n phases for n chambers in a
cycle of a sequence in which two chambers are always closed, in each cycle n-2 boluses
are pumped. Also, the increase in the number of chambers increases the overall actuation
time, considering a fix actuation time for each chamber (T). For example, in the case of
three, four, and five chambers in a sequence in which two chambers are always closed, the
number of boluses (V) in each cycle changes from 1V in the case of three chambers, to 2V
and 3V in cases of four and five chambers. Thus, the overall time of a cycle increases from
3T to 4T and 5T, resulting in flow rates of 1/3 Q, 1/2 Q, and 3/5 Q (Q = V/T) for cases of
three, four, and five chambers. Therefore, the total flow rate (Q) is a function of both the
number of boluses and the number of chambers (see Figure 2.7A). This analysis can be
expanded to more chambers, as depicted in Figure 2.7B.
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Wang and Lee developed a pneumatically-driven SAPMP with an S-shaped compressed
air fluid path on top of the working fluid channel [99]. The structure enables peristalsis
based on the phase-lag in closing the chambers due to the time it takes for the compressed
air to travel through the S-shaped fluidic path. In this cycling scheme, the chambers
close/open consecutively due to activation/deactivation of the compressed air. They
studied the effect of increasing the number of intersections (chambers), while the sequence
is inherently fixed. The results show that having five and seven chambers increases the
flow rate by 10% and 15% respectively compared to the case of three chambers.
Conversely, the maximum flow rate frequency reduces by 24% and 47% respectively, due
to the increased time required to close the chambers by increasing the number of
intersections.
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Figure 2.7. a) An ideal comparison in PMPs with three, four, and five chambers showing that
for an increasing number of chambers, the flow rate increases in a nonlinear manner. The
legend represents with “1” and “0” an active or inactive chamber (closed or open channel
respectively), respectively. The arrows in the channel represent the flow direction. V=
boluses, T= cycle time, Q= total flow rate. b) Ideal peristaltic micropump behavior, where the
increase in the number of chambers increases the flow rate. Note: The flow rate is
normalized to the flow rate of a 3-chamber PMP. In all cases, the actuation sequence always
guarantees to have two chambers closed.
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Yang and Liao investigated the effect of increasing the number of chambers from three to
five and seven while a fixed number of phases, in a thermo-pneumatically-driven PDMSglass-based PMP [113]. They found that increasing the number of chambers to five and
seven, reduces the maximum flow rate by 5% and 6% respectively, under zero back
pressure. On the other hand, they showed that increasing the number of chambers a
significant impact on the flow rate in the presence of higher backpressure. They also
showed that increasing the number of chambers increases the maximum working
backpressure by 15% and 29% respectively. Their results suggest that increasing the
number of chambers requires sequence optimization to achieve higher flow rates.
In another study, Lee et al. fabricated a PMP for gas pumping application with a fixed
channel length and several different number of actuators (ranging from 4 to 32)[129]. They
operate their PMPs using electrostatic actuation method, with a four-sequence cycle which
repeats two, four, and eight times for each case of a varied number of electrodes. By
increasing the number of actuators (not chambers) the actuation area decreases, since the
overall length of the channel is fixed. The maximum flow rate occurs with the 16-electrodes
device, suggesting that there is an optimal number of electrodes for a gas micropump. The
existence of an optimal number of chambers occurs due to the compressibility of the gas
[129]. Leu et al. developed numerical and experimental studies to find the effect of both
the number of chambers and phase-lag between chambers [47]. In the numerical model,
they simulated models with identical geometries but a different number of chambers from
three to eight chambers. According to computational results, the maximum flow rate
increases with the increase of the number of chambers.
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2.3.6 Summary of different parameters

PMPs can be optimized based on the requirements of a specific application. Multiple
parameters can affect operation of a PMP by impacting the stroke volume and the actuation
frequency, as expressed in equation (2.1). The challenge is that these parameters are not
independent of each other. For instance, the geometry of the actuation sites, membrane
material, actuation method, and working fluid affect the response time of the actuator,
which defines the minimum time required to actuate the membranes. This direct effect on
the actuation frequency can influence the overall flow rate that can be addressed by
adjusting the cycling and the number of chambers. In the same way, it seems evident that
the stroke volume increases by an increment of diaphragm deformation amplitude, while
it also increases the response time, causing a reduction in the operational frequency. As
another example, the maximum flow rate of a pneumatic PMP is a function of the
compression and release of the air on the membrane. The compression time is controlled
by many factors such as compression pressure, microchannels geometry, etc. The release
time is dependent on several elements, such as membrane diameter, membrane thickness,
membrane material. Although there are multiple analytical, computational, and
experimental [118] studies in the literature, they are all subject-specific. There is no
comprehensive report in the literature that considers the effect of all these parameters and
provide a general rule of thumb or a general formulation for all cases. It is recommended
that for each specific case, the parameters be optimized with analytical, computational, or
experimental methods, considering all the parameters above.
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2.4 Actuation methods

The actuation method defines the energy source and the mechanism to convert this energy
into a displacement of the working fluid. In this section, different actuation methods that
have been used in PMPs are described, with a brief definition of the actuation method and
chronological development of the method in PMPs.

2.4.1 Piezoelectric

Piezoelectric actuation mechanism works based on the internal mechanical stress due to an
applied electric potential. The piezoelectric actuators are fabricated in the form of discs,
bimorphs, or stacks that are bonded to the actuation membranes, or directly deposited on
them or embedded in the membranes. The first PMP was a piezoelectric-driven siliconbased device fabricated using MEMS fabrication technology. The actuation was enabled
with piezoelectric discs on top of glass diaphragms. This pump had a maximum flow rate
of 100μL/min at 15Hz operation frequency under zero back pressure. The maximum
backpressure was 5.9kPa, with a cut-off frequency of 50Hz. In 2001 a mechanical analysis
of piezoelectric PMPs was developed for system design and analysis [68], which was used
to fabricate a piezoelectric PMP in 2003 [130]. In the latter, the authors used PZT discs
actuators to provide a maximum flow rate of 11.34 μL/min at 130 V operation voltage.
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In 2003, Bu et al. provided the design and the analytical evaluation of a piezoelectric-driven
micropump for lab-on-chip (LOC) applications [97], which were utilized in the fabrication
and characterization of the pump [131], [132]. The pump utilized three 200μm thick PZT
discs on glass membranes bonded to a silicon substrate using anodic bonding. The
micropump was able to provide 500μL/min at an operational frequency of 100Hz and 200V
peak to peak. In 2004, another piezoelectric PMP was fabricated with a silicon-glass
structure with a simple fabrication process for controlling biological fluids [116], [123].
Shuichi Takayama’s group used piezoelectric bimorphs to actuate multiple computercontrolled movable pins of a refreshable Braille display, which is a tactile device by the
visually impaired to read computer text [133]. Each pin can function as a valve that can
completely shut the channel by pressing on the silicone rubber medium on the working
fluid. The synchronization of the pump is realized through the Braille display software.
They demonstrated cell seeding and compartmentalization [133], as well as culture media
recirculation [134].
Geipel et al. presented a two-chamber piezoelectric PMP, which operates based on
simultaneous closing of the inlet valve and opening of the outlet valve [76], [135]. The
micropump works at relatively small actuation frequencies (0.5-5Hz) for piezoelectric
PMPs, which shows the idea of two-actuator PMPs can be potentially applicable for slower
actuation methods. The micropump provided a maximum flow rate of 40µL/min at 4Hz of
operating frequency at zero backpressure. They demonstrated a reasonably constant flow
rate over a backpressure range of up to 30kPa. The cut-off backpressure was shown to be
directly dependent on the closing voltage of the outlet valve with a maximum value of
35

100kPa at 140V. The micropump was utilized in a patient-specific drug delivery
application in follow-up research [69], which provided resolutions as high as 10nL. Graf
and Bowser reported a relatively large PMP using soft lithography for fabrication of PDMS
membranes and piezoelectric bimorph cantilevers [125]. They were able to reach a
minimum flow rate of 53 nL/min and maximum attainable backpressure of 35 kPa. Nguyen
et al. developed a PMP using a lightweight piezo-composite actuator, which is a multilayer
composite actuator typically composed of glass-epoxy, carbon epoxy, and PZT layer,
reaching a maximum flow rate of 900 µL/min. They also found a linear relationship
between the maximum back pressure (Pmax) and its operating voltage. In 2011 Trenkle et
al. fabricated a PMP with a disposable pump body and a reusable actuator, working
independent backpressure up to 40 kPa [136] and normally closed up to 100 kPa
backpressure.
Nakahara et al. reported the first single-actuated piezoelectric PMP using a traveling wave
concept [102], [103] (Figure 2.8A). In this design, a single cantilever-type piezoelectric
actuator stimulates an encapsulated incompressible fluid from the bottom, which drives the
fluid in the microchannel on top of the encapsulation. A hydraulic displacement
amplification mechanism is used to amplify the amplitude of the displacement waves,
enabling 1500 µL/min maximum flow rate. In 2014, Pečar et al. reported a single-actuator
single-chamber piezoelectric PMP with PDMS structure [104]. In this design, the inlet port
is placed in the center of the chamber, while the outlet port is placed further in the chamber.
During the excitation, the loosely attached glass membrane and PDMS deform in a
controlled manner in which the inlet and outlet are compressed and expanded in a
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peristaltic sequence (Figure 2.8B). The micropump provided a maximum flow rate of 240
µL/min and a backpressure performance of 36 kPa. Cazorla et al. employed 1.5 µm thick
Sol-gel PZT thin films for piezoelectric actuation, which reduces the driving voltage down
to 24 V [70]–[72], optimized for implantable drug delivery application.

Figure 2.8. a) A Review On Peristaltic MicropumpsCross-sectional and front view of
peristaltic micropump using traveling waves on a polymer membrane [102]. The bottom
membrane of the hydraulic displacement amplification mechanism is vibrated by an
actuator at its edge, and traveling waves are generated in one direction to drive fluid. The
long and thin format of this micropump could be beneficial when it is attached to cathetertype devices. (Adapted from [102]) b) A single-actuation piezoelectric PMP developed by
Pečar et al. [104]. i) suction phase ii) pumping phase. (Adapted from [104])

37

2.4.2 Hydrogel

Hydrogels have unique properties that are of interest to researchers due to its stimulisensitive characteristic and its relatively ease of fabrication. In 2008, Richter et al.
presented a work on a micropump with working principle based on the swelling and
shrinkage of temperature-sensitive hydrogels. Hydrogels can be used in automatic and
electronically controlled systems. The authors were able to use hydrogels for the
implementation of a micropump for the first time, which was capable to operate in two
modes: peristaltic and pulsatile. Their PMP was able to achieve a maximum flow rate of
4.5µl/min and a back pressure of 15kPa. Their micropump is composed by a microgel
based actuator that is placed in a separate actuation layer, and two active microvalves
[Ritcher 2008 - Hydrogel] (see Figure 2.9).

Figure 2.9. Hydrogel PMP a) Schematic set-up. b) Operating principle. (Adapted from
[Ritcher 2008 - Hydrogel]) c) Photograph. (Reproduced from [137] with permission from the
Royal Society of Chemistry.)
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2.4.3 DC or step motor

DC motors are one of the most popular actuation mechanisms due to their simplicity,
relatively low power consumption, and rotational motion which can provide peristalsis
with reasonably straightforward configurations. To transfer the momentum from the motor
to the working fluid, various transmission methods have been implemented, such as
magnetic balls, magnets and magnetic fluid, cam-follower, and rollers, which are explained
in this section.

2.4.3.1 Magnetic transmission

In this method of transmission, the rotational motion of the DC motor is transferred to the
working fluid using magnetic force with either discrete or continuous scheme. In 2004, a
DC-driven micropump was reported in which three permanent magnets were staggermounted on the shaft of a DC motor, which actuated three chambers that have embedded
permanent magnetic rods within the PDMS membrane [124], [138] (see Figure 2.10). The
locations of the permanent magnets on the shaft were set to provide peristalsis. The
fabricated PDMS-based micropump provides flow rates up to 24 µL/min at a significant
low voltage (1 V).
Magnetic fluid has also been employed as a transmission mechanism to transfer the
momentum from a DC-motor to the working fluid, in a continuous scheme. In this
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mechanism, plugs of the magnetic fluid that are attracted by a permanent magnet push the
fluid using a DC-motor that moves the permanent magnet. The magnetic fluid plug can
work as a valve when the pump is off using a stationary permanent magnet, enabling a
normally closed valve. In 2001, Hatch et al. fabricated a ferrofluidic magnetic PMP in
which the ferrofluid is in contact with the working fluid, but the fluids are immiscible
[139]( see Figure 2.10). This PMP reached a maximum flow rate of 46 µL/min and
maximum backpressure of 1.2 kPa. Kim et al. improved the concept by separating the
magnetic fluid and the working fluid using a silicone rubber membrane to avoid
contamination [140], [141] . In 2008 Yobas et al. reported a self-priming and bubbletolerant PMP with transmission through three spring-loaded stainless-steel ball bearings
rolling on a diaphragm over the microfluidic channel, optimized for a large range of flow
rate and small dead volume [117]. By optimization of the number and size of the ball
bearings, they were able to reach to a maximum flow rate of ~350 µL/min at 10 rpm (0.17
Hz). Du et al. improved the design by miniaturization of the Yobas et al. work while
keeping the broad range of flow rate [142].
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Figure 2.10. a) A DC-motor PMP with magnetic transmission (Adapted from [138]). b) A PMP
with DC-motor as the actuator and magnetic fluid as the transmission medium. The
magnetic fluid rotates with permanent magnets attached to the DC motor to provide a
peristaltic pumping (Adapted from [139]).

2.4.3.2 Roller transmission

Roller-type DC motor mechanism provides continuous-scheme peristalsis, inspired by
benchtop peristaltic pumps [114]. In 2003 Lim et al. developed a PMP using ball bearings
to transmit DC stepper, enabling extremely low flow rates (3.6 to 144 nL/min) and droplets
(50 pL) for microfluidic applications [143]. Koch et al. reported a normally-closed rollertype PMP with both discrete (PDMS-based) and continuous (tubing-based) channels [114]
(see Figure 2.11). A PDMS-based PMP facilitates integration into microfluidic substrates,
while a tubing-based structure provides an inexpensive, modular medium. The maximum
flow rate for the tubing-based and PDMS-based micropumps were 41 µL/min and 27
µL/min, respectively.
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Skafte-Pederson reported a relatively small (40 mm × 80 mm) roller-based PMP. The pump
consisted of 12 microchannels created by computer numerical control (CNC)
micromachining, actuated by eight rollers using a DC motor to promote the portability of
the device [66]. In order to address the pulsatile flow rate of the micropump, they designed
an offset configuration. They reached a maximum flow rate of 1.59 µL/min with a 10%
maximum coefficient of variance between the 12 microchannels. The same research group
improved the system and miniaturized it down to 30 mm × 40 mm in a follow-up work
[50] as a component of a comprehensive microfluidic system.
Loth and Förster suggested a tubing-based disposable roller-based PMP providing
nanoliter handling of the working fluid in high back pressure conditions [45], in which the
tubing can be replaced into the cartridge after usage. They achieved an extremely high
backpressure of 500 kPa. Vinayakumar et al. reported a cam-follower PMP by mounting a
non-concentric cam on the motor shaft and placing a bearing between the cam and a
silicone tubing which almost wraps around the bearing [74]. In this way the squeezing and
pushing action of the cam spans over 210° of the tubing with minimal friction and wearing
because of the valve, enabling normally closed flow path up to 60 kPa backpressure.
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Figure 2.11. A DC motor-driven PMP with roller transmission. Left) A prototype of a tubingbased PMP. Right) a prototype of a PDMS-based PMP (Reproduced from [114] with
permission from Elsevier).

2.4.3.3 Cam-follower transmission

Cam-follower mechanism translates the rotational motion of the motor to the working fluid
in a peristaltic way by sequentially pushing the fluid in different locations, providing
discrete-scheme peristalsis. In 2009 Shkolnikov et al. reported a novel motor-cam
mechanism in which a cam drives a plunger arm that provides peristalsis by closing the
inlet first, pumping the working fluid out and refilling the silicone tubing [106] (Figure
2.12). Probably the most popular PMP for implantable drug delivery is iPRECIO® [144]–
[147], which is a commercially available PMP working based on a patented “Rotary Finger
method™” in which a micromotor drives a cam with seven followers (pin fingers). The
micropump is integrated with a microreservoir and is packaged with a battery for power
supply (Figure 2.12). The micropump is programmable and implantable with a nanoliter
resolution over a broad range of flow rates (0.017-1.7 µL/min) with an accuracy of +/- 5%
under 0-7.8 kPa backpressure.
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Zhang et al. introduced a PMP in which a motor-driven circular cam with a flat side is
placed on top of a microfluidic channel which is placed on a substrate that is hooked to a
spring at the inlet side of the microfluidic channel, and on a slide rail [148]. In 2016 Xiang
et al. developed a cam-follower PMP using soft lithography and 3D-printing technology
utilizing three different cams with 120° phase angle differences to actuate three chambers
in the desired sequence [119]. They enhanced the closure of the channels by designing two
cubic chambers alongside the channel at each compressing zone to reduce the stiffness of
the sidewalls.

Figure 2.12. a) A novel method for transmission of DC motor rotation into a peristaltic
pumping (Adapted from [106]). b) iPRECIO®-SMP300 is one of the most popular PMPs. This
micropump works with a DC motor and seven followers (pin fingers) (Reproduced from [111]
with permission from Elsevier).

2.4.4 Pneumatic

Pneumatic micropumps use fluctuations in the supply gas (typically compressed air or N2)
pressure to actuate the membrane exposed to it. Usually, solenoid valves are employed for
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switching and cycling of the compressed gas. Grosjean et al. demonstrated a self-priming
planar pneumatic PMP using acrylic for the structure and a flexible composite for the
membrane [92]. They tested the micropump in different supply pressures, sequences, and
frequencies to optimize it to provide 120 µL/min. In 2003 Berg et al. reported a pneumatic
PMP, using PDMS as the construction and membrane material capable of pumping up to
7.2 µL/min. They showed, for the first time, that PMPs with two actuators can provide
comparable flow rates to the three-chamber PMPs, comparing similar prototypes of each.
Wang and Lee presented a SAPMP featuring a serpentine-shape (S-shape) microchannel
enabling single source actuation for 3, 5, and 7 actuation chambers [99] (Figure 2.13a). As
the compressed air travels in the microchannels, it deflects the membrane with a phase-lag
due to fluidic loss of the channels, enabling peristalsis. The same group reported another
SAPMP, with time difference actuation due to the different volumes of the chambers [98],
see Figure 2.13b. In this case, when the compressed air travels, it closes the smaller
chambers first, which causes peristalsis from the smallest to the largest chamber. Jeong and
Konishi presented a full-PDMS pneumatic PMP working in the range of tens of nL/min
flow rate [122], [149]. Lai and Folch presented a PDMS-based single-stroke PMP in which
different chambers have different sizes [107]. The peristalsis occurs based on the principle
that the chambers get deflected at different times with a single pneumatic actuation, due to
different sizes. This approach enables independence from the interconnections between the
chambers. Another PDMS-based single-source pneumatic PMP was introduced using
vacuum as the actuation method [90]. Three chambers are connected, and the first chamber
is connected to a vacuum source and a vent source. When the vacuum is switched on three
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normally-closed chambers open sequentially, and when the vacuum switches off they vent
sequentially, enabling peristalsis. In this design, not only vacuum enables peristalsis; it
assists debubbling of the working fluid through the gas-permeable PDMS membrane,
which is highly desired in the microfluidic applications. They also tried adding valves to
increase the flow rates, which enabled up to 600 µL/min flow.
One of the challenges for the operation of complex and integrated chemical and biological
processes on a single microfluidic chip is the limitation of the number of pumps and valves.
Typically, these challenges cause limitations in the number of pneumatic interconnects
available from ancillary hardware. Cole et al. developed a multiplexing approach that
significantly reduces the number of these external pneumatic interconnections [150]. In
2014, So et al. developed a novel single-source actuation pneumatic PMP. The device
consists of a bilaterally symmetric teardrop shape elastomeric membrane. The membrane
was asymmetrically deformed due to pneumatic pressure and then consecutively touched
down to the bottom of the chamber, enabling peristalsis [100].

Figure 2.13 Operation mechanism for two single-actuation mechanism PMPs. a)
serpentine(Adapted from [99]). b) different chamber sizes (Adapted from [98]).
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2.4.5 Electrostatic

Electrostatic actuation is based on the Coulomb attraction force between two plates with
opposite charges. Teymoori & Abbaspour-Sani designed and analyzed a 7×4×1 mm3
electrostatic PMP for medical applications using MEMS fabrication process [151], [152].
According to the simulation results, the threshold voltage of the micropump was 18.5 V,
providing 9.1 µL/min, which is suitable for drug delivery applications such as
chemotherapy. Although the micropump satisfied many drug delivery requirements such
as low power consumption and small chip size, the actual fabricated device with the
measured performance was not reported. Xie et al. designed and fabricated an electrostatic
PMP using a multilayer technology to isolate the working fluid from the electric field to
avoid electrolysis [95], [153]. Furthermore, to avoid electrolysis AC actuation signal was
used. The design parameters were optimized analytically using a lumped-parameter model.
This small chip size micropump (1.2 × 0.6 mm2) achieved a small maximum flow rate of
1.7 nL/min and maximum backpressure of 1.6 kPa at 20 Hz operation frequency.
Patrascu et al. reported an electrostatic PMP compatible with thin film process technology
[154]–[156] using Polyimide as the primary material which features thermal and chemical
stability, high breakdown voltage, and biocompatibility. The effect of polar and non-polar
fluids (e.g., octane) is analyzed, and it was found that polarity reduces electrostatic
actuation effect, as expected. The micropump works properly with nonpolar fluids like
octane and decane, providing a maximum flow rate of 1.38 µL/min with 150 V operation
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voltage. Maffli et al. reported an electrostatic PMP using zipping actuation applied on a
dielectric elastomer [157]. Peristaltic pumping using electrostatic actuation for gas
chromatography applications was developed by Najafi’s group [158]–[164]. Extremely
high pressures (for gas micropumps) and low power was achieved by introducing the first
multi-stage (2, 4, and 18) electrostatic PMP, using fluidic resonance and multi-stage
configuration. They also introduced a honeycomb pump which allows full area utilization,
enabling size reduction, and scalability [162]. Another group also employed electrostatic
PMPs for gas chromatography [51], [120], [129], [165]–[167] (see Figure 2.14). The
micropump has a single chamber with four (or more) electrodes (actuators). They were
able to reach 136 µL/min at 90 V actuation voltage and 15 Hz operation frequency.

Figure 2.14. Electrostatic actuation method for gas chromatography application. a) Top view
of the electrodes design (Vectorized from [51]). b) Fabricated devices (Reproduced from [51]
with permission of Elsevier).
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2.4.6 Thermopneumatic

A thermopneumatic actuation occurs when a fluid other than the working fluid is heated
and then expands without a phase-change, causing the micropump membrane to deflect
and move the fluid. Usually, the heater is a thin resistive film, using air as the expanding
material. In 1992, a silicon micromachined thermopneumatic PMP was reported [168].
Later in 1999, a thermopneumatic PMP with a flexible composite membrane was
introduced. This self-priming PMP uses acrylic for the body and Silicone rubber and
parylene-C for the diaphragm to make three chambers for peristalsis. The micropump can
provide flow rates up to 6.3 µL/min and backpressure of 3.4 kPa with 291 mW power
consumption.
Knight and House provided an electrical characterization for a thermopneumatic PMP for
next-generation implantable medical treatment, by considering biocompatibility, simple
integration with microfluidics, and particle tolerance [169]. In 2005 Jeong et al. presented
a thermopneumatic PMP providing a maximum flow rate of 0.36 µL/min at 2 Hz operation
frequency [170] (see Figure 2.15 a and b). The 2.5-mm diameter diaphragm membrane was
made of PDMS on top of the glass substrate on which the microheaters were realized.
Tuantranont et al. reported a PDMS-based thermopneumatic PMP working in the range of
6-14 V and frequencies of 0.025-0.667 Hz providing 0.82 µL/min [171], [172].
Yang and Liao presented a broad analysis on development and characterization of the
thermopneumatic PMPs by presenting three different designs (3-chamber, 5-chamber, and
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7-chamber) along with equivalent circuit models and analytical solutions [113]. They
fabricated the three PMPs and integrated them with a driving circuit board. A maximum
flow rate of 9 µL/min with a backpressure of 0.5 kPa was achieved at 1.5 Hz operation
frequency with a duty ratio of 40% using a three-phase actuation sequence. Typically, the
disadvantage of the thermopneumatic PMPs is the elevated temperature that the working
fluid is exposed to, for the required membrane deformation. In 2011 Chia et al. addressed
this issue by designing a side chamber for each actuation site [173] (see Figure 2.15c). In
this way, “fluid-squeezing zone” is separated with “air-heating zone,” which significantly
reduces the temperature elevation of the working fluid.
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Figure 2.15. a) An image of a PDMS-based thermopneumatic PMP, chambers with the
resistive heating element. b) size comparison of the fabricated micropump.(Reproduced
from [170] with permission from Elsevier). c) Conceptual view of a peristaltic micropump
with low-temperature elevation on working fluid (Reproduced from [173] with permission
from Elsevier).

2.4.7 Phase-change

In this actuation method, a phase-change material is heated to melt and volume to deflect
a membrane and actuate the working fluid. This method deflects the actuation membrane
with lower temperature increase than thermopneumatic method and depending on the
phase-change material it can generate higher actuation pressures compared to other
actuation methods. In 2016 a normally-closed phase-change PMP was developed using
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gallium as the actuation material [37] (Figure 2.16a). Since gallium shrinks when melted,
the off-condition of the pump resulted in normally-closed chambers due to the expansion
of gallium. When actuated (heated), the gallium shrinks in the chambers and opens the
chambers. This miniature micropump was able to provide low flow rates of 18-104 nL/min
with precision control, suitable for low-flow rate drug delivery and LOC applications. The
micropump had a relatively low energy consumption per unit of flow rate (11 mJ/nL) in
the class of phase-change micropumps.
In 2019, the same group developed a biocompatible, implantable, scalable, and wirelessly
controlled PMP using paraffin wax as the phase-change material for inner ear drug delivery
applications [73] (Figure 2.16b). The micropump was fabricated using 3D-printing
technology around a catheter microtubing, providing a continuous flow channel. The
mechanical components of the micropump were built directly on backside of a PCB, where
the actuation control and wireless electronics embedded on its front side; allowing a
significant reduction of the overall size of the device. The micropump provided flow rates
in the range of 10-100 nL/min flow rate, with 2.4 nL/min resolution. This device was able
to operate at ±3 °C change in the ambient temperature and up to a 5 kPa backpressure with
no significant impact on the flow rate.
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Figure 2.16. Photograph of a gallium-based PMP with plena and capillary tubing. Visible are
the interconnected capillary tubes, heaters, diaphragm chambers, plena, and heater contact
pads (Reproduce from [37] under CC BY 4.0). b) Photograph of a wax-based phase-change
PMP 3D-printed around a commercially available catheter microtubing on the back of a
printed circuit board “Reproduce from [73] with permission from Elsevier”.

2.4.8 Shape memory alloy

This thermal actuation is based on shape memory effect that involves a transformation
between a low-temperature martensite phase and a high-temperature austenite phase (more
details in review papers such as [46]). In 2008 Guo et al. introduced a shape memory alloy
(SMA) PMP for biomedical applications around a tubing, with low voltage operation (5-9
V)[174]. The rectification was improved by using a check valve. The prototype provided
up to 3200 µL/min at operational frequencies of 1-50 Hz. The same group introduced
another SMA PMP prototype that used actuators inside a tubing providing up to 900
µL/min flow rate [175]. Sassa et al. developed a SMA PMP by having two simple strips of
Ti-Ni SMA actuators around a PDMS tubing for µTAS and LOC applications [91]. The
pump provided up to 80 µL/min at ~0.15 Hz, using up to 8 W of power.
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2.4.9 Summary of actuation methods

This section described seven different actuation methods along with examples of reported
research efforts utilizing them for the development of PMPs. Depending on the application
of the PMP, a designer needs to consider the critical characteristics of each actuation
method such as size, fabrication complexity, actuation frequency, power consumption, and
compatibility to the specific environment. Table 2.2 shows a qualitative comparison of all
these methods.
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Table 2.2. Qualitative comparison of different actuation methods for PMPs.
Actuation
method

Advantages

Disadvantages

Piezoelectric

Fast (low response)
High force

High voltage
Complex and bulky driving circuit

DC motor

Simple
Robust

Relatively large
Complex external mechanism for
handling rotary motion

Pneumatic

Robust
Biomedical application compatible

External compressor required
Noisy

Electrostatic

Small
Low power
large displacement
Easy fab process
low temperature

High voltage
Electrolysis (especially at high voltage)

Simple driving circuit
Simple device structure
Low voltage
Small size

High power consumption
Low actuation frequency

Thermal
(thermopneumatic,
phase-change,
SMA)

2.5 Evaluation and discussion of peristaltic micropumps

2.5.1 Advantages and disadvantages of PMPs

The majority of mechanical micropumps use static valves or dynamic valves for
rectification, which both are categorized into passive and active. The dynamic passive
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valves (check valves) require complicated fabrication process for realizing two valves and
a diaphragm and have issues associated to clogging and sedimentation, the potential of
break and foul in operation [79], and wear and fatigue for long-term application [176]. On
the other hand, researchers have used static passive valves such as nozzle/diffuser [177]–
[179], Tesla valves [180], [181], or a combination of both [182] to address these problems.
Although these valves are robust and straightforward to fabricate, they are relatively
inefficient (19-25 % efficiency), vulnerable to backpressure, and inherently unidirectional,
while they take large area on the chip surface [79], [177].
Despite valve-rectified micropumps, PMPs are low-cost and straightforward to fabricate
since they have similar chamber configurations, enabling easy integration between valves
and channels on a single substrate. PMPs have more reliability and endurance compared to
check valve micropumps. They also can provide bidirectional flow, which is unique to
PMPs and can be significantly useful in LOC applications for circulating flow in
microfluidic channels. Also, PMPs have general characteristics of self-priming, bubble
tolerance, high backpressure tolerance [46], [76], [78], and multiple fluid channels which
can be useful for high throughput LOC application for handling multiple samples at the
same time. PMPs provide continuous clean and clogless flow path due to the absence of
inline valves which is critical in small fluid channels, and especially to keep the samples
without contamination, intact, and unclogged [82], [104], [119]. Due to this characteristic,
PMPs have been used in many applications in biomedical, chemical and nutrition, and
pharmaceutical industries [183]. Additionally, sensitive biological media or suspensions
can be pumped with PMPs due to their gentle operation [184].
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Although PMPs have several benefits, they suffer from mechanical wearing, especially the
continuous-scheme PMPs. Further, low efficiency is observed in PMPs due to the absence
of check valves. One other drawback of PMPs is the complexity of independent
synchronized activation of multiple chambers, which is more common in the discretescheme PMPs. Researchers have tried to address this issue by developing SAPMPs [100],
[103], [105], [106], in which the actuation sequence is embedded into the structure of the
device to avoid controlling the sequence with synchronized signals.

2.5.2 Comparison of different PMPs

In this section, we review significant papers that have developed PMPs since their
emergence in 1990. Various PMPs have been developed with different actuation and
rectification methods, and various applications. Maximum flow rate (Qmax) and maximum
backpressure (Pmax ) are two of the most significant merits of a micropump [39], [96]. Since
many PMPs have been used for size-constrained applications, such as drug delivery, LOC,
etc., the overall package size (Sp) is also considered in this report. Where Sp is not reported,
the size is estimated from provided images and scales. Actuation voltage (V) is another
parameter considered here, which is crucial in drug delivery PMPs (especially implantable
devices) due to limitations on maximum voltage. Maximum operational frequency (fmax) is
also considered here along with the voltage, which determines the operational electronics
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and components to drive the PMP. Other parameters are important for PMPs, such as power
consumption, which unfortunately are rarely reported.
PMPs have been reported in a variety of designs and structures. Key features and measured
performance characteristics of different PMPs are summarized in Table 2.3. Various
actuation methods have been reported in the literature: piezoelectric, DC motor,
electrostatic, pneumatic, thermo-pneumatic, phase-change, and SMA. In Table 2.3, the
PMPs are arranged based on their actuation methods, while other characteristics of them
such as application and fluid channel continuity are mentioned. Rectification methods are
mentioned, consistent with the definitions in Figure 2.2. For continuous rectification
methods, the translational mechanism from DC motor (which is the actuation method for
most of them) are provided. Further, the operational characteristics such as V, Qmax, Pmax,
fmax, and Sp are also provided. For all the PMPs, the working fluid is DI water (among other
possible working fluids reported in some papers) unless otherwise mentioned. Figure 2.17
compares reported PMPs based on five different metrics: Flow rate, package size, actuation
method, maximum backpressure, and operating voltage. The flow rate is plotted along the
ordinate, and the reported or estimated package size are along the abscissa. As depicted in
the legend, the actuation methods are distinguished by color, while the data point size
represents the maximum backpressure range, and the marker type distinguishes the voltage
range.
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Table 2.3. Summary of significant PMPs with their experimental output. The data is arranged by groups in based on “actuation method”
and in chronological order.
Reference

Actuation
method

Rectification

Fluid
V (V)
channel

ΔPmax
(kPa)

Qmax
fmax (Hz)
(µL/min)

Hatch 2001

DC motor

cont. (DC - magnet)

disc.

14

1.2

45.8

Kai 2004

DC motor

disc. (3 chambers)

disc.

1

0.33

Kim 2006

DC motor

cont. (magnet)

disc.

n/r

n/r

Abe 2009

DC motor

disc. (DC - cam/follower)

cont.

5

Koch 2009

DC motor

cont. (DC - roller)

cont.

12

Skafte-Pedersen 2009

DC motor

cont. (DC - roller)

cont.

Shkolnikov 2010

DC motor

cont. (DC - cam/follower)

Shen 2011

DC motor

Loth 2016

DC motor

Xiang 2016

Sp (µL)

Application

0.13

2,401

LOC

24

31

2,340

Drug delivery

3.8

0.13

94

LOC

1.7

n/r

2,678

Drug delivery

345

41

80

27,060

LOC

12

370

1.59

0.04

60,800

LOC

cont.

3

48

780

n/r

6,160

General

disc. (3 ch, DC - magnet)

disc.

0.7

7

2400

25

34,560

POC, µFluidics

cont. (DC - roller)

cont.

5.5

500

400

3

57,208

LOC, µTAS, DNA µArray

DC motor

cont. (DC - cam/follower)

disc.

12

36

274

2.83

97,628

POC, µFluidics

Vinayakumar 2017

DC motor

cont. (DC - cam)

cont.

5

120

270

n/r

18,963

insulin delivery

Xie 2004

Electrostatic

disc. (3 chambers)

disc.

140

1.6

0.0017

23

n/r

µTAS

Teymoori 2005

Electrostatic disc. (3 chambers/in_out valve) disc.

23

n/r

9.1

50

28

Medical

Kim 2015

Electrostatic

disc (18 chambers)

disc.

100

17.5

4000

21

479

Gas chromatography

Lee 2016

Electrostatic

disc. (4+ chambers)

disc.

90

n/r

136

30

12,320

Gas chromatography

Richter 2009

Hydrogel

disc. (5 chambers)

disc.

7

15

4.5

n/r

374

Johnson 2016

Phase-change

disc. (4 chambers)

disc.

n/r

n/r

0.12

0.08

36

Forouzandeh 2019

Phase-change

disc. (3 chambers)

cont.

1.8

5

0.1

0.21

192

General
Size-constrained drug
delivery
Drug delivery

Smits 1990

Piezoelectric disc. (3 chambers/in_out valve) disc.

100

5.9

100

50

1,500

Insulin delivery

Cao 2001

Piezoelectric disc. (3 chambers/in_out valve) disc.

100

0.35

11

4

2,450

Drug delivery

Lee 2004

Piezoelectric

disc. (3 chambers)

disc.

60

3.4

12.5

10

600

µTAS, LOC, FIA

Husband 2004

Piezoelectric

disc. (3 chambers)

disc.

100

n/r

550

100

5,852

µTAS, LOC
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Table 3. Summary of significant PMPs with their experimental output. The data is arranged by groups in based on “actuation method”
and in chronological order. (continued)
Fluid
ΔPmax Qmax
V (V)
channel
(kPa) (µL/min)
disc.
110
100
40

Reference

Actuation method

Rectification

Geipel 2007

Piezoelectric

disc. (3 chambers)

Nguyen 2008

Piezoelectric

disc. (3 chambers)

disc.

80

1.8

900

Graf 2008

Piezoelectric

disc. (3 chambers)

disc.

90

35

Trenkle 2011

Piezoelectric

disc. (3 chambers/in_out valve) disc.

140

fmax
(Hz)
4

Sp (µL)

Application

194

Implantable drug delivery

160

1,280

Biomedical

289

40

150,096

n/r

180

120

30

52,272

Medical

Nakahara 2013

Piezoelectric

disc. Single-actuator

disc.

140

n/r

1500

300

1,800

µTAS

Pečar et al. 2014

Piezoelectric

disc. Single-actuator

disc.

500

36

240

300

952

n/r

Cazorla 2016

Piezoelectric

disc. (3 chambers/in_out valve) disc.

24

3.2

3.5

2.5

113

Drug delivery

Berg 2003

Pneumatic

disc. (2 chambers)

disc.

n/r

0.17

6.42

0.5

17,671

LOC

Huang 2006

Pneumatic

disc. Single-actuator

disc.

n/r

0.16

108

28

720

µTAS

So 2014

disc. Single-actuator

disc.

n/r

0.375

18

5

990

µTAS

disc. Single-actuator

disc.

n/r

0.8

600

50

108

biological, chemical

Guo 2008

Pneumatic
Pneumatic
(vacuum)
SMA

disc. (3 chambers)

cont.

9

n/r

4000

50

40,500

Biomedical

Sun 2008

SMA

disc. (3 chambers)

cont.

2.5

n/r

900

2

67200

Biomedical

Sassa 2012

SMA

disc. (2 chambers)

cont.

n/r

n/r

80

0.3

1,718

µTAS, LOC

Grosjean 1999

Thermopneumatic

disc. (3 chambers)

disc.

n/r

3.45

6.3

4

970

n/r

Jeong 2005

Thermopneumatic

disc. (3 chambers)

disc.

20

n/r

21.6

100

530

LOC

Yang 2009

Thermopneumatic

disc. (3 chambers)

disc.

5

0.5

9

10

1,584

Biomedical

Chia 2011

Thermopneumatic

disc. (3 chambers)

disc.

9

0.5

20

10

1,440

POC, µFluidics

Cui 2011
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Figure 2.17. Comparison of several reported PMPs based on flow rate, package size, maximum backpressure, actuation method, and
operating voltage. *Note: As illustrated in the legend, the color indicates the actuation method, the marker size indicates operating
pressure range, and the shape correlates to the drive voltage range.
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2.6 Conclusion

The brief survey given in this paper reviews a variety of PMP concepts, key parameters
affecting pump operation, and actuation methods since their emergence in 1990. The
peristalsis concept was explained in depth, defined as a rectification method in mechanical
micropumps, and distinguishing it from other rectification methods. Various parameters
that substantially impact the operation of PMPs were discussed, including actuation
frequency, peristalsis sequence, and the number of chambers. There have been several
research efforts in the literature to implement PMPs with various actuation methods.
Among different actuation methods, the DC-motor driven ones have gained particular
attention and are now available commercially [147]. For extremely size-constrained
applications, the bottleneck of size reduction for DC-driven devices is the size of the
commercially available DC motors. Reducing the size of reliable and well-controlled DCmotors can substantially assist the miniaturization of DC motor-driven PMPs.
Despite the several advantages of PMPs, such as self-priming, bubble tolerance, and high
flow rate and backpressure capability, the actuation sequence is still a source of complexity
for discrete-scheme PMPs. To address this challenge, the application of two independent
chambers for peristalsis, and SAPMP concept should be considered as a future goal. PMPs
with two actuators have been shown in the literature to be relatively efficient [76], [79] but
did not gain fair attention afterward. Also, the SAPMP concept has been shown in the
literature to be effective for pneumatic [98], [99], magnetic [101], and piezoelectric [102]–
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[104] actuation methods. This concept should be considered for the development of PMPs
using other actuation methods in the future.
Although the actuation sequence, phase lag, and the number of chambers have been studied
subjectively in the literature, a generic model for optimization of these factors can be
immensely useful for researchers as a design rule for developing new devices. The
parameters discussed in this paper (section2.3) should be taken into consideration, along
with the limitations and advantages of each actuation method presented in section 2.4.
Optimized devices (considering all factors mentioned above) can compensate for the lack
of check valve in the system and improve the efficiency of PMPs.
As mentioned in this paper, the most significant application of PMPs are LOC and
biomedical fields, or to be more specific, drug delivery. For both applications, integrability
of the micropumps is extremely important. For LOC applications the PMP should be
integrated into other features on the chip, where integration with flow sensors assists
feedback control in adjusting the flow rate by perhaps changing the actuation frequency as
the most accessible post-fabrication control mechanism. For drug delivery applications,
especially implanted, the driving circuit and power supply (i.e., battery) size and
integration should be considered more thoughtfully, due to extremely size-constrained
nature of the application especially for cochlear and ocular applications and animal studies.
Miniaturization, low operating voltage, and extremely low flow rates while keeping low
power consumption remain essential factors in these applications. Further, implanted PMPs
(and in general, micropumps) should be able to be wirelessly programmed and controlled
with a relatively simple interface for a medical expert, due to lack of post-implantation
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access and reduction of ‘human factor’ in operation of the devices. For drug discovery
applications, scalability should be taken into account to consider animal-to-human
translation. This highlights the importance of micro-scale 3D-printing fabrication
technology, which is inherently scalable. With these goals, the exploration of new pumping
concepts and their realization with MEMS and micro-scale 3D-printing technology will be
substantial scientific and engineering challenges.
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Chapter 3

A Nanoliter Resolution Micropump
For Murine Inner Ear Drug
Delivery

3.1 Introduction

The cochlea of the inner ear is the specialized organ where auditory perception starts, and
is one of the most challenging drug delivery target organs due to its small size and relative
inaccessibility. It is surrounded by the temporal bone, which is the hardest bone in the body
and the diameters of the coiled tubes within the inner ear are < 2 mm for human. The
cellular machinery within the cochlea (e.g., the hair cells in the organ of Corti) are
extremely sensitive to mechanical and chemical damage [2]. Successful therapy
development for protecting or regenerating cochlear cells which are damaged or missing
in cases of hearing loss or deafness, involve the use of transgenic, knock-in, and knock-out
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variants of human disease in the mouse model system requires advanced microsystems.
However, working with mouse models presents new and significant challenges for inner
ear drug delivery due to the extremely small size of the mouse cochlea. For instance, the
mouse cochlea contains approximately 620 nL of fluid (perilymph) [17] while the human
cochlea contains 150-200 µL perilymph [18], [19]. This small volume of perilymph in
cochlea makes it vulnerable to prolonged or high-flow rate intracochlear delivery [20],
[21].
To address these challenges for safe and efficacious inner ear delivery, microsystems-based
approaches have emerged [8], [26]–[29]. Such systems require precise and programmable
ultra-low flow rates with a controllable profile, due to the small volume of the cochlear
perilymph and high sensitivity of the auditory organ to possible damage. Further, a
pumping system must be sufficiently small and lightweight, with a planar form factor [30]
to be subcutaneously implanted. Also, the system must be robust enough to provide highly
controlled, time-sequenced, and ultra-low flow rates over periods of months [2], with the
capability of remote activation/deactivation, and programming for automated delivery
[13].
These and other considerations limit the applicability of many commercially available
inner ear delivery microsystems-based devices. Current osmotic pumps (e.g., Alzet®
micropumps) have been used for preclinical experiments for inner ear delivery in larger
mammals, including some rodents [14], [31]–[33]. However, osmotic pumps lack delivery
precision and cannot be started or stopped, nor can the flow rate be changed once the
infusion is started. Recently, iPrecio® SMP-300 peristaltic micropump was used for
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infusion of fluorescein isothiocyanate-dextran-labeled dextran as a concentration marker
into guinea pig cochlea, using a coupler to connect the tubing of the micropump tubing to
a microcatheter [34]. Although these micropumps can provide controlled low flow rates,
the overall size and the tubing dimensions are prohibitive for practical subcutaneous
implantation in smaller rodents and mice.
Recently inner ear drug delivery microsystems have been an evolving focus of research. A
team from Draper Laboratory and the Massachusetts Eye and Ear Institute developed a
head-mount reciprocating delivery system for direct intracochlear delivery in guinea pigs
utilizing conventional machining and UV laser cutting [13], [35]. The system works based
on infusion and withdrawal of the drug through the cochlear perilymph. Although it
includes a micropump and a drug reservoir, it is too large for implantation, even in the
guinea pig. Microelectromechanical system technologies (MEMS) have also been used for
fabrication of drug delivery microsystems [36]. In 2016, we reported the development of a
miniaturized planar MEMS-based peristaltic micropump for nanoliter cochlear perfusion
[37]. However, the device had to overcome significant microfluidic interconnection
challenges [38] to allow integration of sub-mm scale in-plane microcatheter tubing without
adding significant micropump volume.
In addition to microfluidic interconnect challenges, incorporation of control electronics to
MEMS-based micropumps can be accomplished either through expensive application
specific integrated circuits integrated on-chip, or via a separate PCBA that adds significant
bulk to the assembled system. Scaling of MEMS-based systems also requires modification
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of the fabrication processes and masks, creating challenges for scalability to human clinical
translation.
Here we present a novel miniaturized, wirelessly controlled, fully implantable, and scalable
peristaltic micropump that provides programmable and accurate drug delivery for inner ear
applications. The actuation force of the micropump is provided by expansion/shrinkage of
a thermally phase-change material due to its melting/crystallization. The micropump uses
3D-printing technology and is built directly on the backside of a PCBA around
microcatheter tubing (OD=250 μm, ID=125 μm) to integrate the mechanical and control
electronic components. The flow path is leak-free and biocompatible and is free of complex
microfluidic interconnects. The results of our in vitro characterization indicated that the
micropump provided nanoliter control of flow rates against ten times greater than
physiological backpressures. The in vivo mouse model system results indicate functional
round window membrane (RWM) drug delivery. Biocompatibility was explored using in
vitro and in vivo experiments.

3.2 System overview and concept

The surface area of the microsystem is intended to go as small as electronic components
allow, while the thickness is planned to be smaller than 4 mm, which is approximately half
of the commercially available implantable micropump [147]. The commercially available
programmable, implantable micropump has an overall volume of 24.8 × 15 × 7.2 mm3,
while the microtubing diameter is 1.5 mm. Pump rate and backpressure requirements were
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taken from those used in the literature. Mouse cochlea implantation has been done via a
basal turn cochleostomy or canalostomy at flow rates of 16, 32, and 50 nL/min [8], [25],
[185]. Inamoto et al. reported a 0.33 kPa to 0.53 kPa for endolymphatic pressure in guinea
pigs, which is considered as an estimate for the mouse cochlear backpressure, since there
is no measurement for mice [186].
At a minimum, therefore, the micropump needs to provide a maximum flow rate of 50
nL/min in presence of 0.53 kPa backpressure plus the pressure drop in the fluidic system.
The micropump chamber dimensions were designed for low-flow rate pumping (10 - 60
nL/min) against backpressure of 5 kPa to have a safe margin for inner ear delivery while
enabling pumping for other biological systems.
Drug delivery systems implantation require low operating voltage to protect the animal in
case of failure of the insulation. Cazorla et al. suggested 24 V as the maximum allowed
voltage for an implantable system [72]. Further, for implantable, programmable
microsystem wireless controlling and programming is preferred. Therefore, the micropump
is designed to be able to communicate with an Android device using an antenna in the
range of 1 foot. Having this range, the system can be controlled and programmed from
outside of a mouse cage. Table 3.1 lists the design targets that will enable the creation of
this micropump. Figure 3.1 shows a conceptual drawing of the implantation of the
subcutaneous microsystem in the mice.
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Table 3.1. Targets for implantable microsystem design for inner drug delivery
Characteristic

Design target

Form factor

Planar

Thickness

<= 4 mm

Flow rate

10 – 60 nL /min

Backpressure

5 kPa

Maximum voltage

24 V

Wireless communication range

1 foot

Figure 3.1. A conceptual drawing of the implantation of the subcutaneous microsystem in
the mice.

Using a sub-millimeter microcatheter tubing as the fluid-carrying component limits the
options for pumping approaches. Methods that require the use of in-line rectifying valves
result in bulk that is unacceptable for size-constrained applications. We used peristalsis
with the microcatheter tubing sequentially compressed in three locations to induce
directional flow. Peristaltic micropumps that use a single tube are one the most reliable
mechanisms for drug delivery because one medium is in direct contact with the working
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fluid (drug) and no valves or moving components are in the flow channel, which eliminates
contamination, leakage, and dead volumes, and reduces clogging and bubble generation.
They also benefit from typical advantages of peristaltic micropumps such as resistance to
high backpressure [77], [78], [187], bubble tolerance, endurance [79], and self-priming and
bi-directional flow capability [78].
Different actuation schemes (e.g., piezoelectric [72], [104], [188], pneumatic [100],
thermopneumatic [189], electrostatic [165], and phase-change [37]) are used for peristaltic
micropumps. In this study, a novel phase-change actuation method has been used due to
its low driving voltage, significant displacement, small size, and high actuation force
enabling effective pumping against backpressure. The actuation material was encapsulated
in the body of the micropump surrounded by stiff structures except for one side that is
exposed to the deformable microcatheter tubing. Peristalsis occurred as a consequence of
sequential melting and solidification and associated expansion and shrinking of the phasechange material which drove cyclic compression and release of the microcatheter tubing.
Various phase-change materials can be used for actuating micropumps (e.g., gallium [37]
and paraffin wax [190]). Paraffin wax was used as the actuation material, due to its stable
phase-change behavior and high-pressure actuation [191]. In addition, the paraffin wax
melting point can be chosen for a desired application by selecting the appropriate molecular
weight of the wax.
The micropump was built directly on the back of a printed circuit board (PCB) employing
3D-printing technology. Three pairs of resistive heaters and thermistors were placed on the
PCB to make a linear template for three chambers and a groove between them for the
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microcatheter tubing. The three chambers were fabricated in the designated linear pattern
adjacent to the microcatheter tubing and were separated by 1.2 mm. Paraffin wax was
precisely deposited in the chambers. A peristaltic sequence was applied to the micropump,
with a timing control ensuring two closed chambers at each moment. The chambers closed
in a sequence of 1 and 3, 1 and 2, and 2 and 3, which pumped the fluid from left to right.
Figure 3.2 shows schematic views of the actuation mechanism and the micropump.

Figure 3.2. Left) Cyclic phase-change actuation of the three chambers compressed the
microcatheter tubing and drove peristalsis. The left and right actuators are in the liquid
state, compressing the tubing to eject fluid. Right) Schematic of the peristaltic micropump
built around a commercially available microcatheter directly on the back of a PCBA using
3D-printing technology.
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3.3 Electronic control

3.3.1 Electronic design

The control electronics for actuation and control were fabricated on the front of the fourlayer PCB. Off-the-shelf components were used for the micropump control electronics,
which were designed for ultra-low-power operation. A rechargeable lithium polymer
battery provided power to the system. A step-down buck converter (TPS62743, Texas
Instruments) was chosen to provide sufficient current output (300 mA maximum) during
pumping, a high efficiency (up to 90% at 10 µA load), and low quiescent current (360 nA)
when the system is in shutdown mode. Each pump chamber included a thermistor and a
40-ohm resistive heating element with a discrete N-type metal-oxide-semiconductor for
controlling temperature. A 1.8-V power rail was used for the entire system to optimize the
power consumption of the wireless microcontroller.
The system on a chip (CC2640, Texas Instruments) included an integrated Bluetooth low
energy transceiver (BLE 4.2), a 32-bit ARM Cortex-M3 processor with an up to 48 MHz
clock speed, and an ultralow-power sensor controller. This system was chosen for its
shutdown current of 100 nA since the system will spend the majority of time in deep sleep
mode when the pump is not actively delivering drugs. The system’s real time clock used a
32-kHz oscillator (SiT1532, SiTime) based on silicon MEMS technology; it had the
smallest footprint and lowest power consumption of commercially available oscillators. A
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wire antenna with a length of 10 mm was chosen to keep the overall device footprint as
small as possible. The control electronics were configured and operated using a custom
Android application via BLE. Figure 3.3 shows an image and the block diagram of the
fabricated electronics.

Figure 3.3. Left) Image of the fabricated electronics on front side of the printed circuit board.
The electronics assembly was used for actuation, closed-loop feedback to control chamber
temperatures, and wireless control. Right) Block diagram of the pump control electronics.
Res, resistive heater; Ther, thermistor.

3.3.2 Android application

An Android application has been designed to connect to the micropump to provide on-line
control over the flow rate and sequence. After opening the application (i.e., pump
controller), it starts to scan for ‘NIH Pump.’ If the pump is on, it finds the pump, showing
the unique pump ID at the left along with RSSI value Figure 3.4. RSSI is a measure of
signal strength, with a negative value in ‘dBm’ in a range of -50 to -100. If the signal is
stronger the RSSI value is closer to -50.
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Figure 3.4. Once starting the application, it starts to look for micropumps around. If the
pump is on the application finds it and shows the pump’s unique ID at the left and RSSI
number at the right side of the screen.

After connecting, the screen shows ‘connected’ if the pump is still connected. It also shows
battery supply voltage as ‘VBATT’ and RSSI number. Further, there are ‘start pumping’
and ‘start recording’ buttons for activating/deactivating of the pump and saving the
reported data in the tablet. The ‘update temperature’ button provides the chamber
temperature at the moment. These values are based on thermistor reported temperature.
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Figure 3.5. The main screen of the application for the micropump. Along with RSSI and ID
number the available battery voltage is shown. Also, the ‘start pumping’ starts/stops the
micropump and the ‘start recording’ saves the data in a ‘.txt’ file. The ‘update temperature’
button shows the current temperature.

Before using the micropump, the thermistors need to be calibrated, using the vertical ‘…’
button on top right. The ‘low temp’ and ‘high temp’ need to be in a range of 10-15 °C and
assigned based on a temperature that is read from an external gold standard thermometer
(Figure 3.6). While the calibration is linear, valid and accurate within the small imported
range, it is not quite reliable off the range.
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Figure 3.6. The micropump is calibrated with ‘low temp’ and ‘high temp’ linearly, based an
external gold standard.

To program the pump, ‘configure’ button should be pushed after using vertical ‘…’ button.
Then in the ‘program’ section ‘edit’ should be chosen (Figure 3.7 left). A new screen
displays having options for setting three fields for three chambers for the set temperature
(Figure 3.7 right). For time-related applications, which is the one we are interested in, in
the ‘condition’ row ‘time’ should be chosen, and in the ‘time’ row the desired activation
time of each sequence should be filled in. Multiple sequences can be assigned to the pump
by choosing ‘add after’ button.
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Figure 3.7. Left) the micropump can be programmed in the ‘configure’ section (not shown
in this figure) and by choosing ‘edit’ under ‘program’. Right) Each chamber can be set to
the desired temperature (preferably in calibration range) for a specific time at each
sequence. The pump can have multiple sequences using ‘add after’ button.
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3.4 Heat transfer analysis

Thermal actuation with phase change materials requires effective transfer of heat in and
out of the medium. Heat transfer rates limit actuation frequency and flow rate and affect
power consumption. To optimize the micropump system design, a 3D heat transfer model
was developed in COMSOL Multiphysics®. In these simulations, the wax remains solid
with phase change modeled via changes in heat capacity in the melting temperature range,
a common simplification for wax phase change analysis [192], [193]. The four copper
layers, copper paths, PCB, resistors, thermistors, wax, and resin that covered the entire
system were the elements that most affected the system heat transfer properties. The
geometric details of these elements were designed using SolidWorks® and imported into
COMSOL Multiphysics®.
A user-defined function (UDF) was used to model the phase-change phenomenon based
on the apparent heat capacity method. In this UDF, the phase-change energy of the wax
was spread over the phase-change temperature range of 4 °C [194], [195]. This model
analyzed the thermal behavior of the system based on material properties, geometry, the
difference between the wax melting point and the ambient temperature, and ambient heat
transfer characteristics. This generic model can be used for various ambient temperatures
and selected wax molecular weights (ie. melting point) to evaluate and optimize pump
performance. To present generalized results, all temperatures were presented relative to the
ambient temperature.
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The material properties of the different elements were considered using the COMSOL
library and material datasheets. Since the micropump is going be implanted under the skin,
which is a moist environment, it was tested in the laboratory in a petri-dish full of water.
Therefore, water was considered as the material surrounding the micropump in the
numerical simulation with a free convection boundary condition applied at the micropump
external surfaces. Since the water is still in the petri-dish, a free convection boundary
condition was applied on the micropump external surface. A UDF enabled sequential
heating of the resistive heaters in the chambers based on the desired actuation frequency.
The wax temperature was fixed at the set temperature using a UDF for the heat generator
to apply a closed-loop on-off controller based on the temperature reported by the
thermistor. This simulated micropump heat generation and feedback control.
The results of the heat transfer analysis were first validated using a micropump model. To
achieve the maximum target flow rate of 100 nL/min high actuation frequencies were
required. Therefore, the design and phase-change material optimizations were i) a
minimum of 10°C differential between the wax melting point and the ambient temperature,
and ii) reduction from 36 µm (1 oz) to 18 µm (0.5 oz) of the thickness of the copper in the
PCB. This thickness reduction increased the actuation frequency by 55% due to reduced
thermal mass and heat transfer away from the chamber. The thickness reduction however
is limited to PCB manufacturing. Most PCB fabrication companies do not provide
thicknesses smaller than 36 µm and 18 µm for the external and internal layers, respectively.
Further, the addition of a copper pad to the bottom of each chamber improved the
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homogeneity of the chamber temperature distribution, reducing the standard deviation by
35%. Improving homogeneity of the temperature in the chamber enables well-distributed
melting of the wax, which avoids local tensions to the chamber structure, especially on the
microtubing interface. Details of model validation, geometry, material properties,
boundary conditions, and geometry optimization can be found in Appendix A.
The ability of the system to operate at the required frequencies and the insulation between
the chambers were studied using the model with the optimized material and geometry.
Figure 3.8A shows the simulated temperature elevations when applying 0.33 Hz actuation
signals, which theoretically can provide the target flow rate of 100 nL/min. Six pumping
cycles were simulated, and the results indicated that the chamber temperatures could
fluctuate between the wax melting point and 5 °C lower, which allowed the wax to melt
and solidify during each cycle without thermal saturation. A steady state simulation with
chambers 1 and 3 on and chamber 2 off simulates worst case scenario for insulation
between chambers. The results indicated that the chambers were well-insulated (Figure
3.8B); while two side chambers were set at the melting point, the middle chamber
maintained a temperature approximately 9 °C cooler than the melting point.
A crucial characteristic for implantable devices is that the surface temperature should not
exceed 2°C above ambient temperature. The results of the sixth cycle of a 1-Hz transient
simulations were examined to estimate temperature increases in the micropump exterior
surface. It was found that the micropump surface temperature was never > 0.3 °C higher
than the ambient temperature, due to small power dissipation of the device.
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Figure 3.8. Heat transfer analysis of optimized micropump design demonstrated
temperature prediction and control. A) The temperature elevation of chamber 1 during the
0.33 Hz actuation, which is sufficient to provide target flow rate of 100 nL/min. The chamber
temperatures could fluctuate between the wax melting point (in this case, Nonadecane with
melting of ~32 °C) and 5°C lower, which allowed the wax to melt and solidify during each
cycle. This simulation shows the micropump can work at this frequency without thermal
saturation. B) The design provided effective thermal insulation between the chambers.
During a steady state simulation, the temperatures of chambers 1 and 3 were set at the
melting point and the chamber 2 temperature remained at approximately 9˚C cooler than the
melting point.
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3.5 Fabrication process

A new fabrication process was developed using 3D-printing technology. The mechanical
structure of the micropump was direct-write printed on the back of a PCBA. The control
electronics were populated on the front side using standard PCB assembly technology.
Three pairs of thermistors and resistors were assembled on the back of the board in a linear
offset formation to accommodate subsequent placement of the microcatheter tubing. The
micropump structure was 3D-printed using a polymer inkjet printer (Roland VersaUV
LEF-12, Tokyo, Japan) and an ECO-UV® resin; three chambers were placed around the
resistor/thermistor pairs and a groove for the microcatheter tubing was created.
The pattern of the chambers and the groove for the microtubing (300 µm width) were
designed in Solidworks® and converted to .EPS format using Adobe Illustrator®. The
chamber width is 1 mm, which by taking into account the width of resistors and thermistors
(300 µm each) and a 100 µm clearance between them, leaves 150 µm on the chamber sides.
An alignment jig was 3D-printed to properly place the board on the Roland 3D-printer.
Since each layer thickness was measured to be ~7.7 µm, 45 layers of the pattern were 3Dprinted to create walls with 350 µm height. The chamber structure is taller than the resistor
and thermistor (both 300 µm height), ensuring the wax can be contained.
Polyurethane-based catheter microtubing (ID=125 µm, OD=250 µm; MRE010, MicroRenathane® Catheter Tubing, Braintree Scientific Inc., MA, USA) was placed, fixed, and
sealed in the groove using thick cyanoacrylate resin on chamber sides. A 2.5 mL mixture
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of 4:1 of Epoxy (301, EPO-TEK®, MA, USA) was mixed, and ~4 µL of it was gently
poured outside of the chambers and cured for 2 hrs. The amount of epoxy is enough to
leave a small space to the chamber wall top, to avoid wicking of the wax onto the epoxy
during wax deposition in the molten state.
Docosane (melting point 42-46 °C, CH3(CH2)20CH3; Sigma-Aldrich, USA) is molded in a
catheter microtubing (ID=305 µm, OD=635 µm; MRE025, Micro-Renathane® Catheter
Tubing, Braintree Scientific Inc., MA, USA). The microtubing was placed on a 0.25-mm
graded ruler and cut with a brand-new razor blade and a precise volume of wax inside it
was taken apart and placed in each chamber. The volume of the wax is a crucial parameter
in pump operation. If the wax is too much it can break the structure, usually by leaking
from the interface of microtubing and the chamber. It also needs to be large enough to close
the microtubing by 10-15 % expansion [191] due to melting.
Thin cyanoacrylate resin was used to cover and seal the structure and to provide mechanical
strength to avoid deformation due to phase-change pressure. Finally, the micropump was
encapsulated with an approximately 1-μm-thick layer of Parylene-C using PDS 2010
LABCOATER™ 2 (both Specialty Coating Systems, Indianapolis, IN, USA). The
Parylene-C coating provided a biocompatible moisture barrier around the micropump,
enabling electrical insulation for the electronics.
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Figure 3.9. Fabrication process of the micropump. A) The electronic components for
actuation, temperature control, and wireless communication were assembled on the front
side of the PCB. B) The micro-heaters and thermistors were assembled on the backside of
the PCB, forming a template for three linear chambers and a catheter microtubing. C) A
commercially available catheter microtubing (250μm OD, 125μm ID) was placed within a
printed template. A precise volume of wax was placed in each chamber in contact with the
microtubing and integrated micro-heater and thermistor. D) The chambers were covered
with a rigid resin.
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3.6 In vitro characterization

The micropump was first characterized using in vitro experiments. Flow rate measurements
were taken at different actuation frequencies, backpressures, and ambient temperature
variations. The actuation temperature of each chamber was calibrated across the range of
actuation frequencies and ambient temperatures. The micropump was submerged in
deionized (DI) water in a petri dish to simulate the thermal characteristics of the pump after
implantation. Nanofittings (Idex©, WA, USA) were used to connect the tubing to a Luer
Lock syringe. The micropumps were specifically designed for room temperature operation.
The micropump was powered by a 3.7 V rechargeable Li-ion battery and was programmed
by an Android application. Dyed DI water was used as the working fluid to provide visual
observation of the fluid displacement in the microcatheter. The fluidic system was filled
and visually inspected for no trapped air. The downstream microtubing was placed on a
ruler with the flow rate measured by calculating fluid front advancement in the 125 µm ID
microcatheter.

3.7 In vivo experiment

An in vivo test of the system was performed using a paradigm that induces temporary
hearing loss via administration of sodium salicylate following a protocol developed at our
laboratory [25]. Salicylate causes reversible disruption of outer hair cell motility because
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it can act as a competitive antagonist at the anion-binding site of prestin [196]. Disruption
of prestin reduces the magnitude of otoacoustic emissions [197] and can result in reduced
distortion product (DP) amplitudes and reversible elevation of distortion product
otoacoustic emission (DPOAE) thresholds. Thus, salicylate was delivered to the RWM and
auditory function was assessed using DPOAE methodology.

3.7.1 Drug infusion system and solutions

The salicylate solution consisted of NaCl (120 mM), KCl (3.5 mM), CaCl2 (1.5 mM),
glucose (5.5 mM), HEPES buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 20
mM), and sodium salicylate (50 mM). The pH was adjusted to 7.5 using NaOH. All
solutions were prepared on the day of the experiment using sterile double-distilled water.
The salicylate was loaded into a 3-cc sterilized syringe and was debubbled. Using positive
pressure, the salicylate was pushed until it was 1 mm from the tip of the tubing and then
the micropump was placed on the same level as the mouse. After each experiment, sterile,
double-distilled water, was forced through the tee, fittings, and microcatheter tubing in
order to clean the fluidic elements.
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3.7.2 Animal and surgical procedures

A total of six young adult (age, 2–4 months) CBA/CaJ mice bred and raised in-house were
used for this study. Each animal underwent a bullaostomy surgery to prepare a site for
infusion of the salicylate into the middle ear cavity. All animal procedures were approved
by the University of South Florida Institutional Animal Care and Use Committee and were
performed using National Institutes of Health and veterinary standards of care.
Each animal was deeply anesthetized for the bullaostomy surgery using a mixture of
ketamine (120 mg/kg body weight) and xylazine (10 mg/kg body weight) injected via the
intraperitoneal route. The left ventral surface of the neck was then shaved and cleaned. The
animal was positioned on its back on a heated operative plane maintaining aseptic
conditions.
Surgery was performed on the left (ipsilateral) ear following procedures performed by
Borkholder et al. [25]. Briefly, the tympanic bulla was exposed using a ventral approach,
and an incision was made in a longitudinal direction along the ventral surface of the neck
to expose the bulla. A 300-μm diameter carbide micro drill bit modified to include insertion
stops was used to bore a bullaostomy at a location approximately 1.5 mm laterally below
the stapedial artery [14].

Using a micromanipulator (MM3–3, World Precision

Instruments, Sarasota, FL), a fine metal probe was attached to the polyimide infusion
tubing using adhesive (3M Repositionable 75 spray adhesive, St. Paul, MN). The infusion
tubing assembly was inserted into the bullaostomy to a depth of approximately 300–500
μm, near the opening of the round window. Medical grade adhesive (Loctite 4206, Rocky
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Hill, CT) was used to temporarily secure the infusion tubing to the bulla opening.
Subsequent application of dental cement (3M ESPE Duralon) provided a more permanent
and robust bond and sealed the cannula to the bullaostomy site. The surgery site was loosely
sutured closed to provide strain relief for the infusion tubing. During infusions, each mouse
was immobilized using anesthesia as described in this section. Supplementary doses at onethird of the initial dose were administered as needed to maintain the proper levels of general
anesthesia. After each infusion, the pump was stopped, and anesthesia was maintained for
an additional 40 min while additional auditory assessment data were recorded.

3.7.3 Auditory function assessment

To non-invasively assess the auditory function, the DPOAE method was employed which
serve as a monitor of outer hair cells. The mechanical response of the outer hair cell causes
an acoustic signal propagated back out through the auditory canal, which correspond to
discrete frequencies and can be measured to non-invasively assess cochlear function [2].
This method has been vastly used in newborns and children hearing screening and scientific
investigations [198]. Cochlea generates DPOAE when the ear is exposed to two
simultaneous pure tones (F1 and F2), where the F2/F1 frequency ratio typically varies
between 1.1 and 1.3 to generate intermodulation DPOAE component. The corresponding
amplitudes for these tones are assigned as L1 and L2, where the lower tone is usually the
F1. As a consequence of intermodulation the cochlea generates distortion products, which
are long series of components that are not present in the input stimuli. The most common
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distortion products in clinical practice and animal experiments is the cubic difference
distortion product, denoted as 2F1-F2. The DPOAE protocol that uses unequal primary
intensities (L1 > L2,) is called asymmetrical, which is used in this study. Using this
protocol the intermodulation components are close to F2, which is why the DPOAE
information is referenced to F2. One of the ways to present the DPOAE information is the
DP-gram modality, where the 2F1-F2 amplitudes are measured at various F2 frequencies,
with fixed stimulus intensities [199]. Although DPOAE is an effective non-invasive
method for hearing assessment, there can be errors in the measurements due to calibration
error, misplacement of the probe, object motion. In case of animal studies, the level of
anesthesia should be enough that the animal does not wake up during the measurement.
The auditory function measures were the same as we previously reported [200]. Each
mouse was anesthetized as described in section 3.7.3. Supplementary doses of anesthetic
were administered as needed. Auditory function was assessed via automated DPOAE
threshold measurements at F2 frequencies of 8.9 kHz, 13.5 kHz, 17.9 kHz, 24.6 kHz, 35.8
kHz, and 51.4 kHz. Measurements performed before surgery were used for a baseline to
compare subsequent DPOAE threshold shifts.
Stimuli (F1 and F2) were generated using Tucker Davis hardware (TDT; Alachua, FL)
controlled via ActiveX from a custom Matlab r13 (Mathworks; Natick, MA) graphical user
interface. A Tucker Davis RP2.1 processor at a sample rate of 200 kHz was used to generate
the sound stimuli and acquire the signals. All acoustic signals were emitted through
electrostatic speakers (TDT EC1) connected to a probe via 4-cm tubes. The probe
contained an ER10B+ microphone (Etymotic; Elk Grove Village, IL). Waveforms from
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each presentation were windowed using a Hamming window, and high-resolution 390625point fast Fourier transforms (FFTs) (2× sample rate) were calculated. The resulting FFTs
had a bin size of 0.5 Hz, which allowed for accurate measurement of signal level as a
function of frequency. Frequency-domain averaging was used to minimize artifacts. Before
subsequent analysis, the mean FFT values for multiple repetitions of the same stimulus
were calculated. The probe microphone was calibrated relative to a 0.25” B&K microphone
(Type 4938, Bruel & Kjaer; Naerum, Denmark) using a 0.1 cc coupler (simulating the
mouse ear canal).
DPOAE amplitudes were measured by generating F1 and F2 primaries at 65 and 50 dB
SPLs, respectively (ratio of the two frequencies = 1.25). The output waveforms of the
ER10B+ probe microphone were input to a TDT RP2.1 processor. The FFT values for each
presentation were averaged and signal levels at five frequencies were sampled (F1, F2, DP
(2F1-F2), as well as two noise bins above and below the DP frequency). After FFT
sampling, the dBV was converted to SPL based on the ER10B+ microphone calibration.
DPOAE thresholds were defined as the F1 level required to produce a DP of 0 dB SPL
(+/−1 dB). We developed an automatic threshold search algorithm implemented in Matlab
r13 using TDT hardware and the Etymotic ER10B+ probe microphone.
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3.8 In vitro results and discussion

The completed micropump is illustrated in Figure 3.10A. The overall pump size is 8 × 8 ×
3 mm3 (L × W × H). In vitro experiments were performed to assess the capacity of the
micropump to provide required flow rates for inner ear drug delivery in the presence of
physiological backpressure. The consistency of the micropump to provide a 50 nL/min
delivery flow rate during a 20-min period was also examined. This flow rate was required
for the in vivo experiments. Finally, the micropump performance was tested at different
ambient temperature conditions because after subcutaneous implantation the micropump
may be exposed to variations in ambient temperature. In vivo experiments test three
micropumps in six mice with the microcatheter tubing implanted at the RWM niche
delivering salicylate at 50 nL/min for 20 min, replicating a previous drug delivery system
utilizing syringe pump instead of micropumps [25]. Auditory function was assessed using
the DPOAE method.

3.8.1 Micropump performance characterization at physiological
backpressures

Flow rates were measured at actuation frequencies from 0.015 Hz to 0.21 Hz (i.e., 0.015
Hz, 0.05 Hz, 0.1 Hz, 0.15 Hz, 0.21 Hz) to provide 10-100 nL/min, which covers two times
above the maximum reported drug delivery infusion flow rate [8], [25], [29], [185]. The
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backpressures were 0 and 5 kPa, which covered one order of magnitude larger than the
endolymphatic physiological backpressures of 0.33–0.53 kPa in the guinea pig [186] (no
measurements were available for the mice). The results (Figure 3.10B) indicated that the
micropump can provide almost linear results (R2 = 0.98) through the 10–100 nL/min range,
suggesting wax melting / crystallization kinetics are not a limiting factor in micropump
performance across the actuation frequencies explored. The results also indicated that
applying 5 kPa backpressure did not significantly affect the flow rate. Further, a pulsatile
flow was observed; actuation of each chamber causes a forward pulse, while filling/loading
of chamber 3 results in a backward flow. This can reduce pump efficiency.

3.8.2 Pump performance at different ambient temperatures

Pump performance was characterized at different ambient temperatures to evaluate
functionality after implantation, considering the possible variation in the body temperature
and ambient temperature. The experiments were performed at 0.015 Hz, 0.1 Hz, and 0.21
Hz actuation frequencies, which represented the minimum, middle, and maximum
frequencies, respectively. The ambient temperature was changed to Tamb-3, Tamb, and
Tamb+3 to assess the functionality of the micropump at a ±3˚C variation from the ambient
temperature. The results indicated that the ambient temperature had a minor effect on the
micropump flow rate (i.e., < 5% change) (Figure 3.10C).
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3.8.3 Pump assessment for in vivo acute experiment

The micropump was set to provide 50 nL/min for 20 min to assess its capacity for
replicating the acute in vivo experiment. In the acute in vivo experiment the micropump
was tested using a mouse model system inner ear drug delivery paradigm [25] in which
salicylate was delivered to the RWM niche for 20 min at 50 nL/min using a syringe pump.
To test the capacity of the micropump to replicate the same experiment, it was set to
provide 50 nL/min for 20 min. The results (Figure 3.10D) indicated that the micropump
provided an average flow rate of 50.2 nL/min (standard deviation = 0.96 nL/min). The flow
rate fluctuation was approximately ±2%, and 1,004 nL drug was delivered over the 20 min
period (0.4% error).

3.8.4 Flow rate resolution

Characterization of micropump resolution at different flow rates included the entire
suggested range of 10–100 nL/min. Experiments were performed at 10, 50, and 100 nL/min
to test the minimum, in vivo infusion, and maximum flow rates, respectively (Figure
3.10E). For the 10 nL/min rate, the actuation frequencies were changed by 0.00075 Hz
until the flow rate was statistically different compared with the reference flow rate of 9.94
nL/min. The lowest resolution for this flow rate was 1.24 nL/min. For the 50 and 100
nL/min rates, the actuation frequencies were changed by 0.0025 Hz until the differences
were statistically significant. The lowest resolutions for the 50 and 100 nL/min rates were
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2.35 and 2.39 nL/min, respectively. Therefore, the worst-case flow rate resolution was 2.39
nL/min.

Figure 3.10. A) Photograph of the peristaltic micropump with a commercially available
microcatheter and a 3D-printed structure around it on the back of a printed circuit board. B)
The pump was characterized at 10–100 nl/min flow rates and 0–5 kPa back pressures
optimized for the target intracochlear drug delivery application. Each data point is the mean
value of five trials; error bars represent one standard deviation. C) Performance of the pump
at 50 nL/min (required for the in vivo test) for 20 min indicated precise flow rate control. D)
Characterization of micropump resolution at flow rates of 10, 50, and 100 nL/min; the
greatest resolution was 2.39 nL/min. Each point is the mean value of five trials; error bars
represent one standard deviation. E) Pump performance at different frequencies and
ambient temperatures. The variation in flow rate was not statistically significant by changing
the ambient temperature by ±3˚C. Each point is the mean value of five one-min trials; error
bars represent one standard deviation.
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3.9 In vivo results and discussion

In vivo experiments were performed using three mice. A cannula connected to the same
micropump was placed near the RWM. Figure 3.11 shows the effect of RWM perfusion of
sodium salicylate delivered at a 50 nL/min flow rate. The effects on the DPOAE threshold
shifts were recorded from three different mice over the course of 20-min. The results for
the mean threshold shifts are presented in panel A and compare the changes in DPOAE
thresholds to baseline at four time points (i.e., post-surgery (PS) in which DPOAE values
were acquired immediately before the pump was turned on, 0 min, the time at which the
pump was turned on, and 10 and 20 min following the onset of salicylate perfusion. A
baseline measurement was acquired approximately 10–15 min before the cannula
placement surgery was performed. There was a systematic increase in threshold shift
during the 20-min perfusion; there was a mean shift of 15 dB for the most basal region. In
this case, the same pump was used for the three different mice. Panel B presents the results
for the period for a mean threshold shift at 51 kHz. The perfusion was stopped at 20 min
and DPOAE values were continuously recorded.
Figure 3.12 shows the DP threshold shift for three different pumps implanted in three mice
in which sodium salicylate was perfused. The actual threshold shift was referenced to the
baseline condition. The time course of the threshold shift or the loss of outer hair cell
motility due to dysfunction in prestin was consistent across the three micropumps. The
maximum shift was between 15 to 29 dB and was observed in the most basal (51 kHz)
cochlear location consistent with salicylate delivery to the RWM niche.
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Figure 3.11. In vivo intracochlear delivery of sodium salicylate elevated otoacoustic
emission thresholds from 8 to 51 kHz in three mice. In each mouse, the cannula was
implanted near the round window via a bullaostomy. A) Mean DPOAE threshold shifts from
three mice recorded during 20 min after the start of a salicylate infusion. DPOAE thresholds
systematically increased as a function of perfusion time from the start of the perfusion (0
min) to 20 min. B) The mean DPOAE threshold shift for the most basal cochlear region, 51
kHz plotted as a function of time following the start of the sodium salicylate infusion. Post
20 and post 40 min denote the measurement times after turning off the pump. PS = post
surgery; post 20 = 20 min after stopping infusion; post 40 = 40 min after stopping infusion.
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Figure 3.12. DPOAE threshold shift (51 kHz) for the most basal cochlear region, following
sodium salicylate infusion, plotted as a function of time for three micropumps. The time
points refer to DPOAE acquired at PS-post surgery, 0 min – start of pumping, and 10 and 20
min following the onset of pumping.
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3.10 Conclusion

We developed a novel miniature, fully implantable, and scalable phase-change peristaltic
micropump with wireless control. The micro- pump was realized using 3D-printing
technology to build the mechanical components around catheter microtubing on the back
of a PCB. On the front side of the PCB, the electronic components were assembled to
actuate and control the micropump, along with enabling wireless control. In vitro
characterization results indicated the micropump achieved nanoliter-level resolution of
delivery in the specified range of 10–100 nL/min in the presence of up to 10× larger than
physiological backpressures. Small variations in ambient temperature were found to not
significantly affect the results. An in vivo experiment was performed by implantation of
the catheter microtubing of three different micropumps in the RWM of six mice for
delivery of sodium salicylate. The results indicated that the DPOAE response was
consistent across different micropumps and different animals. This proof of concept in vivo
success of our advanced micropump technology used in the mouse (cochlea volume ~ 620
nL) indicates translational opportunities. Using appropriate scaling of the microtubing size
and actuator volume, the micropump is inherently scalable for use in larger species and
clinical applications in children and adults. Our results indicated that this advanced
micropump can provide organ-targeted drug delivery to avoid systemic side effects and
maximal control of drug concentration and timing parameters.
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Chapter 4

Biocompatibility Of Microsystem
Materials

4.1 Introduction

The biocompatibility experiments on the materials used to make the pump structure and a
pump prototype are described in this section. These experiments were done prior to
subcutaneous implantation tests. Details of in vitro experiments on pump materials along
with quantitative results are presented. Finally, qualitative assessment on a pump prototype
that was implanted for a long time is demonstrated.
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4.2 Materials and methods

Biocompatibility of all materials in contact with the drug or tissue was assessed before
chronic subcutaneous implantation tests. The biocompatibility experiments were
performed on key micropump components: the micropump tubing, parylene-coated tubing,
and Polydimethylsiloxane (PDMS). PDMS will be used for the subcutaneous implantation
tests. An early step in this process involved performing a cell growth curve to set a baseline
for normal cellular growth. The key micropump components were then added to assess
effects on cell health and viability. Biocompatibility of the material was evaluated by
comparing the cell viability assay results when using the micropump materials with the
control baseline cell growth viability results (i.e., without use of the pump materials).
The first experiment established the health and viability of the control cells. The growth of
random samples of human mammary epithelial cells (ATCC-HMEC cell line) was
recorded. Each day for 11 days, ten random samples of human mammary epithelial cells
were removed from a 75 cm2 flask. Cell numbers were assessed in a cross-sectional area
of 0.5 mm by 0.5 mm, or 700 pixels by 700 pixels, using the cell counter program NIHImageJ. Five cross-sectional areas were chosen for each sample (Figure 4.1). The first area
was taken from the top left, the second from the top right, the third from the center, the
fourth from the bottom left, and the fifth from the bottom right of the photograph (Figure
4.1). The cells that were on the boundaries of the top and left sides of the boxes were
counted, and the cells that were on the boundaries of the bottom and right sides of the box
were not counted. The results were recorded in a Microsoft Excel spreadsheet, the mean
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values for the five cross-sectional areas for each sample were calculated, and the mean
results for each day were estimated. The days and mean cell numbers were graphed to
display a cell growth curve that showed the growth of the cells over time.

Figure 4.1. One representative sample from the last day of an 11-day cell growth period. The
five areas indicating where cells were counted are illustrated. The mean values from five
areas were calculated, and then the total cell counts among the 10 samples from Day 11
were averaged to obtain one cell count value for Day 11. Similar analyses were performed
on Days 1–10. The data were plotted to obtain the cell growth curves

The second experiment was performed for quantitative assessment of the cell viability of
the control cells (no pump parts) versus the cells grown in the presence of key pump
components. The cell viability assays used included the XTT, MTT, and BDRU tests of
cell health and viability. These in vitro assays are a first step towards ISO 10993
biocompatibility tests, which are more involved in vivo tests of toxicity, irritation and
hemocompatibility. If the in vitro assays of the present report show biocompatibility of the
pump parts, then the more extensive ISO 10993 tests should be undertaken. The ATCCHEMC human epidermal epithelial cell line was used for the biocompatibility and viability
tests here. The cells were seeded into 96-well culture plates, the groups were set up as non102

treated and treated (e.g., parylene, PDMS, pump tubing, or a combination) groups for 2 or
7 days. Each experiment was repeated three times.
For the MTT assay [201], the cells were seeded in 96-well culture plates and exposed to
different conditions. Then, 20 µL MTT (5 mg/mL stock solution) was added to each well,
and the plates were incubated at 37 ˚C for 5 hrs. Thereafter, the medium was gently
removed from each well, and 200 µl DMSO was added to each well to dissolve the purple
formazan crystals. The absorbance at 570 nm wavelength was recorded using the Dynatech
MR5000 spectrophotometer (Dynatech Laboratories, Inc., Chantilly, VA).
For the XTT assay [202], the electron coupling solution was added to XTT reagent (1:50
volume ratio) to make an XTT detection solution (Cell Signaling, #9095). Five ml XTT
solution and 0.1 ml electron coupling solution were added to each well. Then 50 µL XTT
detection solution was added to each well that contained the 100–200 μl/well culture
medium and the plate was returned to the incubator. Absorbance at a 450-nm wavelength
was recorded. The optimal incubation time for this assay depended on the experimental
setup (e.g., cell type, cell number, and treatment). Optimization of incubation time was
determined by reading one plate at various time points after addition of the XTT detection
solution.
The BRDU-test was performed according to the manufacturer’s instructions (Cell Signal
kit #6813).

Cells were seeded in each well of a 96-well plate, then 100 µL/well

Fixing/Denaturing Solution was added to each well. The solution was removed after a 30min incubation at room temperature. Prepared 1X detection antibody solution (100
µL/well) was then added, and the plate was incubated at room temperature for 1 hr. The
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solution was discarded, and the plate was washed three times with the 1× Wash Buffer.
Prepared 1× HRP-conjugated secondary antibody solution (100 µL/well) was then added
and the plate was incubated at room temperature for 30 min. The solution was removed,
and the plate was washed three times with the 1× Wash Buffer. TMB Substrate (100
µL/well) was then added, the plate was incubated for 30 min at room temperature, the
STOP Solution (100 µL) was added. Absorbance (450-nm wavelength) was then measured.
To obtain the most accurate result, the absorbance was recorded within 30 min after adding
the STOP Solution.
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4.3 Biocompatibility results

The results of the control cell line growth experiment indicated that the numbers of cells
increased each day and cell morphology became more developed over time (Figure 4.2A).
The results for the cell growth function for the cell culture used and the predicted
theoretical exponential cell growth curve are presented in Figure 4.2B. The close
correspondence between the two functions indicated normal, healthy cell growth and
healthy and viable cell cultures. Based on the results of the cell growth curve, during the
subsequent experiments cell growth was measured on days 2 through 7 because during this
period cell growth approached linearity and was the most substantial.
For the second experiment, key pump components were added separately or combined to
the cell culture dishes. Cell viability assays were performed on Days 2 and 7. A
representative micrograph of a cell culture dish with the tubing placed within the growing
cells is presented in Figure 4.2C. The quantitative results for the three-cell health and
viability assays, compatible with the ISO 10993 standard tests for implantable medical
device biocompatibility, for Day 7 are presented in Figure 4.2D. In each case, the assays
were performed with the materials alone as a comparison condition, then with the pump
component materials in the cell culture dishes with the growing cells. The control condition
(far right bar on the histograms) provided the cell viability measurements for the cells alone
(i.e., no pump components in the cell culture dish). The main finding was that there were
no statistically significant between-group differences for cell health, biocompatibility and
viability for any of the pump component conditions compared with the control condition.
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After successful completion of in vitro biocompatibility testing of the pump materials, we
implanted a subcutaneous prototype pump on the back of a young adult CBA/CaJ mouse
(Figure 4.3). The power supply connector was exposed on the top of the skull. The mouse
recovered, and no morbidity was observed following the implantation. Post-implantation,
the mouse was monitored daily and the results indicated that the overall health was
excellent. There were no statistically significant body weight changes; any signs of
inflammatory or immune responses, or any indications of infection, such as swelling,
redness, fever or presence of discolored fluid. Future studies will examine the tissue
surrounding the implanted pump systematically for histological signs of inflammation in
vivo.
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Figure 4.2. A) Micrographs taken from the center of a sample (Section 3 in Figure 4.1) at Day
1, Day 2, Day 5, Day 7, Day 8, and Day 11. The photographs illustrate how the numbers of
cells increased each day, and that cell morphology became more developed over time. B)
Cell growth curve of the human mammary epithelial cells. The curve was similar to the
expected exponential growth curve. This result indicated that the cell line used for the cell
viability biocompatibility assays met the healthy growth metrics requirement. The curve
followed the trend line (blue line, y= 23.322 e0.3262x) exponential curve, residual value = 0.95.
C) Micrograph illustrates the polyurethane-based catheter tubing placed in the well
containing human mammary epithelial cells. Under experimental biocompatibility
conditions, cells were harvested from the regions directly around the tubing and cell
viability assays were performed. The results were quantitatively compared to the cells in the
control dishes, which were presented in Figure 4.1, Figure 4.2A, and B. D) Histogram results
indicate there is no statistically significant difference in the cell health and viability
quantitative measurements for the human mammary epithelial cells, with and without the
pump components. The “materials” measurements represent a comparison condition
where only the components were in the dish, with no cells. Under the “materials & cells”
conditions, the components were placed in the cell culture dishes on Day 0; the components
were in the dishes as the cell size and number increased over a period of 7 days. The farright bar on the three histograms is the “Cells only” Control condition (i.e., no pump
components were present in the dish during cell growth).
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Figure 4.3. Photos showing the system following subcutaneous implantation in a CBA
mouse following one month of implantation. Note the lack of inflammation or infection in
the skin surrounding the implant area, and the mouse health and behavior was normal.
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4.4 Conclusion

Implantability of the micropump was assessed using a biocompatibility evaluation of the
micropump components and a system prototype. Our findings showed that the micropump
components passed key biocompatibility tests, which indicated that they were suitable for
translational applications, including subcutaneous implantation in humans and animal
models.
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Chapter 5

A Modular Microreservoir For
Active Implantable Drug Delivery

5.1 Introduction

Drug delivery systems have become of interest to researchers in the past decades for
improving therapeutic response by providing more consistent blood level compared to
immediate release or sustained release parenteral depot, enabling less frequent and more
efficient dosing, and improving patient comfort, safety, and compliance. Microscale
reservoir-based delivery systems result in miniaturization of the delivery systems while
allowing more precise control of the delivery rate for both systemic and site-directed
delivery [203]. Specifically, these systems assist site-directed delivery by enabling access
to relatively inaccessible sites or a specific tissue type, along with limiting side effects of
systemic exposure. Microscale reservoir-based delivery systems can be categorized into
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three types: oral, dermal, and implantable delivery, which the latter is the focus of this
work.
Implantable microscale reservoir-based drug delivery systems enabled novel and effective
drug delivery concepts for both systemic and targeted drug delivery applications[203].
Implantable drug delivery systems have been classified into two categories [36], [204]–
[207]: (i) passive, where post-implantation drug release control is not feasible since it is
pre-determined by the fabrication methods, materials, and drug formulation, and (ii) active,
where post-implantation drug release control is enabled using electrical, mechanical,
magnetic or other actuation methods. Passive implantable drug delivery systems are driven
by osmotic potential or diffusion. These microsystems were employed in various
applications such as ophthalmology [208]–[214], oncology [215]–[217], interventional
cardiology [218]–[221], precocious puberty [208], acromegaly[222], Hepatitis C [222]–
[224], prostate cancer [225]–[227], pain indications [228], type 2 diabetes and Hepatitis
[229]–[233]. In contrast, active implantable drug delivery systems are driven by
mechanical pumping [144], [145], electrolysis[234], and other actuation methods, which
enable patient or physician to start/modify/stop drug release interactively. These systems
have been used for emergency care [235], [236], treatment of ocular diseases [237], [238]
and cancer [239], and general application in small animals [240]. Active implantable drug
delivery systems generally consist of a drug reservoir and a micropump for precise delivery
of small volumes of a drug from the reservoir to the target organ. These systems are often
normally-closed or have a check valve in the reservoir downstream.
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The drug reservoir is an often overlooked component of the active implantable drug
delivery microsystems. Depending on the application, drug reservoirs can be refillable or
non-refillable. Non-refillable microsystems are usually disposable; they are filled with the
drug, implanted, and actuated to discharge the drug. These microsystems have been used
in insulin delivery [241], [242], ophthalmology [243], and emergency care [235], [236]. In
most of the active implantable drug delivery systems, the drug reservoir is refillable,
enabling physicians to transcutaneously refill the reservoir via injections through sharp,
thin, non-coring needles into septa in a designated refill port in the system housing [244],
[245]. The septa are usually made of silicone rubber[244] with self-healing[246]
capabilities due to high resilience[247] and high deformability and self-adherence[248],
[249]. The ports typically have a base plate for penetration depth limitation and a cavity
between the septum and base plate with an exit channel to provide a fluidic connection to
the cavity membrane[147], [250], [251]. In some cases, a raised ridge[147], [252] or a ring
with different color[238] is incorporated to assist palpation or visual identification for the
surgeon.
Although there are several microsystems in the literature or commercially available that
use a septum for refilling[147], [253], only a few of them report the number of punctures
they can withstand without leakage. The first refillable microelectromechanical (MEMS)
drug delivery device was developed by Lo et al. for the treatment of ocular diseases [237],
[238], [254], [255]. Refilling could take place through the top surface of the microsystem,
made of polydimethylsiloxane (PDMS), while a Polyether ether ketone baseplate was
embedded to control the penetration depth. The refilling port prevented leakage until up to
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24 punctures under ~5 and ~30 kPa backpressures for membrane thicknesses of 250 µm
and 673 µm, respectively. PROMETRA® programmable pumps (InSet Technologies
Incorporation, NJ, USA) use silicone rubber for the septum, rated for withstanding an
average of 1000 punctures. Hamilton® GC Septa are rated for a maximum of 100 injections
using a 26s Ga needle, with a minimum thickness and diameter of 3 and 5 mm.
The dynamics between the fluid stored in the reservoir and the downstream environment
when the pump is deactivated is an important feature in the design of the reservoirs. Since
the reservoir membrane material is typically made of rubber-like or metal materials,
extraction of the drug causes a restoring force. This restoring force can result in a potential
backflow, which in the literature were compensated by either external compression of the
membrane[256] or replacement of the drug with electrolysis gases[255]. If not
compensated in the cavity area, the backflow is usually prevented with normally-closed
micropumps between the reservoir and the downstream system [147], or check valves
[238], [240]. To the best of our knowledge, there is no reported microsystem utilizing a
cavity membrane with negligible restoring force to integrate to micropumps.
Laboratory animal models play an important role in understanding and treating human
diseases. The most common animal models (approximately 95%) in research are rats and
mice[257]. However, mice are preferred since they are easier to be genetically manipulated
[258]. Further, for subcutaneous implantation to be a minor procedure, the surgery should
involve less than 10% of the animal’s surface area [259]. These considerations necessitate
the need for both miniaturization and scalability of a microsystem for experiments in small
animal models (e.g., mice), and later translation to humans. Most of the reported studies
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and commercially available drug delivery microsystems have the reservoir and pumping
mechanism integrated [240], [253]. Due to limitations for scalability of pumping
mechanism, especially for MEMS-based devices, scalability of these devices is
challenging. This necessitates the development of a stand-alone implantable microreservoir
with different capacities for integration to different micropumps with different flow rates.
Here we present a stand-alone, refillable, scalable, and fully implantable microreservoir
platform to be integrated with micropumps as the storing component of an active
implantable drug delivery microsystem. This microreservoir platform is intended to have
a small footprint and a planar form factor for subcutaneous implantation, especially in
small animals (e.g., mouse), while being readily scalable for larger animals and human
translation. Using 3D-printing technology to fabricate the microreservoir structure, three
different capacities of the microreservoir are demonstrated and characterized (1 µL, 10 µL,
and 100 µL). The cavity membrane is fabricated with thin Parylene-C layers using
polyethylene glycol (PEG) sacrificial layer and optimized for minimal restoring force as
fluid is discharged. The septum thickness is minimized by a novel pre-compression concept
enabling thinning of the overall system, while capable of thousands of refills without
leakage. To demonstrate integrability of the microreservoir design, it was integrated into a
micropump reported in our previous work [73] and implanted in mouse models for inner
ear drug delivery. Results indicate functional round window membrane (RWM) drug
delivery. Long-term biocompatibility was assessed in vivo over six months.
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5.2 System overview and concept

To build a microscale, yet scalable structure, stereolithography (SLA) fabrication approach
was employed. Formlabs SLA 3D-printer (Form 2, Formlabs Inc., MA, USA) was used to
fabricate a rigid biocompatible structure comprising a refill port, cavity area, an outlet port,
microchannels to connect them, and a baseplate. This rigid baseplate controls the
penetration depth of the refill needle while provides a surface to form the cavity membrane.
The rigid frame protects the enclosure and ensures sufficient rigidity for handling.
To provide a completely inert and biocompatible environment for therapeutic compounds,
the stored drug was designed to be encapsulated with parylene, which is a USP Class VI
material suitable for implant construction. Furthermore, parylene has less permeability to
liquid compared to other common materials used in the literature for reservoir membrane,
such as PDMS [237] and MDX-4-4210 [240]. After the first layer of parylene deposition,
Molten PEG was deposited on the cavity area and solidified to build a biocompatible
sacrificial layer, a technique that has been used to form parylene-made cavities [240]. A
second parylene layer was deposited on the PEG sacrificial layer to build a thin pre-formed
dome-shape cavity membrane. The pre-formed shape and thinness of the cavity membrane
enable discharge of the fluid and collapse of the cavity membrane without having a
significant restoring force that would result in original shape recovery and undesirable
backflow from the outlet. The seal between two parylene layers is enhanced using a
compressed biocompatible silicone-made gasket on the cavity edge. The thicknesses of the
cavity membranes for three different capacities (1, 10, and 100 µL) were optimized for 100
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kPa backpressure, which is four times larger than maximum physiological backpressure in
human [260]. This backpressure was used as a criterion for both cavity membrane and
septum characterization. For all the cavity sizes, the overall thickness of the microreservoir
is set to 3 mm, which was shown to be suitable for long-term subcutaneous implantation
in mice. An overview of the microreservoir concept is illustrated in Figure 5.1.
The refill port has a 2.5 mm hole for the septum and a built-in septum stopper to ensure
space between the septum and the baseplate, allowing fluid flow to the cavity area. The
2.5-mm septum is micro-molded in cylindrical shape using a biocompatible silicone rubber
followed by parylene deposition, to provide complete encapsulation of the drug by the
parylene. A cap with a raised compression ring was placed and fixed on the septum to
provide vertical compression which improves sealing and facilitates fixation of the septum
in the port during injection, which was a challenge in previous reports [261], [262]. The
compression cap also causes the septum to laterally push the port wall, inducing lateral
compression in the septum, enhancing its self-healing and therefore, increasing its
endurance to punctures without leakage. This feature facilitates a significant reduction of
the septum thickness, enabling septum down to 1mm thickness to be successfully used. A
raised ridge is designed on top of the septum cap to enable subcutaneous palpation and
visual access over shaved skin, for performing refills.
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Figure 5.1. A) Conceptual schematic of the microreservoir. The structure of the
microreservoir is made of two main sections: the refill port for refilling the microreservoir
by injections through a septum, and the cavity area for storing the drug. The structure is
made with 3D-printing technology using a biocompatible resin, enabling printing microscale features that are readily scalable, enabling applications from mice to humans. B) The
septum cap incorporates a compression ring that causes the septum to be compressed
both vertically and laterally. The vertical compression ensures sealing from the bottom and
holds the septum during multiple injections. The lateral compression induces internal stress
in the septum to improve its performance with numerous injections without leakage. This
feature enables reduction of the septum thickness while maintaining high resistance to
numerous punctures. C) The cavity membrane is made of a pre-formed dome-shape thin
parylene layer, enabling negligible restoring force after partial/full discharge of the cavity
when the pumping mechanism is switched off. This feature facilitates the integration of the
microreservoir to normally-open micropumps and eliminates the necessity of using check
valves for low-backpressure environments. Further, when integrated to normally-close
micropumps, the constant backpressure on the check valves are eliminated and the
pumping efficiency increases. Finally, since the entire internal surface of the microreservoir,
including the septum and the cavity membrane, is coated with a parylene layer, long-term
biocompatibility for drug storing is ensured.
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5.3 Fabrication process

The microreservoir substrate was 3D-printed (Form 2, Formlabs Inc., MA, USA) using a
rigid biocompatible material (Dental SG resin, Formlabs Inc., MA, USA) creating a hole
of 2.5-mm diameter and 1-mm depth for the septum, cavity area, outlet port, fluidic
interconnections between them, and a baseplate. In the cavity area, a raised circle-shaped
ring was considered for placing the gasket, with an angled wall to the baseplate to reduce
the cavity dead volume. In the refill port, a septum stopper with a diameter of 1.8 mm was
designed, providing a seat for the septum. A polyurethane-based catheter microtubing
(ID=125 μm, OD=250 μm; Micro-Renathane® Catheter Tubing, Braintree Scientific Inc.,
MA, USA) was fixed and sealed to the output port, using cyanoacrylate. The structure was
coated with a 1-μm-thick layer of parylene using PDS 2010 LABCOATER™ 2 (both
Specialty Coating Systems, Indianapolis, IN, USA).
Cavities with three different capacities (1, 10, and 100 µL) were fabricated, where the
diameters of the cavity area for each of them were empirically found to be 1.5, 3.1, and 10
mm, considering 3 mm objective for the overall thickness. To build the cavity membrane
with parylene-C, a sacrificial layer is required, which defines the capacity of the cavity
after release. PEG (1,500 Mn, melting point: 37 °C, Sigma- Aldrich, MO, USA) was
chosen for the sacrificial layer due to its biocompatibility and solubility in water. PEG was
melted at 70 °C on a hotplate and mixed with a dye (McCormick & CO., MD, USA) for
visual confirmation of its release. Using a heated micropipette (70 °C), PEG was deposited
on the cavity area which was held at room temperature and treated with hydrophobic spray
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(Scotchgard™ Fabric & Upholstery Protector, 3M Co, MN, USA) for quick solidification
of PEG and avoiding its flow into the space under the septum and the gasket raised ring. It
was empirically found that keeping the substrate at room temperature can result in smooth
PEG surfaces, while providing a sufficiently fast cooling rate to avoid the flow of the PEG
in the channel regions. The full volume of required PEG (1, 10, and 100 µL, considering
phase-change expansion of PEG) were deposited with a single micropipette dispense.
To make the cavity membrane on top of the PEG sacrificial layer, the required thickness
of the second parylene layer for different capacities was estimated based on thin-walled
spherical pressure:

σ = pr / 2t

(5.1)

where σ, p, r, and t represent tensile stress on the membrane, internal pressure, cavity
radius, and membrane thickness, respectively. The membrane is designed for 100 kPa
backpressure or refilling pressure (p= 100 kPa), while the radius was determined based on
overall thickness and capacity. The thicknesses of the parylene membrane for each cavity
size was calculated to achieve membrane stresses smaller than the tensile strength of
parylene (69 MPa [263]) by a factor of 5. The thicknesses of deposited parylene membranes
were 2.7, 5.6, and 18.1 µm for 1, 10, and 100 µL capacities.
Silicone rubber (MED-6215, NuSil™ Technology LLC, CA, USA) gaskets with 0.5 mm
width and height with inner diameters of 1.5, 3.1, and 10 mm for capacities of 1, 10, and
100 µL, respectively,

were micro-molded using a parylene-coated aluminum mold

fabricated with conventional machining. The gaskets were cured at 150 °C for 15 min. The
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gaskets were placed on the cavity area and was fixed and compressed using a cavity cap
which was 3D-printed (Form 2, Formlabs Inc., MA, USA) and parylene coated, to provide
mechanical compression on the touching surface of two parylene layers for a tight seal.
The cavity cap also covers the cavity membrane to protect it from external mechanical
stress. Vent holes with 0.2-mm diameter were made in the cavity cap to allow ingress and
egress of air or liquid from the space between the cap and the cavity membrane during
filling and discharging. These holes are smaller than the smallest needle size for this
microreservoir (30 Ga, 311 um OD) to avoid inadvertent puncture of the membrane during
subcutaneously refilling. The use of class VI biocompatible silicone rubber for the gasket
and parylene deposition of the cavity caps minimizes the risk of inflammation with direct
contact to body tissues.
Under visual observation using a microscope (Motic SMZ-168), the substrate was heated
on a hotplate at 70 °C to melt the PEG, allowing it to be rinsed away with 100 mL 70°C
deionized (DI) water. A silicone septum with 2.5 mm diameter and 1 mm thickness was
micro-molded using parylene-coated 3D-printed molds and cured at 150 °C for 15 min and
were coated with 1 µm parylene layer. The septum was placed in the refill port followed
by placing and affixing a 3D-printed septum cap using cyanoacrylate. The septum cap
incorporates a 0.2-mm-thick compression ring (1.8 mm ID, 2.5 mm OD) to compress the
septum to provide internal stress for improving its self-healing properties. A raised ridge
(1.8 mm ID, 3 mm OD, 0.5 mm thickness) was considered for top of septum cap to facilitate
palpation for subcutaneous refilling. All the surfaces were filleted to minimize potential
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mechanical inflammation after implantation. The full fabrication process is illustrated in
Figure 5.2.

Figure 5.2. A cut-view schematic of the microreservoir fabrication process. 1) The substrate
of the microreservoir was 3D-printed using a biocompatible resin, followed by 1 µm
parylene-C deposition. 2)A microtubing (250 μm OD, 125 μm ID) was inserted into the
substrate outlet port and sealed in place with cyanoacrylate. The substrate was placed on
a cold plate at room temperature and molten PEG at 70 °C was deposited on the cavity area
to solidify and create the microreservoir volume. This was followed by another Parylene-C
deposition to create the deformable microreservoir membrane capable of withstanding 100
kPa backpressure. 3) A silicone gasket was fabricated using a micro-molding technique and
was placed within the cavity around the PEG dome. A 3D-printed Parylene-C coated cap was
affixed on top of the cavity area with cyanoacrylate, compressing the O-ring to reinforce
sealing between the two Parylene-C layers, and to protect the cavity from mechanical stress.
The cap has vents to allow egress/ingress of air or fluid between the membrane and the cap
during filling/discharging. 4) The substrate was placed on a hotplate at 70 °C to melt the
PEG and wash it by gentle injection of 100 mL of DI water at 70 °C 5) A 2.5-mm diameter, 1mm-thick septum made of long-term implantable silicone rubber was micro-molded and
coated with parylene-C. The septum was placed in the refilling port (2.5 mm diameter). 6) A
3D-printed, Parylene-C coated septum cap with an extruded compression (2.5 mm OD, 1.8
mm ID) was affixed on top of the septum with cyanoacrylate to compress the septum
providing a sealing force on the bottom and sides while enhancing the self-healing
properties when punctured with refilling needles. 7) schematic cut view of the fabricated
microreservoir being filled by a refilling needle. 8) A schematic full-body view of the
microreservoir.
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5.4 Benchtop experimental method

To assess the functionality of the septum and the cavity membrane, these two parts were
decoupled and tested separately. Two separate sets of test rigs were designed, fabricated,
and tested on samples fabricated following the same fabrication process described in
section 0.

5.4.1 Septum test

The septum was tested utilizing separately fabricated septum samples, consisting of a 3Dprinted refill port with septum stopper and space beneath it along with the outlet coupled
to a Tygon tubing (0.508 mm ID, 1.52 mm OD). The septum and septum cap were then
placed and fixed in the refill port. Although in some studies the septum leakage test is
performed using N2 as the working fluid [261], here we tested the septum using dyed DI
water since it simulates the in situ condition where the septum is in contact with a liquid
drug.
A pneumatic puncture device was designed and fabricated to hold the septum sample and
automatically puncture through the septum in a single location, to test the worst-case
scenario [238], [261]. The structure of the pneumatic puncture device was 3D-printed using
Grey Pro resin (Formlabs Inc., MA, USA), having a groove for the test sample to be placed
and fixed with a set screw beneath the pneumatic puncture mechanism. A miniature
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cylinder (SM-3-1, Clippard Co., OH, USA) was placed and fixed on top of the sample. An
electronic pressure regulator (ITV2030-31N2BL4, SMC Co., Tokyo, Japan) was
connected to the cylinder which was fed with sine waves of 0.2 Hz frequency by a signal
generator, to simulate a realistic manual puncture speed. A needle was affixed to a 3Dprinted needle holder which was press-fit to the piston of the cylinder.
Commercially available 27 and 30 Ga (413 and 311 μm OD) needles were used for the
puncture tests. These sizes were selected as a trade-off between maximizing needle and
septum lifetime: the needles need to be large enough to puncture through the skin and the
septum without bending the tip, while small enough to minimize septum damage.
Furthermore, the opening diameter of the septum cap is 1.8 mm, making needle sizes larger
than 27 Ga impractical. The needles were machined to non-coring shape to minimize
damage to the septum structure [237], [238], [254]. The needle tip was beveled to a point
with a 12° angle recommended for animal injections [264]. Figure 5.3A shows the
pneumatic puncture device with a 30 Ga needle.
Septum samples were prepared for puncture experiments with 27 and 30 Ga needles, where
the septum cap incorporated the compression ring to compress the septum vertically and
laterally for enhanced self-healing. To investigate the effect of the compression ring on the
self-healing characteristics of the septum, one batch of samples (N=4) were fabricated
without the septum cap. Instead, they were fixed and sealed in the refill port using
cyanoacrylate, causing no compression to the septum. 30 Ga needles were used for this
experiment, and the results were compared with the samples with the septum cap
incorporating compression ring, punctured with 27 and 30 Ga needles (N=4 for each).
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To test septum function, the space beneath the septum and 5 cm of the outlet tubing were
filled with dyed DI water using the sharp (12°) non-coring needles, and the septum samples
were fixed in the pneumatic puncture device. The outlet tubing was placed on a ruler. The
signal generator was switched on, and the septum was punctured until switched off after
each step, following a logarithmic scale 100.2 step size. Backpressure of 100 kPa (with
gradual increments) was applied to the outlet tubing for 1 min. The fluid displacement in
the tubing was observed/recorded with a digital microscope (USB-MICRO-250X,
Plugable®, WA, USA) and analyzed with NIH-ImageJ, resulting in a resolution of 2.4
nL/min. Leakage was detected if a backward displacement of the fluid in the tubing was
observed. If no leakage was observed the test continued by switching on the signal
generator until the next step. The number of punctures before leakage was found for each
case based on the last value with no leakage (Figure 5.3B). A manual puncture experiment
was performed to explore septum operation at more practical conditions where a
surgeon/medical doctor refills an implanted device numerous times.

5.4.2 Cavity membrane test

Microreservoir cavity volume, backflow due to membrane restoring force, and total fluid
extraction percentage for three different cavity sizes were characterized. The cavity
samples were fabricated and tested separately, consisting of the cavity membrane
(described in section 5.3), but with modifications to facilitate the test. The cavity inlet was
directly connected to an inlet tubing, a three-way stopcock, and syringes for cavity filling,
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with an outlet tubing aligned over a ruler to quantify fluid movement due to pneumatic
pressure applied to the region above the cavity membrane.
To fill the cavity, the pneumatic pressure was set to zero, and a syringe was connected to
the inlet port and pulled to remove air from the cavity and pull the membrane down to its
minimum volume. The syringe was replaced with a three-way stopcock connecting to the
inlet tubing. Dyed DI water was injected to fill the inlet tube up to the entrance of the cavity
via visual observation under a microscope. A small volume syringe was then connected
via the stopcock to accurately quantify injected volume, with a 25 µL syringe (1702 LT
SYR, Hamilton Co., NV, USA) used for the 1 and 10 µL cavities, and a 250 µL syringe
(1725 TLL, Hamilton Co., NV, USA) used for the 100 µL cavity. With the outlet tubing
open, the syringe was discharged until the fluid was observed to reach the microreservoir
exit. The outlet tubing was clamped closed, and the syringe discharged to fill the cavity,
confirmed by visual observation under a microscope.

The three-way stopcock was

switched to block flow on the inlet side, the outlet tubing clamp released, and the fluid
volume in the outlet tubing quantified. The cavity volume was calculated by subtraction
of the fluid volume in the outlet tubing from the injected fluid volume from the syringe.
The backflow due to restoring force of the cavity membrane was characterized for cavity
fill volumes of ~ 80%, 60%, 40%, 20%, and 0%. Pneumatic pressure was applied above
the cavity membrane for 1 min to induce forward fluid movement, as shown in Figure
5.3D. After discharge of ~20% of the volume, the pneumatic pressure was released, and
the fluid front displacement in the outlet tubing was observed under a microscope for 4 min
(Figure 5.3E). For three different cavity sizes, three different outlet tubing sizes were used
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to have a minimum resolution of 0.1% of the full capacity using a 0.5-mm graded ruler.
The backflow of the fluid front is recorded, and the experiment is repeated for the next
20% of the overall volume. The total fluid in the outlet tubing after the fifth step indicates
the total extraction percentage. Three samples for each of three different cavity sizes of 1,
10, and 100 µL were tested with three replications (N=9 for each size, total N= 27).

Figure 5.3. Benchtop characterization test setup for septum (Top) and cavity membrane
(Bottom) characterization. Septum characterization: A) A custom-made 3D-printed
pneumatic puncture device. Inset: a 30 Ga non-coring 12° beveled needle used for puncture
test. B) The septum test samples were punctured in a single point following a logarithmic
number of punctures with the puncture device fed by a 0.2 Hz sine wave signal. C) With the
needle extracted, backpressure was gradually increased to 100 kPa while the fluid front
displacement was quantified by visual observation under a microscope. Cavity
characterization: D) Following the filling of the microreservoir cavity and fluidically blocking
the inlet, the fluid in the cavity membrane was pumped out via a static pneumatic pressure
on the membrane to provide forward flow. E) The pneumatic pressure was released, and the
backflow in the tubing due to the restoring force of the membrane was quantified under a
microscope. Different tubing sizes were used for the three different cavity capacities (1, 10,
100 µL) to maintain a minimum resolution of 0.1% of the full microreservoir capacity.
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5.5 In vitro results and discussion

The completed microreservoirs are shown in Figure 5.4A. The overall footprints of the
microreservoirs are 4.5 × 3 (1 µL), 7.6 × 4.6 (10 µL), and 14.5 × 11.5 mm 2 (100 µL) with
a thickness of 3 mm for all. In vitro experiments were performed to optimize the septum
design and thickness for thousands of refilling injections without leakage and quantify
backflow due to restoring force after extraction of liquid. Further, the total volume of the
cavities and total extraction percentage of them were assessed. The cavity membrane
experiments were performed on all three capacities of 1, 10, and 100 µL to demonstrate
the scalability of the design.

5.5.1 Septum characterization

The results (Figure 5.4B) indicated that the samples without the compression ring could
not withstand one puncture and leaked at backpressures as low as 5 kPa. In contrast, the
samples with the compression ring withstood up to ~65,000 punctures without any leakage
at 100 kPa backpressure using the 30 Ga needle. However, using the 27 Ga needle reduced
the number of punctures without leakage to 55. Comparison between the results of 30 Ga
needle puncture with and without the compression ring indicates its significance in
increasing the septum lifetime. Further, the results of 27 Ga punctures demonstrate the high
endurance of this septum in taking up to 55 punctures, which is sufficient for many
therapeutic development and clinical applications (e.g., [242], [265]).
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Use of a 33 Ga needle (210 µm OD) dramatically enhances the robustness of this ultrathin
septum to levels that far exceed any practical use case. This smaller gauge needle was
successfully used in our in vivo experiments (section 6.4) with multiple successful
subcutaneous injections in mice. The results of manual punctures of the septum show ~500
punctures without leakage at up to 100 kPa backpressure. The experiment was stopped
after 500 punctures, so the failure point with manual punctures is not known. However,
considering one refill per day, this test indicates that the septum can operate leak-free for
more than one year.
All septum puncture experiments were performed on 1-mm thick septa. Testing on 0.5-mm
thick septa showed poor functionality at low backpressures even with the compression ring.
This could have been due to fabrication limitations for controlling the thickness of the
compression ring and the buckling of the septum due to the lateral force of the compression.
This novel septum design can be employed in any refillable system, independent of the
cavity membrane design.

5.5.2 Cavity membrane characterization

The results indicated that the overall capacities of the cavities were 1.5 ± 0.09, 9.63 ± 0.12,
and 100.04 ± 9.43 (mean ± SD) for target volumes of 1, 10, and 100 µL, see Figure 5.4C.
Figure 5.4D shows the average of extracted volume during pumping and resting for three
different nominal capacities of 1, 10, and 100 µL, normalized by the total volume of each
cavity. Each data point is an average of three sizes, each with three samples and three
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replications (N = 27). The results show that for all steps the backflow was not significant
compared to the overall size (2% average). The backflow at each step occurs relatively
quickly after deactivation of pumping (< 2 min for all cases), ensuring stable behavior of
the cavity membrane for long-term applications. Further, no significant difference in the
backflow was observed across different extraction percentage, except for the last step,
which defines the total extraction percentage of the cavities. The average total extraction
percentage was 95%.
Experiments on samples with twice thicker membranes for all three sizes (N=27) showed
significant more backflow due to restoring force (3.8% average). This significant
difference (p < 0.001) is directly related to the thickness of the membranes. As the
membrane becomes thicker, its resistance to deformation increases, which results in a
higher restoring force and greater backflow when the pneumatic pressure is released. We
hypothesize that the total extraction percentage is a function of the discrepancy between
the surface area of the membrane and the substrate. If the membrane surface area is larger
than the substrate, when fully pushed down by the pneumatic pressure the membrane
wrinkles on the substrate and resists against further pressure. When the pneumatic pressure
is released these areas induce restoring force and backflow. On the other hand, if the
membrane surface area is smaller than the substrate, there is space between the membrane
and the substrate that cannot be swept by the membrane unless with further pressure, which
restores when the pressure is released and causes backflow. The fluid loss due to
evaporation were not explored here because the in situ application of the device is
subcutaneously implanted, which is a moisture-saturated environment.
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Figure 5.4. A) Photograph of completed microreservoirs with capacities of 1, 10, 100 µL,
showing the scalability of the design and fabrication process. B) Septum characterization
results show that the samples without the compression ring leaked at less than 5 kPa
backpressure with just one puncture with a 30 Ga needle. Adding a compression ring to the
septum cap increased the number of punctures before failure to ~65,000 at 100 kPa
backpressure when puncturing with a 30 Ga needle. This design can provide no leakage up
to 55 injections at 100 kPa backpressure when punctured by a 27 Ga needle. N=4, mean ±
SD. C) Comparison between the fabricated volume and the target volume shows 1.5 ± 0.09,
9.63 ± 0.12, and 100.04 ± 9.43 for target volumes of 1, 10, and 100 µL. N=4, mean ± SD. D)
The average results of the backflow due to restoring force for three different capacities of
1, 10, and 100 µL normalized by the total volume of each cavity. The results show that the
overall backflow is not significant (2% average) and occurs quickly (< 2 min) after pneumatic
pressure release, suggesting stable behavior of the cavity membrane in long-term. The last
step of the experiment shows the total extraction percentage. N=27, mean ± SD.
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5.6 Conclusion

We developed a stand-alone refillable, scalable microreservoir designed for integration to
an active pumping mechanism, optimized for subcutaneously implanted microsystems.
The microreservoir structure has two main components: the refill port for refilling with
subcutaneous injection through a septum, and the cavity area to store the drug for longterm applications. The microreservoir was built upon a 3D-printed biocompatible structure,
providing mechanical protection and strength for handling, a stiff baseplate for the needle
at the bottom of refill port, and a baseplate for the cavity area. Further, 3D-printing
technology enables readily scalability of the design, indicating translational opportunities.
The cavity membrane was fabricated with parylene-C using PEG as the sacrificial layer,
over the parylene-C-coated substrate. The septum was fabricated using long-term
biocompatible silicone rubber and coated with parylene-C. The biocompatibility of the
system was reinforced by ensuring that all the materials are biocompatible, even for the
sacrificial layer.
The durability of the septum was significantly improved by adding a compression ring to
the septum cap to induce internal compression in the septum. In vitro characterization
results demonstrate no leakage after up to ~65,000 injections with 30 Ga needle at up to
100 kPa backpressure, which is significantly higher than the maximum backpressure in
human and mice. The suitability of the needle size was verified by in vivo experiments
which showed that needles as small as 33 Ga are sufficient for subcutaneous refills. This
novel septum design can be used in different refillable microreservoirs. Scalability of the
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design and fabrication process was demonstrated by the fabrication of three different cavity
sizes (1, 10, 100 µL) while keeping the overall thickness 3 mm. In vivo experiments
demonstrated the suitability of this thickness for long-term (6 months) subcutaneous
implantation in mice. The thickness of the cavity membrane was optimized to have nearzero restoring force to avoid backflow after pumping the fluid out of the cavity. In vitro
characterization results show that the optimized membrane reduces the backflow as low as
2% of the overall volume of the cavity. This feature permits integration of the
microreservoir to normally-open micropumps for applications with low backpressure (e.g.,
RWM in the inner ear). Further, it eliminates the long-term backpressure on check valves
when integrated to normally-closed micropumps, and improves pumping efficiency.
The presented microreservoir was shown to be able to be refillable for thousands of
injections with minimal backflow due to the extraction of the fluid, when the pumping
mechanism is off. Scalability of the design and fabrication process was demonstrated by
the fabrication of three different cavity sizes (1, 10 100 µL), indicating translational
opportunities. It was also shown that this microreservoir could be integrated with a
pumping mechanism that either sucks the fluid from the outlet tubing (the integrated
microsystem) or pushes the fluid directly from the top surface of membrane using
pneumatic pressure (the cavity membrane test). Future work will incorporate a pumping
mechanism from the membrane top surface for LOC or drug delivery applications.
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Chapter 6

Fully Implantable Microsystem For
Inner Ear Drug Delivery

6.1 Introduction

The micropump presented in Chapter 3 and the 10 µL microreservoir demonstrated in
Chapter 5 were integrated, making an implantable microsystem for inner ear drug delivery.
In this chapter the fabrication process of the microsystem for integration of these two
devices are presented along with details of implantation surgery. Inner ear drug delivery
using this microsystem is briefly described here, while more details can be found in section
3.7. Details of a long-term biocompatibility experiment is presented along with details of
histology methods. Results of acute delivery of Salicylate into RWM matched with syringe
pump. Further, the long-term biocompatibility experiment showed that the microsystem
can be subcutaneously implanted for long-term without significant inflammation or
infection.
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6.2 Fabrication process

To demonstrate integrability of the microreservoir to a micropump, a 10 µL microreservoir
was integrated with an implantable micropump for inner ear drug delivery, recently
developed in our group [73]. A miniature container was 3D-printed for the micropump
right beside the microreservoir, while the overall thickness was kept at 3 mm. Fillets with
1 mm radius were applied to the container walls to provide curved surfaces to improve
long-term subcutaneous implantability. The microreservoir was built following the
fabrication process outlined in Figure 5.2. The micropump was placed in the container, and
its microtubing was placed and sealed to the microreservoir outlet using cyanoacrylate. The
micropump was then fixed in the container using cyanoacrylate, and the silicone rubber
(MED-6215, NuSil™ Technology LLC, CA, USA) was poured in the container and cured
at room temperature for 48 hrs. To soften the device surface, the entire microsystem except
the cavity cap was covered with a thin layer of silicone by manually applying droplets of
silicone to evenly coat the outer surface and cured at room temperature for 48 hrs.
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6.3 Experimental methods

The integrated microsystem (microreservoir + micropump) was tested in vivo to show its
suitability of subcutaneous implantation, functionality for acute drug delivery to the mouse
inner ear, and capability for long-term implantation. The drug delivery test was performed
following a protocol developed by our laboratory [25], for the administration of sodium
salicylate, leading to temporary hearing loss – reversible shifts of otoacoustic emissions
thresholds and levels. Salicylate can act as a competitive antagonist at the anion-binding
site of prestin [196], which causes reversible disruption of outer hair cell motility.
Specifically, this disruption of prestin causes a reduction in distortion product otoacoustic
emission (DPOAE) amplitudes and thresholds. Therefore, salicylate was delivered to the
round window membrane (RWM) and auditory function was evaluated using DPOAE
measurements. To evaluate long-term biocompatibility, the microreservoir was implanted
for six months with frozen sections of surrounding tissue analyzed histologically for signs
of inflammation. Finally, to explore capability of the micropump for self-priming was
explored.

6.3.1 Subcutaneous implantation and biocompatibility

The anesthetic used was ketamine (120mg/kg body weight), xylazine (10 mg/kg body
weight) in combination with topical application of 4% lidocaine for analgesia for the
implant surgery. Specifically, a young adult CBA/CaJ mouse was positioned on a servo135

controlled heating pad maintaining aseptic conditions, and when the proper plane of
anesthetic was achieved (toe pinch, heart rate, respiratory rate), the upper back was then
shaved and cleaned, and the microsystem was inserted subcutaneously in the center of the
upper back via a small incision. Supplementary doses at one-third of the initial dose were
administered as needed to maintain the proper levels of general anesthesia. Following
insertion ventral to the dermis, Medical grade adhesive (Loctite 4206, Rocky Hill, CT) was
used to secure the wound closure, along with several stitches to close the incision over the
microsystem.
After survival for six months, the mouse was sacrificed by an overdose of anesthetic via
intracardial perfusion with 4% paraformaldehyde fixative. Next, tissue samples were
dissected from around the microsystem and prepared for standard frozen sectioning
followed by hematoxylin + eosin (H&E) tissue staining to visualize cellular locations and
structure around the microsystem. All animal procedures were approved by the University
of South Florida Institutional Animal Care and Use Committee and were performed using
the National Institutes of Health and veterinary standards of care.

6.3.2 Inner ear drug delivery

Two young adult (2-4 months of age) CBA/CaJ mice bred and raised in-house were used
for this study. After subcutaneous implantation of the microsystems in the center of the
upper back (section 0), a bullaostomy surgery was performed to prepare a site for infusion
of the salicylate into the middle ear cavity. A mixture of ketamine (120 mg/kg body weight)
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and xylazine (10 mg/kg body weight) injected via the intraperitoneal route to deeply
anesthetize the mice for the bullaostomy surgery. The left ventral surface of the neck was
then shaved and cleaned. Surgery was performed on the left (ipsilateral) ear following
procedures described by Borkholder et al. [25]. During infusions, each mouse was
immobilized using anesthesia with supplementary doses at one-third of the initial dose
administered as needed to maintain the proper levels of general anesthesia.
Auditory function was assessed via automated DPOAE threshold measurements at F2
frequencies of 8.9 kHz, 13.5 kHz, 17.9 kHz, 24.6 kHz, 35.8 kHz, and 51.4 kHz.
Measurements performed before the surgery were used for a baseline to compare
subsequent DPOAE threshold shifts. Further details of auditory function assessment are
presented in our previous work [73], [200].
The salicylate solution consisted of NaCl (120 mM), KCl (3.5 mM),CaCl2 (1.5 mM),
glucose (5.5 mM), HEPES buffer (4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid,
20 mM), and sodium salicylate (50 mM). The pH was adjusted to 7.5 using NaOH. All
solutions were prepared on the day of the experiment using sterile double-distilled water.
The salicylate was loaded into a 25 µL sterilized syringe (1702 LT SYR, Hamilton Co.,
NV, USA) with a needle (33 Ga, 7747-01, point style 4, 12°, 1”, Hamilton Co., NV, USA)
and was debubbled. The microreservoir was filled by injection through refill port using the
needle and the salicylate was pushed through the tubing using positive syringe pressure
until it was 1 mm from the microtubing tip.
The infusion of the salicylate was enabled by a novel biocompatible, implantable, scalable,
and wirelessly controlled peristaltic micropump recently developed at our laboratory [73].
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The mechanical components of the micropump were fabricated using direct-write 3Dprinting technology on back of a printed circuit board assembly (PCBA), around the
catheter microtubing outlet of the microreservoir to provide a biocompatible leak-free flow
path while avoiding complicated microfluidic interconnects. The peristalsis is enabled by
phase-change actuation of three chambers made adjacent to the microtubing. The actuation,
control, and Bluetooth communication electronics were fabricated on the front side of the
PCBA, effectively integrating mechanical and electronic components in a thin structure.
The micropump operation is completely controlled through Bluetooth communication
using a custom-made Android application. The micropump in vitro characterization results
showed by tuning the actuation frequency of the micropump, nanoliter resolution flow rate
across the range of 10-100 nL/min is generated, in the presence of 10× physiological inner
ear backpressures and ±3 °C fluctuation in ambient temperature. It was also shown that the
micropump could provide 50 nL/min for 20 min with 0.4% error in overall delivered drug
volume, which was shown to temporarily impact the DPOAE threshold shift [73]. The
integrated micropump operation was optimized for working in the subcutaneous
temperature of mice (~33 °C) in a liquid environment (glycerin) with similar thermal
characteristics to subcutaneous tissues to provide a flow rate of 50 nL/min for long-term
performance.
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6.3.3 Micropump air bubble-tolerance experiment

Bubbles are one of the sources of inaccuracy and defection in microfluidic systems. In this
device also bubbles can be introduced during refills, when the needle punctures the septum
and enters the microfluidic system. The maximum bubble size that could be trapped
between the fluid in a 12° beveled non-coring 30 Ga needle and the septum was calculated
using Solidworks® to be ~7.5 nL (Figure 6.1). It should be noted that since the microtubing
end of this device is implanted at the RWM which is open to atmospheric pressure, air
bubbles do not induce challenges for the organ. In addition, it has been shown in the
literature that bubbles as small as 10 nL do not have any disruptive effect on auditory
function even when injected directly into the basal turn of scala tympani [29].

Figure 6.1. Fluid in a 12° beveled non-coring 30 Ga needle and trapped air between it and
the septum. The trapped air can introduce air bubbles to the system as big as 7.5 nL.
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To explore micropump capability of propelling the fluid in presence of air bubbles an air
bubble of ~60 nL was introduced to the microsystem and the micropump was switched on.
This bubble is ~8 times larger than the practical air bubbles that can be introduced to the
system during refills.

6.4 Results and discussion

The completed integrated microsystem is depicted in Figure 6.2A. The overall microsystem
size measures 19 × 13 × 3 mm3 (L × W × H) which is significantly smaller than a typical
mouse and can be subcutaneously implanted due to its planar form factor (Figure 6.2B).
To evaluate the functionality of the microsystem, the outlet microtubing of the microsystem
was implanted at the RWM niche to deliver salicylate at 50 nL/min for 20 min, replicating
a previous drug delivery system utilizing a syringe pump [25]. Auditory function was
measured during the infusion using the DPOAE method. Finally, the capability of the
microsystem for long-term implantation was tested via standard frozen sectioning analysis
of the tissue around it.

6.4.1 Inner ear drug delivery

The accessibility of the refill port of the microreservoir was explored by palpation and
observation of the raised ridge of the refill port when the shaved skin of the mouse is
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stretched (Figure 6.2C). Subcutaneous injections through the mouse skin were successfully
performed by a 33 Ga (210 µm OD) non-coring needle (7747-01, point style 4, 12°, 1”,
Hamilton Co., NV, USA), demonstrating in vivo validity of the larger 27 and 30 Ga syringe
needles used for the septum characterization test.
Drug delivery experiments were performed using the integrated microsystem to show the
performance of the system while implanted (two microsystems in two mice). Acute
deliveries were run to deliver salicylate at the RWM niche at 50 nL/min for 20 min, while
the DPOAE threshold shifts were recorded during the infusion, to replicate a previous
experiment that was performed using a syringe pump [25]. The Android application
enabled readily control of the device for staring/stopping the infusion. The results of the
mean threshold shift of the most basal region (F2 = 51.4 kHz) for microsystems and the
syringe pump are presented in Figure 6.2D. A baseline measurement was acquired
approximately 10–15 min before the cannula placement surgery. The results compare the
changes in DPOAE thresholds to baseline at four time-points: post-surgery (PS) in which
DPOAE values were acquired immediately before the micropump was turned on, 0 min,
the time at which the micropump was turned on, and 10 and 20 min after the onset of
salicylate perfusion. There were mean shifts of 6.8 and 22.1 dB after 10 min and 20 min
infusion for the implanted microsystems, in consistency with the syringe pump results,
suggesting the successful performance of the implanted microsystem.
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6.4.2 Long-term biocompatibility

The mouse recovered well from the surgery, and over the six-month survival period, was
in good health. Post-implantation, the mouse was monitored daily and the results indicated
that the overall health was excellent. This included no signs of fever or infection, no
significant swelling, no redness or lumps around the micropump location or incision, nor
presence of discolored fluid, and no weight loss. Cage behaviors, including feeding,
grooming, and drinking were normal. The mouse was photographed on a weekly basis
during the six months period.
The histological processing of the tissue surrounding the microsystem revealed a
significant fibrotic layer around it, along with some ingrown hair follicles associated with
the incision site. Otherwise, there were no cellular indications of infections or additional
inflammatory responses, or abnormal cellular structures or responses.
A typical section of the skin surrounding the microsystem is shown in Figure 6.2E. The
skin surface is on the bottom, showing the normal dermal layers, with no sign of any active,
inflammatory cells. The microsystem was in the cavity on the upper surface; here a fibrotic
layer is seen (pink) which fully encapsulated the microsystem. This was the only abnormal
features of the tissue surrounding the microsystem after six months survival, other than the
dark hair follicles (upper right of the Figure 6.2E) associated with the incision site.
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Figure 6.2. A) Photograph of the microreservoir integrated with a micropump for inner ear
drug delivery that was recently reported [60]. The microsystem is optimized for
subcutaneous implantation in mice with an overall thickness of 3 mm. B) Photograph of a
microsystem before implantation demonstrates thinness of the microsystem, which makes
it optimized for subcutaneous implantation in mice. Inset: An image of the microsystem
after implantation via insertion of the microsystem in a small incision made in the center of
the upper back of a mouse. C) Side view and top view of a microsystem implanted showing
the visibility of the refilling port. D) Results of the mean threshold shift of the most basal
region (F2 = 51.4 kHz) for implanted microsystems and the syringe pump show perfect
consistency, demonstrating successful performance of the microsystem (N=6 for syringe
pumps, N=2 for microsystems). E) A typical 60 µm-thick section of the skin surrounding the
microsystem shows no sign of any active inflammatory cells. A fibrotic layer (pink) fully
encapsulated the microsystem.
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6.4.3 Bubble-tolerance capability

Figure 6.3 shows the capability of micropump to propel the fluid in existence of a 60 nL
air bubble in the fluid path. In existence of a large bubble, the micropump sucks the liquid
(Figure 6.3A and Figure 6.3B) and pumps it out of the device to downstream (Figure 6.3C
and Figure 6.3D). This indicates that the micropump can operate in presence of air bubbles
introduced by refills.

Figure 6.3. Self-priming of the micropump at 50 nL/min in presence of ~60 nL air bubble. A)
t = 0, the bubble is introduced to the micropump. B) t = 20 s, the micropump sucks in the
liquid. C) t = 40 s, the micropump pushes the fluid further toward downstream. D) t = 60 s,
the micropump pushed the bubble toward the downstream completely.
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6.5 Conclusion

The integrability of the microreservoir was demonstrated by building a microsystem
consisted of the microreservoir and a recently developed micropump, designed and
optimized for inner ear drug delivery. Two microsystems were implanted in the center of
the upper back of two mice, and the outlet microtubing was implanted at the RWM niche.
The drug delivery was performed following a protocol previously developed in our
laboratory for infusion of salicylate using a syringe pump, while the auditory function was
assessed using the DPOAE method. The in vivo results show that the mean value of changes
in the DP threshold shift for the implanted microsystems matches the shifts caused by
infusion with a syringe pump, demonstrating the suitability of the microreservoir to be
integrated to a pumping mechanism for subcutaneously implanted active drug delivery
systems. Further, long-term biocompatibility of an implanted microsystem in a mouse was
tested, showing very favorable signs of biocompatibility for long-term implantation, along
with the development of the fibrotic layer surrounding the microsystem. Finally, the ability
of the micropump to drive the liquid in presence of bubbles much larger than maximum
bubble size introduced during refills was explored. The results show successful pumping,
demonstrating device capacity to operate in existence of bubbles that could be introduced
to system during practical applications.
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Chapter 7

Future work and final remarks

7.1 Introduction

The present work details design, fabrication, characterization, and implantation of an
implantable microsystem for inner ear drug delivery. The microsystem consists a refillable
microreservoir to store a drug and a micropump to deliver the drug from the reservoir to
the target. The microreservoir was shown to provide near-zero backflow when the pumping
mechanism is switched off, while it can operate with zero leakage after thousands of
injections. The micropump was demonstrated to provide flow rates in the range of 10-100
nL/min in the presence of up to 10 times physiological backpressure and ±3 °C fluctuation
in the ambient temperature. The microsystem has been proven to be a robust drug delivery
mechanism with in vivo experiments. As this work lays the foundation for many future
studies that can build upon the success of the present work. This chapter provides detailed
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future studies for technology enhancement and application extension of the microsystem
or individual components, along with concluding remarks.

7.2 Technology enhancement

7.2.1 Normally-closed pumping mechanism

The current microsystem was intended to deliver the drug to RWM, which is a moist
environment with atmospheric pressure. Therefore, the fluid in the microtubing does not
experience backflow due to diffusion or advection. However, to avoid backflow and
mixing the fluid in the microtubing for broader inner ear applications (e.g., cochleostomy)
having a normally-closed fluidic path is substantially beneficial. To do so, a phase-change
material can be developed that shrinks due to melting at a melting point higher than 37 °C.
Using this material, as the micropump is working it propels the fluid similar to the current
device, while after switching the pump off it will block the microtubing because of
expansion due to solidification of the phase-change material. Therefore, it avoids advection
when the pump is off.
Another way to achieve this goal is to develop a check valve or a normally-closed external
valve in the downstream of the micropump. In microfluidics, usually, these normallyclosed valves are designed to withstand high backpressures. In this application however
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the valve requires to be leak-free at very low backpressures since the maximum
physiological backpressures for mouse models are smaller than 0.53 kPa [186].

7.2.2 A single actuator micropump with check valves

The diameter of current microtubing (Micro-Renathane® Catheter Tubing, Braintree
Scientific Inc., MA, USA) can be significantly modified by simultaneous heating and
pulling [266]. This facilitates the implantation of the microtubing for RWM niche surgery.
Besides, this feature enables using larger tubings at the micropump end, while in the pump
downstream, the tubing diameter can be engineered. Having larger tubing at the
micropump end enables tight-fitting of in-line check valves with larger diameters (e.g. 0.51 mm) in the microtubings.
Using a modified microtubing where the larger diameter is at the micropump end, and the
smaller diameter is at the target delivery organ enables development of a micropump with
a single phase-change actuator similar to the presented one in this work. Two in-line check
valves on the sides rectify the flow. This proposed micropump reduces the power
consumption per pumped fluid by reduction of number of actuators from three to one and
implementing check valves in the fluidic path. Further, since there are check valves in the
system there would be no backflow when the pump is switched off (see section 7.2.1). To
reduce the chance of infection due to refill process, a filter between the refill port and the
cavity area can be added. A port at the outlet plugs the micropump to a microtubing with
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modified diameter in downstream. Primitive experiments demonstrated that a fitting
without leakage at 200 kPa for 48 hrs is achievable.
Primitive experiments in our laboratory showed that dimensions of a tubing of 1.02 mm
ID × 1.27 mm OD (MRE-050, Micro-Renathane® Catheter Tubing, Braintree Scientific
Inc., MA, USA) can be reduced to as small as 40 µm ID × 50 µm OD. Utilizing Hagen–
Poiseuille equation, for a flow rate of water at 100 nL/min (maximum flow rate for inner
ear application) in a tubing of 40 µm ID and 10 cm length at 37 °C a pressure drop of ~1.9
kPa is expected. This pressure drop is smaller than the backpressure the presented
peristaltic micropump can pump against with insignificant change in flow rate. This
demonstrates demonstrating capability of the presented micropump to overcome this
pressure, especially considering two check valves in the system. Figure 7.1 shows a
schematic view of the proposed micropump.
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Figure 7.1. A schematic view of the proposed single actuator micropump with check valves.
A filter between the refill port and the cavity area reduces possibilities of infections due to
refills. One phase-change actuator pushes the microtubing and moves the working fluid,
while two in-line check valves rectify the fluid flow in the microtubing. An outlet port
connects the pump to a microtubing with a larger diameter in the micropump end and orders
of magnitude smaller diameter in the downstream. Inset) A photograph of the fitting at the
outlet port, which has been tested at 200 kPa for 48 hrs without leakage.
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7.3 Application extension

7.3.1 Chronic drug delivery of Salicylate to the inner ear

The microsystem was shown to successfully deliver salicylate to RWM in acute
experiments (see section 6.4.1). However, after one or two days of implantation, fibrosis
occurs around the microsystem and the microtubing. To address this issue a mixture of
dexamethasone and salicylate can reduce the possibility of microtubing clogging due to
anti-fibrosis characteristics of dexamethasone [267]–[270]. Since fibrosis can occur in one
day, delivery of small doses (0.5 µL) of the mixture once or twice a day may avoid the
clogging at the tubing end. By resolving the fibrosis at the microtubing tip, the micropump
can run for multiple days in a long-term application with different therapeutic compounds.

7.3.2 Pneumatic-driven pump for LOC applications

The cavity membrane of the microreservoir has been shown to induce near-zero backflow
(and forward flow) when the pumping mechanism is switched off (see section 5.5.2). This
feature enables precise control of the flow by applying certain pneumatic pressure on top
of the membrane. This can be used for developing a pump for LOC applications, where a
pneumatic force on top of the membrane drives the fluid ahead. A bubble trapper and a
fluidic resistor can be used to assist in removing potential bubbles introduced to the system,
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and controlling the flow rate, respectively [271], [272]. Figure 7.2 shows a schematic view
of this pneumatic-driven pump.

Figure 7.2. A schematic view of a Pneumatic-driven pump for LOC applications.
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7.3.3 Pulse-free flow

Pulsatile flow has been described as ‘intrinsic’ property of peristaltic micropumps [273].
In the presented micropump actuation of each chamber results in a forward pulse, while
the filling/loading phase of chamber 3 causes a backward pulse. Although the pulsatile
flow of peristaltic micropumps have been shown to be beneficial in some LOC applications
[274], in a case when the pump is desired to run continuously, it is impractical to modify
the working mechanism to address it [273]. Therefore, the pulse can be minimized by
adding a pulse dampener in the downstream of the micropump [273].
Pulse dampeners typically have a compliance element in the fluidic system that expands
during a forward pulse and compress during a backward pulse, keeping the fluid flow at a
near-constant rate. The compliance element can be a micromachined component [275] or
deformable walls in microchannels [276]. A more widely used approach is to utilize
compressible gasses such as air or Nitrogen, including the MASTERFLEX® L/S® pulse
dampener (Cole-Parmer Instrument Company, USA), the pulse dampeners made with
elastomer or plastomer membranes (Pulse- Guard Inc., USA), the ACCU-PULSE (Primary
Fluid Systems Inc., Canada), stainless steel pulsation dampers (OLAER Fawcett Christie
Ltd., UK), the bladder type made from different materials (Flowguard Ltd., UK), etc.
Although pulse-dampeners reduce the flow fluctuations they do not eliminate backflow,
thus, they do not improve the pumping efficiency. Adding a check valve at the pump
downstream, however, removes the backflow and consequently enhances the efficiency.
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Since check valves do not eliminate forward pulse, integration of check valve and a pulse
dampener at the pump downstream enables high-efficiency flow with minimized pulsation.
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7.4 Conclusion

A fully implantable, scalable microsystem for inner drug delivery has been presented. The
microsystem consists of a micropump and a microreservoir. The micropump is fabricated
directly on top of a PCB, around a miniature microtubing (125 µm ID × 250 µm OD)
providing a leak-free flow channel for the drug. The refillable microreservoir is capable of
thousands of injections without leakage. Further the microreservoir is optimized to be
integrated to a normally-open micropump by having near-zero backflow due to restoring
force of the membrane.
Table 7.1 compares the presented microsystem with state of the art and commercially
available microsystems for inner ear drug delivery. Compared to iPrecio® SMP-300 the
presented microsystem has slightly less resolution in drug delivery, smaller reservoir
capacity, and is normally-open. However, the presented device can be wirelessly controlled
and programmed after implantation, with thousands of leak-free injections. Further, the
presented microsystem is thin and light, with small footprint and tubing size, optimized for
size-constrained applications such as mice inner ear drug delivery. Although presented here
on the small murine cochlea, this low-cost design and fabrication methodology is scalable
for use in larger animals and for clinical applications in children and adults. This device
can potentially have other implantable biomedical applications, such as ocular drug
delivery.
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Table 7.1. Comparison of current microsystem with other state of the art and commercially
available microsystems for inner ear drug delivery.

Current device

iPrecio® SMP-300

Tandon et al. 2016 [13]

Flow rate range
(nL/min)

10-100

0-166

4500-5500

Flow rate
resolution
(nL/min)

2.37

1.66

N/R

Wireless control







Wireless
programming







Tubing OD (µm)

250

1500

360

Normally-closed







Reservoir
capacity (µL)

10

130

238

Max number of
refills

~ 65000

N/R

N/A

Footprint (mm3)

19 × 11

24.8 × 15

39.5 × 28.3

Thickness (mm)

3

7.2

7

Weight (g)

0.8

3.3

N/R

Mouse
implantation
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Appendix A. Details of COMSOL® heat transfer
model

A.1 Model Geometry
The detailed geometry of the micropump was made in Solidworks® and imported to
COMSOL (Figure A.1). Although the microtubing and fluid in it have a circular cross
section, they were modeled as a square shaped cross section due to importing difficulties
using COMSOL Multiphysics. All four layers of the copper in the PCB are considered but
are masked by PCB in the schematic view.
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Figure A.1. The model geometry of the micropump used in the COMSOL simulation. The
resin around the chambers and on top of it are not shown. The resistive heaters in the
chambers are covered with wax. All four layers of the copper are considered in the geometry
model, but in this view they are masked with PCB.

A.2 Model validation
The COMSOL model was validated at the primitive step of analysis by comparing with a
micropump working in air environment. Two validation schemes of steady and transient
state were investigated, both in air environment. In the steady state one the two side
chambers (chambers 1 & 3, see Figure A.1) were turned on for 10 min, while chamber 2
was off and its temperature was increased due to the heat from side chambers. The
comparison between numerical and experimental results shows acceptable matching
(Figure A.2). In the transient experiment two side chambers were turned on for 10 s and
turned off for 10 s. During the 20 s chamber 2 was off. The numerical results are consistent
with experimental data (Figure A.3). In both experiments the heating chambers work with
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15 mW power which was the power of the pump in the experiment. In both graphs values
for chamber 3 are not shown, since they are almost identical with chamber 1. The
consistency between the experimental data and numerical model validates the model for
further design and analysis for both steady and transient states.
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Figure A.2. Consistency between numerical and experimental data where two side chambers
are on and the middle chamber is off shows validity of the model to predict steady state
conditions.
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Figure A.3. Consistency between numerical and experimental data where two side chambers
are on for 10 s and off for 10 s, while the middle chamber is off shows validity of the model
to predict transient conditions.

A.3 Material properties
Table A.1 shows the material properties of key parameters in the model. The drug in the
microtubing is modeled as water since the large percentage of the drugs are made of water.
Water (water, liquid in COMSOL) properties are defined in COMSOL library. The density
of the wax is adjusted based on the mass in the device. The material properties of the
thermistors and resistors were found according to manufacturer datasheet. The transistor is
considered as copper.
The material for wire is considered copper. The wire length was modeled 100 times smaller
than the realistic ones, which are unproportionally long (~30 cm) for such a small device
(0.8 × 0.8 cm2). Therefore, the density and thermal conductivity are adjusted accordingly.
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For a long component such as the wire the heat transfer can be estimated 1-D along the
length of the wire. The simplified equation for conduction is Qconduction = kAΔT/d, where k,
A, ΔT, and d are thermal conductivity, surface area, temperature difference, and distance.
Since in this model d is 100 times smaller than the realistic value, kequivalent was 100 times
reduced (from 400 to 4 W/mK) to have the Qconduction intact. Further, stored energy in the
wire is defined as Qstored = mcΔT where m,c, and ΔT are mass of object, specific heat of
object, and temperature difference. To keep the mass of the object fixed while having 100
times less length/volume, the density of the wire is considered 100 times of copper.
The thermal behavior of the wax (Nonadecane) however was modeled using apparent heat
capacity method. In this method the phase-change phenomenon is modeled as a drastic
change in the melting range by defining the specific heat as a function of temperature. This
function was defined as a user-defined function (UDF) in the present COMSOL model. In
this UDF, the latent heat of the wax (170 kj/kg) was spread over the phase-change
temperature range of 4 °C [194], [195], [277]. Also the solid-solid energy of the wax is
spread over 1 °C at 295 K [277]. Equation (A-1) shows the heat capacity of the wax as a
function of temperature.

5000
14000
Cp,wax (T) = {
42500
5000

T < 294 K
294 K < T< 295 K
302.65 < T < 306.65 K
T > 306.65 K
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(A-1)

Table A.1. Components and their material properties used in the COMSOL heat transfer
simulation.
Component

Material

Density (kg/m3)

Specific heat
(J/kgK)

Thermal
conductivity
(W/mK)

PCB

FR4

1900

1369

0.3

Copper traces

Copper

8960

384

401

Microtubing

Polyurethane

950

1800

0.29

Thermistor

Murata® NCP
series*

4247

1128

120

Resistive heater

Panasonic® ERJ
series*

3900

900

27

Super glue

Fastcap® 2P-10*

1043

850

0.1

Solder

60Sn-40Pb 1

9000

150

50

Wire

Copper

896000†

384

4†

Drug

Water

997

4157

606

Paraffin wax

Nonadecane
CH3(CH2)17CH3*

1435

Cp,wax (T)

0.22

*Material was found from or based on manufacturer release data. Other materials were in COMSOL library.
†Equivalent values based on the simplified geometry.
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A.4 Boundary conditions
The external surface of the model are exposed to free convection in water with adjusted
convection coefficient of 1200 W/m2°K, which falls in the typical range for free convection
in water and liquids (50-3000 W/m2 K)[278]. The convection coefficient was tuned by
matching a sample test with experimental pump model. For all the simulations the power
of the heaters (P) are 80.6 mW which is consistent with having 1.8 V across 40.2 Ω resistive
heaters in the pumps. Similar to the pumps, a closed-loop control limits the generated heat
in the chambers. Further, each chamber follows a peristaltic sequence. The generated heat
in the chambers are therefore defined as:

Pboundary = P × h(t) × (Tchamber < Tset)

(A-2)

where Pboundary, h(t), Tchamber, and Tset stand for applied heat to the chamber, ON/OFF (1 or
0) condition of the chamber based on peristaltic cycle, temperature of the chamber sensed
by the thermistor, and set temperature of the chamber. Figure A.4 shows the peristaltic
cycle of chamber 1 defined in the COMSOL model.
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Figure A.4. A sample peristaltic cycle of chamber 1. Similar cycles are defined for chambers
2 and 3 with phase-lags of 120° and 240°.

The radiation between the pump external surface and the surrounding is neglected since it
is orders of magnitude smaller than the convection heat transfer. If the pump is considered
a small object in a large enclosure the formula for radiation is:

Q = σ ε A (T41 − T42 )

(A-3)

where σ, ε, A, T1, and T2 are Stefan-Boltzmann constant (5.669 × 10-8 W/m2 K4), emissivity
of the body, pump overall surface, pump surface temperature, and ambient temperature,
respectively. Considering ε = 1, A = 2.24 × 10-4 (pump dimensions: 8 × 8 × 3 mm3), and
(according to COMSOL simulation results) pump external temperature 0.3 higher than the
ambient temperature (20 °C), the power loss due to radiation is 0.38 mW. This value is
three orders of magnitude smaller than the convection at the same conditions,
demonstrating validity of the assumption of neglecting radiation.
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By using the COMSOL® Heat Transfer in Solids module, the convection in the chamber
due to phase change from solid to liquid is neglected. It is a simplification of the simulation,
since considering phase-change phenomenon required Heat Transfer in Fluids module and
using COMSOL Multiphysics® to model their interaction which significantly increase the
calculation cost. Instead, some of the parameters in the model were tuned by comparison
to experimental models.

A.5 Geometry optimization
The COMSOL model was used to optimize the geometry of the pump. The four copper
layers in the PCB are the most important element beside the wax, due to high thermal mass
and conductivity. Two changes in the copper structure was examined: thinning the copper
layers from 36 µ down to 18 µm, spreading copper in the chamber. Due to limitations of
the manufacturer we could not reduce the thickness of the copper at the external layers,
therefore, just two middle layers were thinned.
A set of experiment was designed to examine effects of each of these geometry
modifications. Three models were made: Reference, Spread copper, and Thin copper. The
Reference model has copper layers with 36 µm thickness, without copper spread in the
chamber. The spread copper model has the same copper thickness, with an additional sheet
of copper connected to thermistors and resistors spread in the chamber. The Thin copper
model has two internal layers of 18 µm, without any spread of the copper in the chamber.
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A peristalsis sequence of 101, 110, 011 is considered (1 is ON, 0 is OFF, numbers in the
order of chamber number). The test here has two steps. At the first step the pump is at
steady state at phase 3 of the peristalsis cycle (011), where chamber 1 is off and chamber
2 and 3 are ON. At the second step a transition between phase 3 to phase 1 occurs (011 →
101), where chamber 1 is powered on with a realistic power of 80.6 mW, chamber 2 is
turned off, and chamber 3 is kept at the set temperature. No closed-loop control on the
chamber temperature is applied here, to save computational cost. The results presented in
this section are for the second step which runs for 3s. The wax for this simulation is
Nonadecane, with a melting range of 4 °C around 32 °C. All temperatures are relative to
ambient temperature.
Comparison of the wax temperature of the Reference and Spread copper shows that
spreading copper in the chamber increases the actuation frequency by 21% (Figure A.5).
In other word, the temperature of the wax in the chamber can get to the set temperature
faster. In addition, a histogram graph is generated to show the distribution of temperature
in the chamber, at the moment that the wax in each chamber reaches the set temperature
(i.e., t ≈ 2s for the Reference, and t ≈ 1.7s for the Spread copper). In the Reference, the
temperature elevation of the wax is distributed in a range of ~ 3-20 °C, with a relatively
flat profile. In converse, in the Spread copper a significant peak of the amount of the wax
in melting range can be observed (Figure A.6). The temperature elevation range also
reduces to ~5-17 °C. The spread copper reduces the temperature standard deviation by
35%. The results of Thin copper shows that using thinner copper layers can increase the
actuation frequency by 55% (Figure A.7).
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Figure A.5. Comparison of the temperature elevation of the wax in chamber 1 shows that
spreading the copper increases the actuation frequency by 21%.

Figure A.6. Temperature distribution of the wax in chamber 1, at the time that it reaches
the set temperature shows a significant improve in the homogeneity of the temperature
using the Spread copper, compared to Reference. Spread copper reduces the temperature
standard deviation by 35%.
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Figure A.7. Reducing the thickness of the copper layers on the PCB increases the
operation frequency by 55% due to reduced thermal mass and heat transfer away from the
chamber.
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